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CHAPTER 1
SYNTHESIS, DELIVERY AND REGULATION OF EUKARYOTIC HEME AND FE-S
CLUSTER COFACTORS
1.0 Prelude
Iron plays an important role in all biological systems. Its utility in biology comes
from its unique electrochemical characteristics that impart the ability of the biomolecule
for which it binds to mediate complex chemical reactions required to sustain life. Iron
participates in a myriad of indispensable reactions including oxidation-reduction,
electron transfer, and substrate activation used in a variety of cellular processes
including cellular respiration, metabolism, and photosynthesis. In humans, the majority
of iron is incorporated into heme, but a minority gets stored bound either within the iron
storage protein ferritin or incorporated into proteins either as metal alone or as a metal
containing cofactor1. Among the several iron containing cofactors, Fe-S clusters are the
second prominent class after heme and they can be found ubiquitously in all organisms.
These inorganic cofactors exist in a number of different configurations but their main
function is the transfer of electrons for redox reactions. When bound to proteins, the
range of reduction potentials of Fe-S clusters is expanded and fine-tuned by solvent
accessibility and by the amino acids in the vicinity of the cluster2,3. Hence Fe-S clusters
associated with proteins can function as excellent electron carriers in almost all cellular
processes. As a few examples, they are present in primary and secondary metabolic
enzymes, some DNA repair enzymes, and iron regulatory proteins (IRPs)4. The list of
Fe-S proteins is numerous and their function is a thesis by itself, so I will limit my
description of Fe-S clusters in this chapter to their assembly and steps related to their
utilization.
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The remarkable and diverse electronic potentials of Fe-S clusters allow them to
be exploited in many systems, and this makes their assembly indispensable for cell
viability. This is best highlighted by the number of human diseases associated with
defects in Fe-S cluster assembly proteins, disease states of which are outlined in detail
below. Studying the characteristics of proteins involved in Fe-S cluster assembly has
been a main focus of research within Stemmler lab. My research was centered on
uncovering the structural and functional details of cysteine desulfurase, a protein that
provides sulfur for the Fe-S cluster assembly within the mitochondria. My original project
in this context proposed to individually characterize Isd11, the accessory protein
associated with cysteine desulfurase enzyme Nfs1 in yeast mitochondria. But due to
inherent insolubility of Isd11, an issue described in detail in chapter 4, continuation of
that project was not feasible. Since then, my research focus deviated to study the
characteristics of Nfs1-Isd11 as a complex and the effect of frataxin (a proposed iron
delivery protein) on its function. Chapter 2 and 3 describes what I accomplished in those
regards.
This first chapter serves to deliver the required background information on the
field and it highlights the main characters within the Fe-S cluster bioassembly pathway;
essential for one to follow the details within the subsequent chapters. It discusses two
major iron cofactor assembly pathways: heme and Fe-S cluster synthesis. This report
has already been published as a review article which I was the primary author:
“Barupala, D. P., Dzul, S. P., Riggs-Gelasco, P. J., & Stemmler, T. L. (2016). Synthesis,
delivery and regulation of eukaryotic heme and Fe–S cluster cofactors. Archives of
biochemistry and biophysics, 592, 60-75”. My role in writing this review included
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organizing the entire content and submitting the article for review in addition to writing
the text within the introduction and heme assembly sections. Although the discussion
about heme cofactor assembly is far from my research interest, it is included here to
emphasize the significant amount of time and effort spent to draft that section solely by
myself.
1.1 Abstract
In humans, the bulk of iron in the body (over 75%) is directed towards heme- or
Fe-S cluster cofactor synthesis, and the complex, highly regulated pathways in place to
accomplish biosynthesis have evolved to safely assemble and load these cofactors into
apoprotein partners. In eukaryotes, heme biosynthesis is both initiated and finalized
within the mitochondria, while cellular Fe-S cluster assembly is controlled by correlated
pathways both within the mitochondria and within the cytosol. Iron plays a vital role in a
wide array of metabolic processes and defects in iron cofactor assembly leads to
human diseases. This review describes progress towards our molecular-level
understanding of cellular heme and Fe-S cluster biosynthesis, focusing on the
regulation and mechanistic details that are essential for understanding human disorders
related to the breakdown in these essential pathways.
1.2 The role of iron in biology
Iron’s abundance and unique chemical characteristics are often exploited by
nature to drive the complex chemistry required by cells to maintain life. Iron is the fourth
most abundant element on the earth’s crust5, so its high prevalence during early
evolution is certainly a factor for its current ubiquitous presence in nature. The human
body contains 3 to 4 grams of the metal and absorbs 1 to 2 mg of it each day6. The
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reactivity and ability of the metal to cycle between the Fe(II), (III) and (IV) oxidation
states makes it extremely useful for driving intricate reactions in biology that include
substrate activation, electron transfer, and oxidation-reduction reactions. Because of
this chemical versatility, iron plays a role in nearly every biological pathway. While its
utility within biology is apparent, the Achilles heel of this essential metal is its tendency
to precipitate in aqueous solutions7. Through coordination to biomolecules, however,
the solubility of the metal can be controlled and its reactivity attenuated. At the
elemental level, first coordination sphere ligands stabilize the solubility of the metal
while at the same time tune its chemical properties for selective participation in only
desired reactions 8. Ligand variability in this first coordination sphere helps control how
the metal behaves, however at the cellular level a complex network of proteins,
controlled at the genetic level, helps ensure metal availability to specific protein partners
in the cell1.
Pathways related to eukaryotic iron homeostasis are shown in Figure 1.19. Iron is
brought into cells either via the transferrin Fe uptake pathway or through direct
membrane transporter (ex. the DMT1 pathway)10. Once in the cell, imported iron can
bind to iron regulatory proteins where it serves to control concentration, it can be stored
within the ferritin complex, it can be exported, or it can be incorporated as cofactors into
apoprotein partners. In humans, the bulk of iron in the body (over 75%) is directed
towards heme-6 or Fe-S cluster cofactor11 biosynthesis. Assembly of the Fe-cofactors
follows highly regulated pathways that have evolved to safely build and load these
inorganic Fe-containing cofactors into the apoprotein partners while controlling metal
reactivity. In eukaryotes, heme biosynthesis is initiated and completed within the
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mitochondria, while Fe-S cluster assembly is controlled by separate but correlated
pathways within both the mitochondria and the cytosol. Iron plays a central role in a
wide array of metabolic processes, so it is not surprising that defects in cofactor
assembly leads to human diseases. This review details progress towards elucidating
the molecular details of cellular heme and Fe-S cluster biosynthesis. A focus on both
regulation and mechanism will be critical for understanding human disorders related to
the breakdown in these essential pathways.

6

Figure 1.1: Major cellular Fe utilization pathways in humans. Under physiological
conditions, most Fe is internalized as the Tf-bound form, which undergoes receptormediated endocytosis via binding to TfR1. Decrease in endosomal pH releases Fe(III)
from Tf, which is then reduced by the endosomal reductase STEAP3 to Fe(II). Fe(II) is
then transported to the cytosol via DMT1 to join the LIP. Fe in LIP can be utilized for
storage in ferritin, import to mitochondria for storage and heme and Fe-S cluster
synthesis, export to the cytosol via ferroportin, cellular Fe regulation via IRPs and
incorporation into other Fe proteins in the cytosol. Under non-physiological conditions
Fe(III) can enter the cell after being reduced to Fe(II) and imported by DMT1. Tf:
Transferrin, TfR1: Transferrin receptor 1, DCYTB: duodenal cytochrome b, DMT1:
divalent metal transporter 1, STEAP3: six transmembrane epithelial antigen of the
phosphate 3, LIP: labile iron pool, PCBP: poly (rC)-binding proteins, OMM: outer
membrane of mitochondria, IMM: inner membrane of mitochondria, MFRN: Mitoferrins,
FTMT: mitochondrial specific ferritin, ABCB7: transporter for unknown source of sulfur
X-S from mitochondria to cytoplasm, IRP: iron regulatory proteins, IRE: iron-responsive
elements of mRNA.
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1.3 Heme cofactors
1.3.1 Introduction
Among the many metalloporphyrins found in nature, heme is one of the most
abundant. It is utilized in many vital biological processes including photosynthesis,
oxygen transport, biological oxidation and reduction, and many more. Most of the total
iron content in human body is incorporated into heme-containing proteins such as
hemoglobin,

myoglobin,

catalases,

peroxidases,

nitric

oxide

synthases,

and

cytochromes12. The unique structure of heme, which consists of the iron cation
coordinated to four nitrogen atoms from a tetrapyrrole ring, allows for fine tuning of the
metal’s reactivity to carry out the function of the biomolecule to which it is attached.
Here we discuss the different heme types, their biosynthesis and regulation, their
function in biology, and finally the diseases linked to a loss of heme function.
1.3.2 Heme structure and types of heme in nature
Modifications to the basic heme molecule allow for the diverse array of heme
functions found in nature. The parent heme molecule, also known as heme b,
protoheme IX or protoporphyrin IX, serves as the platform in each case. The
tetrapyrrole unit of heme consists of four pyrrole units linked by four methine bridges. A
nitrogen atom from each pyrrole coordinates the iron atom in the center of the planar
tetrapyrrole ring. Distortions from planarity can be critical to heme function and reactivity
(examples include hemoglobin13 and myeloperoxidase, MPO14). Fifth and sixth ligands
to the Fe can be provided by amino acid side chains from the apoprotein or by small
inorganic molecules coordinating above and below the plane of the ring. Eight positions
in the tetrapyrrole carry side chain modifications, particularly methyl groups on carbons
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2, 7, 12, and 18, vinyl groups on carbons 3 and 8, and propionyl groups on carbons 13
and 17 (Figure 1.2). Substitutions to the same carbons with various other side chains
create several biologically important heme types found in nature (Figure 1.3). Heme A,
B, and C are found in a wide spectrum of organisms and take part in vital biochemical
processes such as respiration, photosynthesis and oxygen transport. The additional
cofactor types (Heme D, D1, I, M, and O) are species-specific and carry out highly
specialized functions. Table 1 summarizes the structural features, occurrences, and
known functions of each heme type.
1.3.3 Heme biosynthesis pathway
Since heme serves as an essential cofactor to several proteins involved in
central metabolic processes, all organisms have established a conserved biosynthetic
pathway to synthesize the cofactor. Atomic detail is available for many of the enzymes
involved in bioassembly of heme, and these enzyme structures have provided key
insights into reaction mechanisms. The general assembly process consists of four
stages: the synthesis of a single pyrrole, the assembly of four pyrroles to make the
tetrapyrrole ring, modification of the side chains, and the insertion of iron into the ring
(Figure 1.4)15. Specific details for this conserved pathway are outlined below.
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Figure 1.2: Structure of heme. Standard 1-24 IUPAC numbering system is used to
number the carbon atoms of the tetrapyrrole16.
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Figure 1.3: Important types of heme found in nature. Side chain differences with
respect to the parent heme molecule (heme B) are shown in blue.
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Table 1.1: Comparison of different heme types in nature.
Type
Heme A

Structure Remarks
C3= hydroxyethylfarnesyl
group
C18= formyl group
Conversion of heme to heme
A is catalyzed by Heme A
synthase.
Parent heme molecule also
known as protoheme IX, Feprotoporphyrin IX or heme.
Binds to apoproteins noncovalently.
C3 and C8= thioether bonds
with cysteine residues.
Binds to apoproteins
covalently.

Organisms
Bacteria, archaea, plants
and animals.

Proteins
Cytochrome a containing
heme-Cu oxidases.
E.g. Cytochrome c
oxidase/Complex IV in
mammalian mitochondria.

Function
Terminal reaction of aerobic
respiration. Reduction of oxygen
to water.

In a variety of organisms.

Cytochromes b and
hemoglobins.

Diverse array of functions
associated with heme b such as
electron transport and oxygen
carrier.

In a variety of organisms.

Heme D

C12= hydroxylated, in a trans
conformation to the γspirolactone.
C13= hydroxylated, propionyl
group forms a γ-spirolactone
with the hydroxyl group.

In diverse bacteria including
Azotobacter, Proteus,
Acetobacter, Salmonella,
Bacillus, Pseudomonas,
Haemophilus and E. coli.

Cytochromes c
E.g. bacterial alcohol
dehydrogenase, bacterial caa3
and cbb3 oxidases,
mitochondrial and bacterial bc1
complex, and cytochrome cd1
nitrite reductase.
Terminal respiratory oxidases.
E.g. Cytochrome d oxidase.

Serve as electron carriers to
perform single electron transfers
in energy transduction processes
such as photosynthesis,
respiration and N and S cycles.
Other functions include
apoptosis, detoxification of ROS.
Terminal reaction of aerobic
respiration. Reduction of oxygen
to water at low oxygen levels.

Heme D1

C3 and C8= an acetyl group
and a methyl group on each
carbon.
C2 and C7= keto groups on
each carbon.
C13 propionyl side chain has
reduced to incorporate a vinyl
group between second and
third carbons.
C2 and C12= hydroxymethyl
groups, they form ester bonds
with carboxyl side chains of
amino acids.
Binds to apoproteins
covalently.
C2 and C12= hydroxymethyl
groups, they form ester bonds
with carboxyl side chains of
amino acids.
C3= vinyl group on C3 forms a
sulfonium ion linkage with the
sulfur of a methionyl residue.
C3= hydroxyethylfarnesyl
group.

In Pseudomonas
perfectomarinus,
Alcaligenes faecalis,
Paracoccus denitrificans,
Thiobacillus denitrificans,
and Thiosphaera
pantotropa.

Nitrite reductase that functions
in dissimilatory nitrogen
metabolism.
E.g. Cytochrome cd1 nitrite
reductase.

Catalyzes the one-electron
reduction of nitrite to nitric oxide
and four-electron reduction of
oxygen to water.

22,23

In mammalian secretory
fluids.

Peroxidases such as bovine
milk enzyme lactoperoxidase,
eosinophil peroxidase and
thyroid peroxidase

Peroxide-driven oxidation of
halide and pseudohalide ions as
a nonspecific antimicrobial
defense mechanism for the
protection of mucosal surfaces.

24

In mammalian neutrophils

Myeloperoxidase

Peroxide-driven oxidation of
chloride and bromide ions as an
antimicrobial defense
mechanism.

14,24

Bacteria such as E. coli.

Cytochrome o containing quinol
oxidases.
E.g. Cytochrome bo3

Terminal reaction of aerobic
respiration. Reduction of oxygen
to water.

25,26

Heme B

Heme C

Heme I

Heme M

Heme O

Ref.
17

18

19-21
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Figure 1.4: Heme biosynthesis pathway. ALA: 5-aminolevulinic acid, ALAS: ALA
synthase, PBGS: porphobilinogen synthase, ALAD: ALA dehydratase, PBGD:
porphobilinogen
deaminase,
UROS:
uroporphyrinogen
synthase,
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Ferrochelatase, IMM: inner membrane of mitochondria, IMS: intermembrane space,
OMM: outer membrane of mitochondria.
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1.3.3.1 Important steps in heme biosynthesis
The first step in eukaryotic heme biosynthesis is the mitochondrial formation of 5aminolevulinic acid (ALA), which is the precursor that serves as the only source of
carbon and nitrogen atoms required to build the basic heme unit. Depending on
species, one of two major pathways directs formation of this precursor leading to
production of tetrapyrroles. In the Shemin pathway, the enzyme ALA synthase (ALAS)
that resides on the matrix side of the mitochondrial inner membrane catalyzes the
condensation of glycine and succinyl-CoA27-30. ALAS is found in animals, fungi, nonphotosynthetic eukaryotes, and α-proteobacteria (organisms that resemble bacterial
ancestors of mitochondria). Mammals have two ALAS isoforms; the first isoform
(ALAS1) provides housekeeping functions and a second erythroid specific isoform
(ALAS2) provides for the more robust heme requirements in erythrocytes31. Both forms
of ALAS are homodimers and require pyridoxal 5’-phosphate (PLP) bound as a Schiff
base covalent adduct to a catalytic lysine. During the joining of glycine and succinyl CoA
on the PLP scaffold, both CO2 and Coenzyme A are released as byproducts32. Upon
formation, ALA exits the mitochondria to serve as the substrate for the subsequent fourenzymatic conversions that occur in the cytosol. Little is known about the specifics of
export, but it has been suggested that SLC25A38, a member of the SLC25 family of
transporters of the mitochondrial inner membrane, facilitates import of glycine into the
mitochondria in exchange for ALA transfer across the mitochondrial inner membrane33.
In the second major pathway for ALA synthesis, also known as the C5 pathway,
glutamyl-tRNA reductase (GluTR) converts glutamyl-tRNA to glutamate-1-semialdehyde
(GSA) in the first of the two-step ALA production pathway34. The second step involves
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the conversion of GSA to ALA by the enzyme glutamate-1-semialdehyde-2, 1-amino
mutase (GSAM)35-37. This second major pathway is found in plants, archaea and most
bacteria.
Once exported to the cytosol, ALA serves as the building block to synthesize
uroporphyrinogen III following three consecutive steps. The first step involves
condensation of two ALA molecules to form porphobilinogen (PBG) by porphobilinogen
synthase (PBGS), also known as ALA dehydratase (ALAD)38,39. PBGS is a
homooctamer in which each dimer contains one catalytic site40. Each active site binds
an ALA molecule at two distinct sites and each subunit binds one zinc atom41. Of the
eight Zn atoms on PBGS, four zinc atoms stabilize the enzyme structure while the other
four engage in catalytic activity42,43. Four molecules of porphobilinogen undergo
polymerization

to

form

1-hydroxymethylbilane

in

a

reaction

catalyzed

by

porphobilinogen deaminase (PBGD). PBGD uses a covalently attached dipyrromethane
cofactor (made of two linked PBG molecules) to prime the polymerization of four PBG
molecules. Six PBG molecules form a linear hexapyrrole covalently bound to PBGD,
which is then cleaved to yield 1-hydroxymethylbilane and the protein bound cofactor44.
This unstable tetrapyrrole serves as the substrate for uroporphyrinogen synthase
(UROS), the enzyme that synthesizes uroporphyrinogen III. UROS functions as a
monomer and completes ring inversion and the subsequent closure of the tetrapyrrole,
yielding uroporphyrinogen III45,46. Spontaneous ring closure is also possible, but the
resulting product uroporphyrinogen I cannot be converted to heme. Uroporphyrinogen III
also serves as the branching point for the synthesis of chlorophylls and corrins. In heme
biosynthesis, this cyclic intermediate is converted to coproporphyrinogen III, a product
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that lacks four acetic side chains. Subsequent decarboxylation steps are carried out by
uroporphyrinogen decarboxylase (UROD) within the cytosol to yield four methyl groups
in place of the acetic side chains47. UROD is a homodimer with each subunit carrying an
active site cleft that faces the other in the dimer interface48.
Three enzymes associated with the mitochondrial inner membrane complete the
terminal steps in the eukaryotic heme biosynthesis. Their arrangement suggests they
act

as

a

multiprotein

complex

that

facilitates

substrate

channeling49.

Coproporphyrinogen III entry into the mitochondria is likely mediated by the peripheraltype benzodiazepine receptor (PBR), located on the mitochondrial outer membrane50. In
the first of the three terminal steps, coproporphyrinogen III undergoes oxidative
decarboxylation of its propionyl side chains on two pyrrole rings to form
protoporphyrinogen IX. This reaction is completed in higher eukaryotes and in a few
bacterial species by the oxygen-dependent coproporphyrinogen III oxidase (CPO), an
enzyme located in mitochondrial intermembrane space51. CPO requires molecular
oxygen as the terminal electron acceptor52.
In the next step, protoporphyrinogen IX is oxidized to protoporphyrin IX, following
the removal of six hydrogen atoms from the porphyrinogen ring, to provide an
alternating double bond structure to the macrocycle; this reaction is catalyzed by
protoporphyrinogen IX oxidase (PPO)53. In eukaryotes, the oxygen-dependent PPO is a
homodimer that utilizes molecular oxygen as the terminal electron acceptor and
functions as an integral membrane protein located in the mitochondrial inner
membrane54. The active site of the protein faces the intermembrane space and uses a
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FAD cofactor for electron transfer. The complete reaction uses three O2 molecules that
are reduced to three H2O2 molecules.
Ferrochelatase (FC) is responsible for the insertion of ferrous iron into
protoporphyrin IX to form Fe-protoporphyrin IX or heme, in the next step of heme
biosynthesis. FC is a mitochondrial inner membrane protein with its catalytic site located
on the mitochondrial matrix side. Channeling of protoporphyrin IX from PPO to FC may
occur via direct interaction between the two proteins that allows efficient substrate
transfer54. FC functions as a homodimer and each monomer contains a 2Fe-2S cluster
whose function is unknown55,56. The reaction mechanism involves distortion of the
planar porphyrin molecule into a saddle conformation to facilitate the insertion of ferrous
iron57. Once synthesized, heme can undergo side chain modifications (e.g. heme A and
heme O synthesis) or covalent attachments (e.g. heme C in cytochrome c biogenesis)
to produce additional heme types depending on cellular needs.
1.3.3.2 Regulation of heme biosynthesis
In humans, heme is synthesized at two locations, in erythroid progenitors within
bone marrow to provide for developing red cells, and in the liver to provide for numerous
heme-containing enzymes. Liver responds to various metabolic states in the body,
hence heme synthesis in liver is regulated accordingly. Erythroid progenitors on the
other hand maintain heme production at a steady pace to meet the demand of red blood
cells. Mechanisms for regulation of heme synthesis in these two origins therefore differ.
The first step, catalyzed by two different isoforms of ALAS in liver (ALAS1) and
bone marrow (ALAS2), is the rate-limiting step of heme synthesis. Both isoforms are
post-transcriptionally regulated by two different mechanisms. Heme has a negative
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feedback effect on ALAS1 transcripts and two alternate splice forms of ALAS1 facilitate
this regulatory mechanism. One splice form is subjected to heme-mediated decay58-60
but the other is resistant to this effect and requires translation in order to be regulated
by heme-mediated decay61,62. Heme itself blocks translocation of a precursor form of
ALAS1

from

cytoplasm

to

mitochondria

contributing

to

its

downregulation63.

Transcription of ALAS1 is upregulated by the peroxisome proliferator activated
coactivator 1α (PGC-1α) in correlation to cellular glucose levels64. In contrast, erythroidspecific transcriptional factors such as GATA1 regulate ALAS2 transcription by binding
to the promoter region65. In translational regulation of ALAS2, iron responsive elements
(IRE) in ALAS2 transcripts can bind iron regulatory proteins (IRP). This prevents ALAS2
mRNA translation, allowing heme synthesis in differentiating red cells to be regulated in
relation to cellular iron availability and mitochondrial function66,67.
In addition, three enzymes within the heme biosynthesis pathway (PBGS, PBGD,
and UROS) are transcriptionally regulated, yet they utilize a dual promoter system that
allows erythroid specific or non-erythroid specific regulation of a single gene. Alternative
splicing of exons creates two different PBGS transcripts, either with a housekeeping
promoter or with an erythroid–specific promoter that binds erythroid-specific
transcription factors including GATA168. Both PBGS transcripts encode identical
proteins because they share the same translational start site despite their difference in
lengths. On the contrary, alternative splicing of transcripts of the PBGD gene produces
proteins of different lengths69,70. Erythroid-specific promoters of PBGD contain several
specific cis-acting sequences (including GATA1, NF-E2 and CACCC motifs) that are not
seen in the housekeeping promoter71. Similarly, alternative splicing of UROS gene

18
creates two transcripts. Erythroid-specific promoters of UROS contain eight GATA
binding sites while the non-erythroid promoter contains NF1, AP1, Oct1, Sp1 and NRF2
binding sites. Both transcripts produce identical proteins72. The remaining enzymes
within the pathway have single promoters; regardless, they exhibit erythroid and nonerythroid expression differences. The UROD gene carries a promoter of non-erythroid
origin but UROD levels in erythroid tissue are significantly elevated compared to
ubiquitous tissue and the specific mechanism resulting in this upregulation has yet to be
determined73. The human CPO gene contains a single active promoter with six Sp1
sites, four GATA binding sites and a novel regulatory element named CPRE that aids in
the elevated expression in erythroid tissue74. The PPO gene contains a GATA1 binding
site in its single promoter, suggesting potential erythroid-specific regulation50. Ciselements like NF-E2, GATA1 and the Sp1 binding sites are present in the human FC
gene promoter and they have been found to induce FC expression during erythroid
differentiation while the GC box maintains housekeeping expression of the gene75.
Expression of ferrochelatase is also regulated by iron availability of the cells, related to
the Fe-S cluster of FC 76.
It is evident that the heme biogenesis enzymes in the erythroid pathway are
transcriptionally induced by erythroid-specific transcription factors in coordination with
iron uptake. Liver on the other hand maintains sufficient heme levels by combining
synthesis and degradation in response to changes in cellular heme pools. Both systems
are important however for maintaining cellular iron homeostasis and they are therefore
areas of interest for understanding heme related diseases.

19
1.3.4 Incorporation of heme into apoprotein recipients
Although diverse in their function, heme-containing proteins share a structurally
conserved element, the heme cofactor. Primary factors contributing to the functional
diversity of heme proteins are the protein ligands coordinating Fe in the proximal/distal
positions and the covalent linkage of the heme to the biomolecule. Insertion and
stabilization of the heme unit within a heme containing protein has been studied
extensively within cytochrome c. Heme C forms two thioether bonds between C3 and
C8 vinyl groups of heme and the cysteine residues of CXXCH motifs in the
apocytochrome c. Three systems driving this association have been studied extensively
(reviewed in77,78). System I/CCM (Cytochrome C Maturation) is most prevalent in α and
γ proteobacteria, all plant mitochondria, some protozoal mitochondria and red algae,
and typically involves nine assembly proteins including CcmA through CcmH79.
Although system II/CCS (Cytochrome C Synthesis) was originally studied in green algae
Chlamydomonas reinhardtii, it can also be found in chloroplasts, most Gram-positive
bacteria, cyanobacteria and some β, δ, and ε proteobacteria. Several of the
components in system II vary in different organisms but the major components include
CcsA, CcsB and CcsX. System III/CCHL (Cytochrome C Heme Lyase) is mostly
restricted to fungal, vertebrate and invertebrate mitochondria and some protozoal
mitochondria. This system employs a cytochrome c heme lyase enzyme, which is now
known as holocytochrome c synthase (HCCS)80 to convert apocytochrome c to
holocytochrome c. These three systems carry out a similar function: to keep both Fe in
heme and sulfur in cysteine residues of the apoproteins in the reduced state to facilitate
correct covalent attachment. Mechanisms of incorporation of additional heme types into
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different heme binding proteins can be quite diverse and species specific: hence their
discussion was eliminated from this review but is discussed in additional sources81-84.
1.3.5 Heme function
Heme proteins are ubiquitous in nature and perform a wide variety of functions.
One abundant class of heme proteins is the photosynthetic and respiratory
cytochromes. Other classes include globins, catalases, peroxidases, cytochrome
P450s, oxygenases and others. Here we discuss the versatile chemistry of the heme
unit in several categories of heme proteins.
Peroxidases use H2O2 to oxidize substrates without oxygen transfer. Their
catalytic cycle includes three steps: 1) H2O2 oxidizes Fe3+ and porphyrin to generate a
porphyrin π cation radical with water as a product; 2) oxidation of substrate reduces the
porphyrin π cation radical; and 3) a second substrate reduces Fe4+ to Fe3+ 85. Examples
from mammalian peroxidases include myeloperoxidase (MPO), eosinophil peroxidase
(EPO), and lactoperoxidase (LPO)86, and these enzymes can oxidize a wide variety of
substrates due to their high reduction potentials. The covalent vinyl sulfonium heme
linkage in heme M of MPO enables heme distortion and the resulting reduction in
electron density in the heme best explains the unusually high reduction potential of
MPO87. These peroxidases are capable of generating oxidants such as hypohalous
acids, hypothiocyanous acid, reactive nitrogen species, singlet oxygen, phenoxyl and
hydroxyl radicals, all which are key components in antimicrobial properties exerted by
the immune system86.
Cytochromes P450 represent another subgroup of heme proteins in high
abundance in nature; humans alone carry more than fifty P450 enzymes. These
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enzymes are mostly known for xenobiotics detoxification in liver, where drugs and other
xenobiotics are hydroxylated and made more soluble, facilitating their conversion to
easily eliminated products. In addition, P450s also participate in the biosynthesis of
steroids, highlighting their importance in metabolism.
Additional noteworthy heme enzymes include nitric oxide synthase (NOS) and
heme oxygenase (HO). NOS catalyzes the oxidation of L-arginine to L-citrulline and
nitric oxide (NO), a signaling molecule important for regulation of the cardiovascular and
nervous systems as well as participating in immune response. Heme oxygenase is
responsible for the degradation of free heme, resulting in its efficient elimination and the
recycling of iron85. The complete list of heme proteins is extensive and exceeds the
limits of this review. Instead, we will focus on human disorders that result from loss of
heme protein function, many of which are severe, and merit detailed discussion.
1.3.6 Diseases of heme synthesis
Several human diseases are associated with disruption of the heme biosynthetic
pathway. Many of these diseases are associated with inherited mutations in heme
biosynthesis genes, however some are caused by environmental factors affecting their
enzyme products. Along with nine major porphyrias, we will focus on diseases
associated with disruption of the heme biosynthesis pathway.
1.3.6.1 Porphyrias
The clinical presentation of porphyria includes skin lesions and acute
neurovisceral attacks which are related to the accumulation of specific intermediates in
the heme biosynthetic pathway. Nine such diseases have been identified and they are
categorized as hepatic or erythropoietic, pertaining to the organ in which the
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intermediates accumulate. However, a more clinical classification of porphyria divides
these into three groups: acute, cutaneous and rare recessive.
Even though no disease causing mutations for ALAS1 has ever been found in
humans, many mutations affecting the function of the ALAS2 isoform have been
identified. Although not commonly seen as loss of function mutations in the heme
biosynthesis pathway, gain of function deletions in ALAS2 are found to be causative of
a cutaneous porphyria called X-linked dominant erythropoietic protoporphyria (XLDPP).
This disease is characterized by increased ALAS2 activity and excessive protoporphyrin
production. ALA production is increased such that the final step catalyzed by
ferrochelatase is rate-limiting, resulting in the accumulation of protoporphyrin. Liver
damage and photosensitivity are the clinical manifestations of this disease88.
Deficiency of ALAD causes a rare recessive porphyria named ALAD porphyria,
for which only less than ten cases have been reported. In this autosomal disorder, loss
of ALAD activity in liver and erythroid precursors leads to excretion of ALA and
coproporphyrinogen III into the urine. Patients suffer from intermittent acute
neurovisceral attacks and/or chronic neuropathy, and onset of this disorder ranges from
childhood to adulthood89.
An additional disease related to the first steps in heme biosynthesis is acute
intermittent porphyria (AIP). As in all acute porphyrias, acute life-threatening
complications occur mostly in the adulthood, however in rare cases severe attacks can
occur in the childhood. Urinary excretion of ALA and porphobilinogen is increased due
to decreased PBGD activity. Activity loss is caused by mutations in the PBGD gene and
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over 200 mutations have been identified. This disorder is seen in homozygous
dominants for the trait and a majority of heterozygotes remain disease-free90.
Congenital erythropoietic porphyria (CEP) is another rare recessive type of
porphyria caused by the deficiency of UROS. This autosomal recessive disease that is
a result of loss of UROS function leads to the spontaneous formation of
uroporphyrinogen I, the isomer of uroporphyrinogen III that cannot be converted to
heme, so it is accumulated and excreted91. Clinical features of this disease include
chronic

hemolysis

and

cutaneous

photosensitivity

caused

by

diffusion

of

uroporphyrinogen I to plasma, and these conditions begin to manifest in early infancy.
There have been over twenty UROS mutations that cause this disease identified to
date92.
Porphyria cutanea tarda (PCT) is the most common porphyria and it falls under
the category of cutaneous porphyrias. This disease only shows symptoms in the skin,
including lesions in areas exposed to sun, skin fragility leading to secondary infections,
and hypertrichosis. Ocular pain and photophobia have also been reported rarely93. The
cause of these symptoms is accumulation of excessive porphyrin in the skin.
Tetrapyrroles are highly photoreactive and hence they absorb energy from the visible
region of electromagnetic spectrum. Excited ring structures reach ground state by
transferring

energy,

which

drives

peroxidation

and

oxidation

of

biological

macromolecules such as membrane lipids, nucleic acids and proteins. Familial PCT,
one of the two forms of PCT, is an autosomal dominant trait similar to AIP in that only a
minority of heterozygotes is affected. In familial PCT, uroporphyrinogen III is
accumulated and excreted in urine due to UROD mutations. Patients with sporadic
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PCT, although not associated with UROD mutations, show decreased UROD activity
and hepatic Fe overload, similar to that seen in familial PCT94. Hepatoerythropoietic
porphyria (HEP) is a rare porphyria associated with UROD deficiency. Symptoms are
similar to that seen in PCT (skin lesions, red urine, hypertrichosis and scarring) however
they can be much more severe. This rare recessive porphyria often onsets in infancy or
childhood and shows high porphyrin concentrations in erythrocytes and less than 10%
UROD activity95.
Hereditary coproporphyria (HCP), another acute porphyria, is caused by
mutations that destabilize the enzyme CPO. Clinical characteristics are very similar to
other acute porphyrias (i.e., AIP) and show a high coproporphyrinogen III content in
urine and feces, as well as increased photosensitivity. Also similar to other acute
porphyrias, HCP is mostly seen in dominant homozygotes for the trait, with only some
heterozygotes developing the disease96.
An additional porphyria caused by mutations in a heme biosynthesis enzyme
includes variegate porphyria (VP), characterized by dysfunctional PPO. Symptoms are
again very similar to any acute porphyria, showing acute neurovisceral attacks and
cutaneous photosensitivity. Onset of the symptoms is in adulthood and over 100 PPO
gene mutations (including nonsense, missense, deletion, insertion and splice mutations)
have been identified97. As in AIP, urinary excretion of ALA and porphobilinogen and
fecal content of protoporphyrinogen IX and coproporphyrinogen III is increased during
acute attacks. In addition, PPO activity is dramatically reduced (50%) in tissues of VP
patients98.
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The last of the nine porphyrias associated with heme synthesis is another
cutaneous porphyria named erythropoietic protoporphyria (EPP). Mutations in the
ferrochelatase gene cause a deficiency in mitochondria leading to accumulation of free
protoporphyrin IX, primarily in erythrocytes. Excess protoporphyrin IX is behind the
predominant clinical feature of photosensitivity, which begins in childhood99,100.
1.3.6.2 Additional diseases
Loss of function mutations of ALAS2 is the cause of the disorder X-linked
sideroblastic anemia (XLSA). A group of point mutations alter the protein’s ability to bind
the PLP cofactor, however other mutations affect protein domains outside the cofactorbinding region. The decrease in heme synthesis efficiency prevents normal erythroblast
development in the bone marrow. The resulting overload of iron results in characteristic
iron granules surrounding the nucleus (a sideroblast). This disease is characterized by
microcytic hyperchromic anemia, the presence of mature but pale and smaller than
normal erythrocytes and Fe overloaded mitochondria in erythroblasts in the bone
marrow101.
ALAD requires Zn for function, and Zn deficiency makes ALAD susceptible to Pb
inhibition. Pb replaces Zn in ALAD and the inhibited protein leads to high levels of ALA
in blood, which is responsible for neurological manifestations due to its toxicity at high
concentrations102.

A

similar

disease,

named

hepatorenal

tyrosinemia,

shows

neurotoxicity due to high ALA levels, with abnormal liver and kidney function. This
disease is caused by mutations in fumarylacetoacetate hydrolase gene, which
hydrolyzes fumarylacetoacetate to fumarate and acetoacetate during the tyrosine
catabolism pathway. In the event of enzyme deficiency, fumarylacetoacetate is
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metabolized to succinylacetone, which is structurally similar to ALA, hence it acts as a
potent inhibitor for ALAD103. Excess ALA and succinylacetone can be seen in patients’
urine and blood samples.
1.4 Fe-S clusters
1.4.1 Introduction
Iron-sulfur (Fe-S) clusters are the second major form of complex iron cofactors
found in biology. Due to the high abundance of iron and sulfur on the earth’s surface,
and the easy association of these atoms under anaerobic conditions, Fe-S clusters
likely developed early in evolution before the earth’s transition to an aerobic
atmosphere. Consequently, these cofactors are ubiquitous in all organisms and play a
role in almost every biological pathway. Here we provide an overview of the structure,
formation, and function of Fe-S cluster cofactors.
1.4.2 Fe-S cluster structure
In many ways, Fe-S clusters are simpler than heme. While heme is a mixture of
organic (protoporphyrin) and inorganic (iron) components, Fe-S clusters are strictly
inorganic. Iron atoms in biological Fe-S clusters interact directly with protein residues
and sulfur atoms bridge neighboring iron atoms. Fe-S clusters exist in a variety of
configurations depending on their respective number of iron and sulfur atoms. The three
most common forms (2Fe-2S, 3Fe-4S and 4Fe-4S) are illustrated in Figure 1.5. More
complex Fe-S clusters have also been observed, including the 7Fe-8S and 8Fe-8S
clusters identified in ferredoxins from Desulfovibrio africanus104.
The Fe atoms within the Fe-S cluster can exist in either ferric or ferrous forms
and cycling between these redox states allows the transfer of electrons for redox
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reactions. The tendency of the oxidized Fe-S cluster to gain an electron is termed the
“reduction potential”. By convention, this potential is expressed in comparison to a
reference standard hydrogen electrode, which is assigned a potential of 0V. Depending
on Fe-S cluster type, interactions with neighboring amino acids, and solvent
accessibility, a single Fe-S cluster can take up to two electrons with a reduction
potential spanning ~1000 mV105. This remarkable range of accessible reduction
potentials can largely explain the biological utility of the Fe-S cluster.
Fe-S clusters do not exist freely but are intimately connected to their apoprotein
partner. Free iron will form an insoluble complex when bound to sulfide, so the protein
plays a critical role in solubilizing the Fe-S unit. Fe-S proteins usually bind their
corresponding Fe-S cofactor via ionic interactions between cysteine thiols and iron in
the Fe-S cofactor. In some cases, Fe-S clusters are alternatively ligated via histidine
residues. Subsets of 2Fe2S clusters, such as those found in Rieske proteins (see
section 1.4.5), are coordinated by two cysteine and two histidines (Cys2His2)106 and a
common coordination theme of proteins involved in Fe-S cluster biogenesis is Cys3His1
coordination107.

28

Figure 1.5: Structure for the 3 most common forms of Fe-S Cluster: 2Fe-2S, 3Fe4S, and 4Fe-4S.
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1.4.3 General Fe-S cluster biogenesis pathway
Production of Fe-S clusters must be highly regulated to prevent unwanted
reactions of both free iron and sulfur. Similar to heme-proteins, Fe-S proteins are
synthesized in their apo-state and obtain their Fe-S cluster cofactor from a dedicated
Fe-S cluster formation pathway. At present, there are three known general pathways for
Fe-S cluster formation: the iron sulfur cluster (ISC), cytosolic iron sulfur assembly (CIA),
and sulfur assimilation (SUF) pathways. These three pathways provide Fe-S clusters for
the majority of Fe-S proteins in almost all organisms. While dedicated Fe-S cluster
forming pathways can exist for individual Fe-S proteins, such as the nitrogen fixation
(Nif) pathway that provides an Fe-S cluster for the nitrogenase enzyme in nitrogen-fixing
bacteria108, this review will focus only on the general Fe-S cluster production pathways.
1.4.3.1 Iron sulfur cluster (ISC) pathway
The most robust and best-characterized pathway for Fe-S cluster biosynthesis is
the iron sulfur cluster (ISC) pathway. A simplified description of this pathway is provided
in Figure 1.6. The ISC pathway, present in bacteria and in the mitochondria of
eukaryotes, provides general housekeeping Fe-S clusters to a large number of Fe-S
proteins. In eukaryotes, this pathway provides Fe-S clusters for several key
mitochondrial Fe-S proteins. ISC was initially identified in the Azotobacter vinelandii and
Escherichia coli bacterial species, where ISC genes are arranged in the isc operon.
Additional early work in eukaryotes (in Saccharomyces cerevisiae and human proteins)
revealed a highly homologous system localized to the mitochondria. In addition to
providing for mitochondrial Fe-S proteins, the ISC system provides a component to the
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cytosolic and nuclear Fe-S cluster formation pathways, thus ISC is essential for the
maturation of all cellular Fe-S proteins in eukaryotes109,110.
ISC serves as a template for understanding general Fe-S cluster production. In
human ISC, de novo 2Fe-2S synthesis occurs on the dedicated scaffold protein
ISCU111. Sulfur for this reaction is provided by ISC’s dedicated cysteine desulfurase
enzyme ISCS via a persulfide intermediate that gets transferred to ISCU112 upon
formation of an ISCU-ISCS complex. In eukaryotes, ISCS has a dedicated protein cofactor ISD11 that is essential for ISCS function113. Electrons for ISCS persulfide release
are provided by the 2Fe-2S cluster containing ferredoxin FDX, which in turn gets
reduced by the ferredoxin reductase FDXR that uses NADPH as its final electron
source114,115. FDX also interacts with ISCU, providing 2 reducing equivalents for
assimilation of two 2Fe-2S clusters on an ISCU dimer to form a single 4Fe-4S cluster111.
An additional Fe-binding protein Frataxin interacts with the ISCS-ISCU complex and
regulates ISCS activity116. Additionally, there are alternate scaffold proteins (ISCA117
and NFU1118) that interact with ISC proteins and these are believed to be required for
the maturation of a specific subset of Fe-S proteins.
Despite intense study, the physiologic source of iron for ISC remains a subject of
debate. Several potential iron donors have been investigated and iron delivery to ISCU
has been demonstrated from several potential sources in vitro within a variety of
systems. The protein frataxin119,120 interacts with the ISCU-ISCS complex and could be
the source of iron for the pathway120. In the bacterial system, two additional members of
the isc operon have been investigated as potential iron donors, IscX and IscA. The
small acidic protein IscX binds iron and regulates cysteine desulfurase activity in a
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manner very similar to Frataxin121. The alternative scaffold IscA is also an interesting
candidate because of its tight (KD~1019) binding affinity for mononuclear iron122 and its
capability of delivering iron to IscU123,124. An additional interesting hypothesis is that iron
may come from a glutathione-glutaredoxin complex125. The lack of conclusive evidence
for a specific iron source suggests that in vivo, there could be multiple iron sources or
that the mode of iron delivery may be atypical.
A detailed mechanism for Fe-S cluster delivery from ISCU to downstream targets
is currently under investigation. The Fe-S cluster bound to ISCU is transferred to the
glutaredoxin GLRX5126,127. Efficient transfer from ISCU to GLRX5 requires involvement
of the ATPase SSQ1, which binds to both ISCU and GLRX5128. Binding of SSQ1 to
ISCU, along with the interaction of a DnaJ-like co-chaperone JAC1129, destabilizes the
Fe-S cluster on ISCU facilitating its transfer from ISCU to GLRX5130. GLRX5 is
considered the end of the ISC pathway because it is the last common Fe-S cluster
carrier for all mitochondrial Fe-S proteins. GLRX5 continues the cluster transfer
process, however, and it is able to interact with a variety of downstream Fe-S
proteins131-133. The specific recipient depends on the ultimate destination of the Fe-S
cluster. For example, 4Fe-4S cluster conversion and delivery is facilitated by GLRX5’s
interaction with two other Fe-S proteins, ISCA and IBA57134.
Despite being mostly localized to mitochondria135, ISC is required for maturation
of all cellular Fe-S proteins110. The mechanism by which cytosolic Fe-S proteins depend
on mitochondrial ISC is actively being investigated. Because Fe-S clusters are not able
to cross the mitochondrial inner membrane136, this mechanism likely involves the
transport of an Fe-S cluster precursor out of the mitochondria and into the cytosol.
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Recent work has identified an unknown compound produced by mitochondrial ISCS
(named ‘X-S’) that may provide reduced sulfur for cytosolic Fe-S cluster formation137.
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Figure 1.6: Diagram depicting de novo Fe-S cluster formation and the main Fe-S
cluster transfer steps in the ISC, SUF, and CIA systems. Protein names used are
from the human system for ISC and CIA, and from the bacterial system for SUF.
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1.4.3.2 Cytosolic iron sulfur assembly (CIA) pathway
Recent studies have revealed the involvement of another essential and highly
conserved Fe-S biosynthetic pathway that is present within the cytosol and nucleus of
eukaryotes. This pathway is called cytosolic iron-sulfur assembly (CIA)138. This pathway
has been identified in many eukaryotic systems and is essential in almost all cases139.
CIA is unique among Fe-S maturation pathways in that it does not obtain reduced sulfur
via a dedicated cysteine desulfurase. A simplified description of the CIA pathway is
provided in Figure 1.6. Instead of an ISCS analog, CIA relies on mitochondrial export of
a sulfur-containing compound, ‘X-S’, via the mitochondrial export protein ABCB7140 and
the intermembrane space protein ALR141. The identity of X-S is currently unknown, but
may be glutathione-complexed to an Fe-S cluster139. In human CIA, the primary scaffold
for de novo Fe-S assembly is a tetrameric complex formed between CFD1 and NBP35,
which binds a bridging 4Fe-4S cluster between the CFD1 and NBP35 subunits142.
Reducing equivalents for this reaction are provided by an Fe-S containing protein
CIAPIN1 (similar to FDX in ISC), which in turn gets reduced by the diflavin reductase
NDOR1 (similar to FDXR in ISC), utilizing reducing equivalents from NADPH143,144.
The 4Fe-4S clusters from the NBP35-CFD1 complex get transferred to another
Fe-S protein IOP1, which binds two 4Fe-4S clusters per monomer145,146. IOP1, in turn,
delivers its Fe-S clusters to a multi-component complex called the CIA targeting
complex, which consists of at least three proteins CIA1, CIA2B, and MMS19147. The CIA
targeting complex is able to interact with a variety of recipient Fe-S proteins, likely an
indication of its function in downstream Fe-S cluster delivery.
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1.4.3.3 Sulfur assimilation (SUF) pathway
Of the three Fe-S general cluster formation pathways, the sulfur assimilation
(SUF) pathway is probably the most ancient. SUF predominantly exists in prokaryotes,
however it is found in specific locations in eukarya, including the chloroplasts in some
plants148 and the apicoplasts in some plasmodium species149, and recently proteins
homologous to bacterial SUF were discovered in the cytosol of a blastocystis
species150. At present, SUF has been best characterized in the Gram-negative bacteria
Escherichia coli and Erwynia chrysanthemi where its genes are organized into the suf
operon (Figure 1.7).
The SUF pathway is similar to ISC in many ways. Like in ISC, SUF provides
general Fe-S cluster formation to accommodate a variety of Fe-S proteins. In fact, SUF
and ISC seem to be redundant in Gram-negative bacteria, as the removal of the entire
isc or suf operon results in no deleterious effects. Simultaneous suf/isc operon deletion,
however, is lethal151. While ISC and SUF follow the same general mechanism for Fe-S
cluster formation (Figure 1.6), SUF seems to be favored under conditions of oxidative
stress and iron limitation152 and the SUF proteins are correspondingly more stable
under adverse conditions in vitro153. In E. coli, the SUF pathway centers around two
heteromeric complexes called SufBC and SufSE.
The primary scaffold SufB requires a binding partner SufC for activity, forming
the SufBC complex in a SufB2C2 arrangement. The SufBC complex can form a 4Fe-4S
cluster on SufB that can be transferred to recipient proteins154. The exact role of SufC in
this process is unknown, but it has ATPase activity that is essential for Fe-S cluster
formation on SufB155. SufB, on its own is relatively unstable and prone to spontaneous
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oligomerization. There is also a paralogue of SufB, named SufD that is able to replace a
SufB in the SufBC complex, resulting in the SufBCD complex156. However, SufBC is
likely the most active form157. The SUF cysteine desulfurase SufS functions in a similar
manner to ISCS, accepting sulfur from cysteine via a persulfide intermediate. SufS has
an essential binding partner SufE, which is required for activity, forming the SufSE
complex158. While it may seem SufE is similar to ISD11 from eukaryotic ISC, SufE
functions differently from ISD11 in that it accepts the persulfide from SufS and allows
the SufS enzyme to complete its turnover159.
Details of SUF’s downstream cluster delivery are not as well established as in the
ISC pathway. The 4Fe-4S cluster formed by SufBC can be transferred to the A-type
carrier protein SufA in vitro154,157, but SufBC also may be able to transfer directly to
recipient apo-proteins. In vivo, SufA is functionally redundant with the ISCA bacterial
homologue160 and possibly acts as an intermediate carrier of the 4Fe-4S cluster from
SufB, passing it off to downstream apoproteins161,162. Another protein involved in this
process (ErpA) has redundant function with SufA but is necessary for the development
of active Fe-S proteins163.
Several important details of the SUF pathway remain to be identified. As in ISC,
the in vivo source of iron is unknown. Also of interest is SufD’s incorporation in the
SufBCD complex, which allows SufB to accept iron in vivo155 and facilitates binding of a
FADH2 cofactor156. This cofactor may be able to reduce ferric iron, facilitating potential
Fe3+ sources such as ferritins or ferric citrate164. While SufA can deliver mononuclear
iron to SufBC in vitro123, it is currently believed to function downstream of de novo Fe-S
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formation (Figure 1.6). The source of electrons for SufS turnover and for Fe-S formation
remains in question3.
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Figure 1.7: Illustration of suf and isc operons, with corresponding promoters (Pisc
and Psuf), which play a central role in regulation of SUF and ISC at the genetic
level in bacteria. Operons depicted are from the E. coli model system. Steps are
colored based on the encoded protein’s function as follows: red (regulatory), yellow
(sulfur delivery), green (primary scaffold), blue (downstream Fe-S cluster delivery), cyan
(electron transfer), and gray (unknown).
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1.4.4 Fe-S cluster biogenesis regulation
The best-developed model for Fe-S biogenesis pathway regulation comes from
work done in Gram-negative bacterial systems, where both the ISC and SUF pathways
are present. This work reveals a fascinating interplay between ISC and SUF, where the
necessary ISC and SUF genes are organized into their respective isc and suf operons
(Figure 1.7). While this review has focused on eukaryotic systems, regulatory
mechanisms in bacteria may provide insight into how this regulation occurs in
eukaryotes. At the center of E. coli Fe-S cluster biogenesis regulation is a DNA-binding
protein IscR, the first member of the isc operon, which directly regulates both the ISC
and SUF systems.
Under non-stressed conditions, ISC is favored over SUF for general
housekeeping of Fe-S cluster biosynthesis165. The transcriptional regulator IscR can
bind a 2Fe-2S cluster (forming holo-IscR), obtaining its Fe-S cluster from the same ISC
machinery utilized by other Fe-S proteins166. In the holo configuration, IscR binds to the
isc promoter and prevents binding of RNA polymerase167. Thus, holo-IscR acts as a
feedback regulator, inhibiting transcription of the entire isc operon when ISC activity is
sufficient168. IscR is a relatively poor substrate for ISC-mediated Fe-S cluster loading169
and holo-IscR can only form after the ISC proteins have exhausted their interactions
with other apo-Fe-S proteins. In addition to being a weak ISC substrate, IscR does not
bind its Fe-S cluster tightly and effectively acts as a sensor of cellular iron and oxygen
conditions170. Under high-oxygen or low-iron conditions, holo-IscR quickly reverts to
apo-IscR. Therefore under typical aerobic conditions, high oxygen levels cause holo-
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IscR to revert to apo-IscR. Apo-IscR dissociates from the isc promoter and isc is
uninhibited.
In the apo configuration, IscR does not bind to the isc promoter but instead
favors binding to the suf promoter, activating transcription of SUF genes171. Appropriate
interaction of apo-IscR with the suf promoter involves two additional transcription
factors: the ferric uptake regulator (Fur) and the peroxide responsive regulator (OxyR).
Suf expression is constitutively repressed by Fur, which binds Fe2+ under non-stressed
conditions when iron levels are sufficient and oxidative stress is low. With its Fe2+
cofactor, Fur binds to the suf promoter at the same site as apo-IscR, inhibiting suf
expression172. When the cell faces iron deficiency, Fur loses its iron cofactor,
dissociates from the suf promoter, thus triggering transcription of suf. The cell’s
preference for SUF over ISC in the presence of oxidative stress also reveals the
involvement of another transcription factor (OxyR), as oxidized OxyR recruits RNA
polymerase to the suf promoter.
There are additional regulatory mechanisms for cluster bioassembly beyond the
level of gene expression. The small non-coding RNA RyhB, for example, is encoded
just upstream of the SUF promoter and can bind to the iscRSUA mRNA to prevents its
translation173. RyhB expression, however, is constitutively repressed by Fur-Fe2+, so
RyhB effectively inhibits ISC when conditions favor SUF174.
1.4.5 Fe-S cluster function
Fe-S clusters are versatile biological cofactors found in the most fundamental
biochemical pathways, including aconitase and succinate dehydrogenase of the citric
acid cycle and respiratory complexes I-III of the electron transport chain135. Nuclear Fe-
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S proteins also have a unique role in DNA damage recognition and repair. Several
forms of DNA polymerase, helicase, glycosylase, and primase all contain Fe-S
clusters139. Considering their remarkable range of functions, a thorough summary of
various Fe-S proteins is well beyond the limited scope of this review. New Fe-S proteins
continue to be discovered but in many cases, the role of the Fe-S cluster within the FeS protein remains unknown, even if the cluster’s presence is essential for proper protein
function.
Fe-S clusters can be found in the active site of many essential enzymes and
usually are involved directly in catalysis. Being stable in a variety of redox states, Fe-S
clusters are best known for their role as electron carriers. Fe-S clusters can carry
usually one, but sometimes two electrons and are, subsequently, stable in various
reduced states. 2Fe-2S clusters, for example, can exist in oxidized (Fe3+/Fe3+) or
reduced

(Fe3+/Fe2+)

(Fe3+/Fe3+/Fe3+/Fe2+),

forms

while

intermediate

4Fe-4S

clusters

are

(Fe3+/Fe3+/Fe2+/Fe2+),

stable
and

in

oxidized
reduced

(Fe3+/Fe2+/Fe2+/Fe2+) forms175. The reduction potential of an Fe-S cluster is often
modulated by interactions with nearest neighbor protein residues and by access to
solvent, allowing for a large range of biological functions. Ferredoxins are considered
the archetypical Fe-S cluster electron carriers and were the earliest Fe-S proteins to be
functionally characterized176. Ferredoxins are involved in many essential biochemical
pathways, transferring electrons for cellular respiration, photosynthesis, and nitrogen
fixation177. A ferredoxin is even involved in the ISC iron sulfur cluster biogenesis
pathway, as discussed previously (see section 3.3.1)178.
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But Fe-S cluster-mediated electron transfer is not limited to ferredoxins. In fact,
one of the most the fundamental electron transfer processes, the electron transport
chain (ETC), utilizes numerous Fe-S clusters. Respiratory complexes I, II, and III of the
ETC all contain Fe-S clusters. Respiratory complex I uses a network of 8 Fe-S clusters
for step-wise electron transfer179. Similarly, complex II contains an Fe-S protein
component called SDHB with a 2Fe-2S, 3Fe-4S, and 4Fe-4S cluster180. Lastly, complex
III utilizes a unique Fe-S cluster called a “Rieske center”181. The Rieske center is a 2Fe2S cluster where one of the iron atoms is coordinated by histidines instead of cysteines,
resulting in a Cys2His2 coordination182.
Fe-S clusters can also be involved in non-redox reactions. The 4Fe-4S cluster in
aconitase, for example, catalyzes a hydration-dehydration reaction, ligating directly to
the citrate substrate183. In some cases, Fe-S clusters appear to only serve a structural
function and not participate in chemistry directly, as is the case in endonuclease III184.
1.4.6 Fe-S clusters in human disease
Unlike in Gram-negative bacteria, where ISC/SUF redundancy allows for removal
of an entire pathway, in humans the absence or mutation of a single component is often
incompatible with life. In select cases there are human diseases that have been linked
to defective Fe-S cluster biogenesis pathways. Below we describe several diseases
directly linked to dysfunctional Fe-S cluster formation.
1.4.6.1 Friedreich’s ataxia
With an incidence of 1 in 50,000185,186, and a carrier prevalence of 1 in 100187,
Friedreich’s ataxia (FRDA) is by far the most prevalent disease linked to defective Fe-S
cluster formation. FRDA is an autosomal recessive genetic disease caused by a GAA-
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trinucleotide repeat expansion in an intron of the frataxin gene, a protein involved in the
ISC pathway188. This trinucleotide repeat expansion leads to under-expression of the
frataxin gene and subsequently, low levels of frataxin189. These insufficient frataxin
levels are responsible for the pathophysiology of FRDA, but the precise role of frataxin
is still unknown190. Frataxin may deliver iron to the ISC pathway191, be an allosteric
activator of the ISCU-ISCS complex116, or may have a combination of roles. FRDA
tissues demonstrate increased mitochondrial iron deposits192 which leads to increased
oxidative stress and cell death in metabolically active tissues such as cardiomyocytes
and neurons of the dorsal root ganglia. FRDA presents early in adolescence with
progressive ataxia, or difficulty coordinating movement, sensory loss, weakness, and
dysarthria. FRDA patients are usually wheelchair bound in their teens with a
significantly reduced quality of life and life expectancy193. Median age of survival is 35
years with cardiac dysfunction usually being the cause of death194.
1.4.6.2 ISCU myopathy
ISCU myopathy (IM) is an additional condition related to a defect in Fe-S cluster
biogenesis. It is the 2nd most common disorder linked to defective Fe-S cluster synthesis
but is much less common than FRDA with only 25 known cases. To date, all patients
identified with IM have come from families of Swedish ancestry135. Similar to FRDA, the
IM phenotype is inherited in an autosomal recessive pattern. IM is caused by a splicing
defect during ISCU post-transcriptional processing that leads to defective ISCU
protein195,196. Loss of ISCU leads to lower ISC activity and a resulting deficiency of
essential Fe-S proteins, including succinate dehydrogenase and aconitase of the citric
acid cycle197. Symptoms are exacerbated in cells that are metabolically active, such as
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the myocytes of skeletal muscle during exercise, and patients with IM experience
exercise intolerance198. Prolonged activity can lead to tachycardia, tachypnea, and
muscle pain199. Unlike FRDA, IM is not progressive and most cases have a normal life
expectancy.
1.4.6.3 GLRX5 sideroblastic anemia
GLRX5 Sideroblastic Anemia (GSA), a disease caused by mutated GLRX5, has
only been identified in a single patient to date. While GSA is exceedingly rare, this
particular case study has revealed a unique mechanism linking Fe-S cluster production
to general iron homeostasis66,200. GLRX5, involved in the last step of the ISC pathway,
directs Fe-S cluster delivery from ISCU to downstream targets. One target is the ironresponsive protein IRP1, an Fe-S protein activated when its Fe-S cluster is absent200.
Defective GLRX5, therefore, leads to constitutively active IRP1. IRP1 regulates several
proteins involved in iron homeostasis201, including those involved in heme production. In
particular, apo-IRP1 inhibits expression of the final enzyme in heme synthesis,
aminolevulinate synthase (ALAS2). Defective GLRX5, therefore, leads to insufficient
heme and impaired erythropoiesis, resulting in anemia. Iron that would be directed
towards heme production accumulates in the cytosol of erythroblasts, creating the
characteristic ringed-sideroblasts3.
1.4.6.4 Additional diseases
Succinate Dehydrogenase (SDH) subunit B, the Fe-S cluster containing protein
of the succinate dehydrogenase complex, is a known tumor suppressor. Succinate, the
substrate for SDH, stabilizes hypoxia-inducible factor (HIF), which regulates key
processes in cell division and blood vessel growth under hypoxic conditions. Mutations
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in SDHB or in fact any of the other main subunits of SDH (SDHA, SDHC, and SDHD)
cause
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to
in

tumor
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formations
disorder
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paragangliomas

Hereditary

or

Paraganglioma-

Pheochromocytoma202, stemming from the accumulation of succinate and stabilization
of HIF. SDHAF2, an assembly protein that flavinates SDH, is also implicated in
paragangliomas. Recently, two additional Fe-S assembly proteins, SDHAF1 and
SDHAF3, were found to stabilize Fe-S cluster assembly in SDH203. The later two
proteins have LYR-motifs (Leu-Tyr-Arg) common to proteins involved in Fe-S cluster
assembly. SDHAF1 deficiency is known to cause leukoencephalopathy204.
Lastly, mutations in either NFU1 or BOLA3, two different genes involved in Fe-S
cluster biogenesis, leads to multiple mitochondrial dysfunction syndrome, a condition
characterized by defects in Complexes I, II, and III and pyruvate/a-ketoglutarate
dehydrogenases. NFU1 is thought to be an alternative to ISCU as a scaffold for Fe-S
assembly. Both BOLA3 and NFU1 appear to be involved in lipoate synthesis, possibly
related to a role in assembling Fe-S clusters in lipoic acid synthase (LIAS), thus
providing an explanation for the reduced PDH and a-KGDH activities characteristic of
this

syndrome.
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impaired

energy

production
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encephalopathy205 and early death.
1.5 Summary
The utilization of complex Fe cofactors in biology requires a tightly controlled
process of cofactor assembly and of delivery to the correct apoprotein partner.
Numerous ailments, some of which outlined within this review, result when there is a
breakdown in the assembly process or in delivery of the cofactor. The development of
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treatment strategies for these disorders will require a more advanced molecular
understanding of each protein malfunction outlined above. Therefore cooperation of
bioinorganic chemists with the cell biologists alike will be essential to provide the
broader understanding of how these complex pathways harness the power of iron in
complex cofactors within the biological milieu.
1.6 Acknowledgements
DPB was supported under an NIH Cardiovascular Training grant (T32
HL120822). SPD was supported by a American Heart Association/Friedreich’s Ataxia
Research Alliance pre-doctoral fellowship (14PRE18830036), and recently by the NIH
(F30 DK101230). TLS is supported by the NIH (R01-DK068139 and R01-GM107542).

47
CHAPTER 2
COOPERATIVITY BETWEEN CYSTEINE DESULFURASE “NFS1” AND ITS
ACCESSORY PROTEIN “ISD11” PROMOTES STABILITY AND ACTIVITY OF THE
YEAST PROTEIN COMPLEX
2.0 Prelude
During eukaryotic de novo Fe-S cluster biogenesis within mitochondria, the Nfs1Isd11 protein pair serves as the functional cysteine desulfurase complex. Isd11 does
not have any prokaryotic orthologs, and was reported to have an activation function on
the eukaryotic Nfs1. Lack of association between them leads to deficient sulfur
mobilization in vivo, reduced Fe-S protein levels and retarded cell growth. However,
molecular and atomic level understanding of how complexation occurs, and how Isd11
exerts its effect is still lacking. This chapter describes the work I have done to provide
comprehensive molecular level information on the Nfs1-Isd11 structure and function.
The subunit composition and molecular weight of the complex was elucidated as a part
of biophysical characterization. Extensive thermal stability imparted by Isd11 on the
Nfs1 was discovered as a significant factor in activating Nfs1 within Fe-S cluster
assembly while substrate binding affinity was only minimally affected by Isd11. Taken
together these results provide comprehensive knowledge on the level of cooperativity
between yeast Nfs1 and Isd11. This work is being prepared for publication at the
moment and will be referred as: Barupala, D. P., Murugesan, Y., Dancis, A., Pain, D., &
Stemmler, T. L. (2016). “Cooperativity between cysteine desulfurase Nfs1 and its
accessory protein Isd11 promotes stability and activity of the yeast protein complex”.
Biochemistry.”
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2.1 Abstract
The versatility of oxidation states in Fe-S clusters is a key reason for their
extensive prevalence in biology, serving as electron reaction centers in several
functionally indispensable proteins. Due to their essential nature, it is not surprising that
Fe-S cluster synthesis is so carefully controlled by a dedicated set of proteins that work
in an orchestrated manner. Cluster synthesis and proteins that utilize these cofactors
have been studied extensively. During Fe-S cluster biosynthesis, cysteine desulfurases
function as the sulfur source and they operate by enzymatically obtaining sulfane sulfur
from L-cysteine and subsequently delivering it to the assembly scaffold protein via
transfer of a persulfide intermediate. In yeast, the function of the cysteine desulfurase
“Nfs1” is supported by an accessory protein “Isd11”. Although several functional studies
support the physiological activity of Nfs1 and Isd11 working as a complex, less attention
has been given on studying the molecular properties of this complex and also on
elucidating the biophysical basis of their activity. Here we report that the isolated Nfs1Isd11 complex posses higher thermal stability as a protein complex, and that an Isd11
induced conformational change on Nfs1 is the key to this profound stabilization. We find
that the Nfs1-Isd11 complex has a millimolar affinity towards its substrate L-cysteine,
and that the substrate binding is facilitated by a conformational change on Nfs1.
Combined with previously published data, these molecular details assist in helping us
understand the role of the Nfs1-Isd11 complex and its role in Fe-S cluster synthesis.
2.2 Introduction
Fe-S clusters are found ubiquitously in nature and their function is indispensable
within almost every cell. As the second most prominent iron cofactor (after heme), Fe-S
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clusters play a role in nearly every cellular pathway2. Their utility is centered on their
capability to direct redox chemistry by transferring electrons in a modulated manner.
Key factors that allow for their varied activity is their unique protein bound architecture
and their evolutionarily adapted coordination environment, which are optimized for their
individual activity. Fe-S clusters can fluctuate between oxidized (Fe3+ based) and
reduced (Fe2+ based) states and contain a wide distribution of iron and sulfur
stoichiometries (different types of clusters include 2Fe-2S, 3Fe-4S, 4Fe-4S, etc.). Their
redox versatility, coupled with their structural diversity, allows these clusters to drive
several distinctive chemical processes, including mitochondrial respiration (complexes I,
II, and III), gene regulation (SoxR) and product catalysis (radical SAM enzymes)3. Given
the importance of these clusters in all of biology, it is not surprising that their
bioassembly is tightly regulated, a process that is highly conserved between
prokaryotes and eukaryotes.
In all cells, Fe-S cluster assembly is driven by a dedicated set of proteins that
function in a coordinated manner to produce the iron containing cofactor. In eukaryotes,
cluster assembly is performed by two major pathways: 1) the iron sulfur cluster (ISC)
pathway, which operates within the mitochondria, and 2) the cytosolic iron sulfur
assembly (CIA) pathway, which operates within the cytosol but is dependent on sulfur
from the ISC3,109,110. The eukaryotic ISC pathway provides Fe-S clusters to meet most
of the cellular demand, and proteins within this pathway are generally conserved
between eukaryotes and prokaryotes. In Saccharomyces cerevisiae, 2Fe-2S clusters
are assembled within the mitochondria de novo on Isu1, the assembly scaffold protein,
using sulfur provided by the cysteine desulfurase Nfs1 working together with its
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accessory protein Isd113. Electrons are provided by the ferredoxin Yah1 which is
recharged in an NADPH driven manner by the ferredoxin reductase Arh1126. While the
iron source for the process is unclear, yeast frataxin homolog Yfh1 has been shown to
serve as an iron chaperone in vitro as well as serving as a regulator of Nfs1 activity3,206208

. Assembly of Fe-S clusters is accomplished through the coordinated assembly

activity of these proteins, and downstream cluster delivery and utilization proteins drive
the targeted transfer of these clusters to recipient proteins3,209. During cluster assembly
however, the protein complex constructed in yeast of Isu1, Nfs1, Isd11, Yah1 and Yfh1
accomplish Fe cofactor biosynthesis with assistance from additional proteins including
the acyl carrier protein (ACP)210; exact details of how these proteins work together to
accomplish product formation are however lacking. Deficiency of activity in even a
single protein within this complex has a disastrous effect on cell (and in the case of
humans, patient) viability.
Several diseases states related to insufficient Fe-S cluster synthesis have been
identified, however the neurodegenerative disorder Friedreich’s ataxia (FRDA) is the
archetypal disease. GAA- triplet repeat expansions of variable length found in the first
intron of the human frataxin (FXN) gene lead to a stark reduction in protein levels, and
this is at the heart of the disorder. Frataxin deficiency gives rise to mitochondrial iron
deposits, a reduction in Fe-S cluster bioassembly, and reduced activity for Fe-S
containing proteins. FRDA patients suffer from progressive spinocerebellar and sensory
ataxia with hypertrophic cardiomyopathy as well as an increased risk of developing
diabetes211. While diseases associated with deficits in the other ISC proteins, including
the human cysteine desulfurase (NFS1) and its binding partner (ISD11) are rare, NFS1
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deficiency and a compromised NFS1-ISD11 complex are suspected to cause infantile
mitochondrial II/III deficiency, which is an autosomal recessive disorder characterized
by lactic acidemia, hypotonia, and a deficiency in respiratory complex II and III212. A
mutation in the LYRM4 gene encoding for ISD11 in humans causes combined oxidative
phosphorylation deficiency (COXPD), a disease that impairs activity of respiratory
complexes I, II, and III213. As a result, ISD11 is unable to form a stable complex with
NFS1214. These severe human deficiencies related to reduced activity of the ISC
proteins underscore the point that understanding the molecular activity of these proteins
is fundamental for understanding the pathophysiology and biochemistry underlying
crucial events in these disease states. This molecular and atomic level characterization
of two of the yeast ISC proteins, Nfs1 and Isd11, is the goal of this study.
In cells, cysteine desulfurase provides sulfur for Fe-S cluster assembly by
liberating sulfide from L-cysteine in a pyridoxal 5’-phosphate (PLP) assisted manner.
Cysteine desulfurases generally exist as homodimers215,216. Eukaryotic cysteine
desulfurases require the accessory protein Isd11 for activity, however interestingly
Isd11 is absent in prokaryotes113,217. The reaction mechanism of cysteine desulfurase
was first elucidated using the bacterial NifS ortholog from Azotobacter vinelandii218,219.
Characterization studies on the yeast Nfs1 protein solidified this enzyme’s role in iron
homeostasis220 and Fe-S cluster assembly221. Unfortunately, structural details for the
eukaryotic enzyme, and an understanding of how it interacts with its Isd11 accessory
protein, are lacking. Structural studies on this topic have had a reliance on modeling of
the Nfs1 architecture from using the bacterial orthologs222,223. While the exact function of
Isd11 is unknown, yeast Isd11 was shown to promote persulfide formation on Nfs1 by
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bringing the bound substrate in close proximity to the Nfs1 active site cysteine
residue116,224.
In order to provide a molecular and atomic level understanding of how the Nfs1Isd11 complex is formed, and to provide a basis for understanding the effect of Isd11 on
Nfs1 activity, we isolated yeast Nfs1 and Isd11, both individually and as a co-expressed
Nfs1-Isd11 complex. The optimal Isd11 to Nfs1 protein stoichiometry related to complex
activity was characterized. The thermal stability that Isd11 imparts on Nfs1 during
complex formation is shown to be a contributing factor in Nfs1 activity related to Fe-S
cluster formation. An Isd11 induced conformational change on Nfs1 produces a
profound stabilization effect of the enzyme that leads to activity. Finally, the affinity of
the substrate L-cysteine for the Nfs1-Isd11 complex is only moderately altered by Isd11
binding. Combined, these studies paint a picture for how Nfs1 and Isd11 work together
to produce and deliver the sulfur required for Fe-S cluster biosynthesis within the
eukaryotic ISC pathway.
2.3 Materials and methods
2.3.1 Expression of yeast Fe-S cluster synthesis proteins
Nfs1(and C421A)-Isd11 co-expression: The pST39 co-expression vector
containing Δ1-33 Nfs1-6xHis-Isd11 or Δ1-36 Nfs1(C421A)-6xHis-Isd11 was transformed
into BL21 (DE3) cells. In both these constructs Nfs1 lacks the mitochondrial targeting
sequence but Isd11 remains full length. Starter cultures were made by inoculating a
transformed colony in Luria Bertani (LB) broth supplemented with 100 µg/ml ampicillin;
These cultures were incubated in a rotating shaker for 16 hours (overnight) at 230 rpm
and 37 °C. Starting OD of the growth cultures (1 L) supplemented with 100 µg/ml
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ampicillin were set to 0.075 by adding the appropriate amount of starter culture and the
cells were grown until cell density reached 0.4 OD600. Growth temperature was then
switched to 18 °C and cells were induced at 0.7 OD600 using 0.8 mM IPTG
supplemented with 10 µM PLP. Cells grew for 18 hours before harvesting by
centrifugation at 7900 x g for 30 min.
Nfs1 expression: The pET21b vector containing Δ1-33 Nfs1-6xHis was
transformed into BL21 (DE3) codon plus cells. Starter cultures and growth cultures were
treated exactly as mentioned above except they were supplemented with 34 µg/ml
chloramphenicol in addition to 100 µg/ml ampicillin. Cells were grown at 37 °C in LB
broth (1 L) until cell density reached 0.4-0.5 OD600. Growth temperature was then
switched to 25 °C and cells were induced at 0.7 OD600 with of 1 mM IPTG,
supplemented with 10 µM PLP. Cells were continued to grow at 25 °C for 3 hours
before harvesting by centrifugation.
Isd11 Expression: Expression and purification of Isd11-6xHis followed the
protocol that was previously published225. Briefly the pET21b vector containing Isd116xHis tag was transformed into BL21 (DE3) codon plus cells. A starter culture was
made by inoculating a transformed colony in LB broth, supplemented with 100 µg/ml
ampicillin and 34 µg/ml chloramphenicol and it was incubated in a rotating shaker for 16
hours (overnight) at 200 rpm and 37 °C. Growth cultures (200 ml) were also
supplemented with 100 µg/ml ampicillin and 34 µg/ml chloramphenicol and the starter
culture was diluted in LB to a 1:40 ratio. Cells were grown at 37 °C in LB broth until cell
density reached 0.7-0.8 OD600 and then these samples were induced with 0.5 mM
IPTG. Cells were grown at 37 °C for 3 hours before harvesting by centrifugation.
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2.3.2 Purification of yeast Fe-S cluster synthesis proteins
Purification of Nfs1 and Nfs1(and C421A)-Isd11 Complexes: Frozen cell pellets
were resuspended in pH 7.5 lysis buffer containing 50 mM Sodium Phosphate, 150 mM
NaCl for Nfs1(and C421A)-Isd11 complexes/300 mM NaCl for Nfs1 alone, 5% Glycerol,
20 mM Imidazole, and 5 mM β–ME (4 ml/g of cells). In addition, cOmplete™ EDTA-free
protease inhibitor cocktail (Roche), lysozyme (10 mg/ml), and DNase (10 µg/ml)
supplemented with 5 mM MgCl2 were also included in the lysis buffer. Protein
purification was performed at 4 °C. Cell suspensions were incubated at 4 °C for 30 min
while stirring at a slow pace before passing through the Emulsiflex cell homogenizer
three times for cell lysing. Cell lysate was then centrifuged at 53300 x g for 1 hour.
Crude soluble fraction was filtered (0.20 µm) before passing through His-Trap HP 5 ml
Ni column (GE Healthcare) using an AKTA FPLC chromatography system (Amersham
Biosciences/GE Healthcare); Nfs1 or Nfs1(C421A)-Isd11 was passed through high
density Nickel Agarose Beads (GoldBio) manually packed in a bench-top column. Ni
columns were first washed with 20 column volumes of binding buffer to eliminate any
residual unbound proteins. Bound proteins were then eluted by flowing an imidazole
gradient of 20-500 mM across the columns and fractions containing Nfs1 or Nfs1(and
C421A)-Isd11 complexes were identified using SDS-PAGE. Active fractions were
pooled and concentrated to ~ 1 ml using 10 kDa molecular weight cutoff Amicon
centrifugal filter devices (Millipore). All proteins were incubated with excess PLP to
ensure 100 % loading of PLP to all Nfs1 units. Concentrated protein(s) was passed
through a Superdex 200 size exclusion column to further remove impurities and to
transfer to the final buffer at pH 7.5 comprised of 20 mM HEPES and 5mM β–ME plus
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150 mM NaCl for the Nfs1(and C421A)-Isd11 complexes and 300 mM NaCl for Nfs1
alone. Fractions containing Nfs1 or Nfs1(and C421A)-Isd11 complexes were pooled and
concentrated to store at -80 °C in aliquots until further use for experiments. These
purification protocols yielded >95% pure proteins (Figure 1).
Purification of Isd11: The majority of overexpressed Isd11 was found in bacterial
inclusion bodies. Cell pellets were resuspended in a buffer containing 50 mM Tris HCl
(pH 8.0), and 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were lysed by passing
through the Emulsiflex cell homogenizer three times followed by six rounds of sonication
(20 s each round and 2 min intervals). The lysate was spun at 53300 x g for 30 min and
crude soluble fraction was removed. Pellet containing insoluble Isd11 was dissolved
with a buffer at containing 50 mM Tris HCl (pH 8.0), 8M urea, and 1 mM PMSF, and the
resulting suspension was spun at 65000 x g at 20 °C for 30 min. Supernatant was
mixed with a His-select Ni affinity gel (Sigma P6611), pre-washed with water and 50
mM Tris HCl (pH 8.0) with 1 mM PMSF buffer, for 1 hour at room temperature on a
rocking platform to allow end-to-end mixing. After removing unbound protein, the resin
was further washed with a 50 mM Tris HCl (pH 8.0) and 1 mM PMSF binding buffer to
eliminate any residual unbound protein. Bound protein was then eluted using an elution
buffer containing 50 mM Tris HCl (pH 8.0), 8M urea, 400 mM imidazole, and 1 mM
PMSF. Fractions containing denatured Isd11 identified using SDS-PAGE were pooled
and stored at room temperature until further use. This purification protocol yielded
approximately completely pure protein (see Figure 1).
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2.3.3 Protein size and stoichiometry characterization
Size exclusion chromatography: Concentrated and purified proteins were passed
again through Superdex 200 (120 ml column bed volume) column using AKTA FPLC
system (GE Healthcare) to identify the molecular size and oligomeric states of
protein(s). The Superdex 200 column was pre-equilibrated with 20 mM HEPES, 300
mM NaCl, and 5 mM β-ME running buffer at pH 7.5, and concentrated protein at a 1 ml
volume was injected onto the column. The separation flow rate at 4 °C was set at 0.5
ml/min. BioRad gel filtration standards containing Thyroglobulin (670 kDa), γ-globulin
(158 kDa), Ovalbumin (44 kDa), Myoglobin (17 kDa), and Vitamin B12 (1.35 kDa) were
passed across the column in the same manner to calibrate the molecular size of the
target proteins.
Gel densitometry: Gel densitometric analysis was used to identify the relative
oligomeric stoichiometry of protein samples. Purified Nfs1-Isd11 complex was subjected
to denaturing SDS-PAGE to separate Nfs1 and Isd11 based on their molecular weight.
Several samples of Nfs1-Isd11 complex were run across multiple lanes to reduce
uncertainty in the measurement. Each lane carried a total of 2-5 µg of protein, as
measured by Direct Detect Infrared Spectrometer for protein quantification. After
staining/destaining, gels were imaged using Bio-Rad Gel Doc EZ Imaging System and
analyzed using Bio-Rad Image Lab software. Bio-Rad gel imaging system provides a
tool to measure the volume of a protein band, and then calculates the sum of all
intensities within the band boundaries. The band % is the calculated percentage of a
particular band’s volume compared to the total of all band volumes in a lane, and this
measurement was used to calculate the ratio between Nfs1 and Isd11. Gel signals
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corresponding to Nfs1 and Isd11 was divided by the expected molecular weight of the
respective protein to calculate the molar band % and the ratio between molar band %
values from Nfs1 and Isd11 (per Nfs1 monomer) provided the stoichiometry of Nfs1 and
Isd11 in the protein complex. Stoichiometry between Nfs1 and Isd11 in the Nfs1-Isd11
complex obtained here was then compared to the size of the protein complex obtained
from size exclusion chromatography.
2.3.4 Biophysical properties of proteins
Differential scanning calorimetry: The thermal stability of Nfs1 and Nfs1(and
C421A)-Isd11 complexes was assessed using differential scanning calorimetry (DSC).
Purified and concentrated proteins were diluted to 2-3 mg/ml, using 20 mM HEPES, 300
mM NaCl, 5 mM β-ME at pH 7.5 buffer degassed to remove dissolved air. Protein
samples were loaded in the sample cell of a TA Instruments Nano-DSC calorimeter; the
reference cell was filled with matched buffer. The total volume for the capillary cell is 0.3
ml, however an excess of solution (~0.6 ml) is used for loading to prevent trapping air
bubbles. Both capillary cells were manually pressurized to maintain a constant pressure
of 3 atm during the scan. Each protein sample was scanned at a rate of 1 °C/min from
10 °C to 90 °C and the melting curves for Nfs1 and Nfs1-Isd11 were compared to
assess differences in thermal stability resulting in complex formation. In addition,
melting curves for Nfs1-Isd11 and Nfs1(C421A)-Isd11 were compared to assess any
difference in thermal stability between wild type and mutant protein complexes.
Experiments were done in duplicate on independently isolated proteins to ensure data
reproducibility. The thermal profiles were simulated using the TA instruments
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NanoAnalyze software package to identify the best-fit values for melting temperatures
(Tm).
ANS fluorescence spectroscopy: Fluorescence spectroscopy was used to
identify protein structural changes due to complexation and substrate binding. Binding
with 1,8-Anilinonaphthalenesulfonate (ANS), a fluorophore which selectively binds to
solvent exposed hydrophobic regions in molten globule proteins226, was used to
determine structural differences between Nfs1 and Nfs1-Isd11. ANS binding
experiments were carried out using 40 µM samples of either purified Nfs1 or Nfs1-Isd11
diluted in 20 mM HEPES, 300 mM NaCl, and 5 mM β-ME at pH 7.5. All buffers were
initially degassed to remove dissolved air. Samples were incubated for 10 min after
addition of 50 µM ANS. The ANS probe was excited at 371 nm and the fluorescence
emission spectra were measured using a Horiba Scientific Spectrofluorometer at 5 nm
intervals with 1 s spectral integration time and 1 mm slit width. A fluorescence cuvette
(Starna), with 1 ml capacity and 1 cm path length was used to collect fluorescence
emission spectra at 25 °C. Spectra were collected in triplicate using different protein
preparations

to

ensure

spectral

reproducibility.

Similarly

ANS

fluorescence

measurements were used to assess the changes in protein fold upon addition of Lcysteine to Nfs1(C421A)-Isd11. Duplicated 20 µM Nfs1(C421A)-Isd11 samples in 20
mM HEPES and 300 mM NaCl buffer at pH 7.5 were incubated with 20 equivalents of Lcysteine for 10 min and then with 50 µM ANS for another 10 min before acquisition of
spectra using same experimental parameters as above.
Tryptophan fluorescence spectroscopy: Tryptophan fluorescence spectroscopy
was used to measure structural changes in Nfs1(C421A)-Isd11 that occur upon binding
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of substrate L-cysteine. Freshly made L-cysteine was titrated consecutively to 20 µM
Nfs1(C421A)-Isd11 in 20 mM HEPES and 300 mM NaCl buffer at pH 7.5. Protein
samples were carefully mixed and incubated for 10 min after each addition of Lcysteine; emission spectra were measured at 25 °C following excitation of the samples
at 300 nm as above. Each addition was timed 1 min after the start of spectra acquisition
to maintain consistency between data points. All spectra were corrected for dilution.
Experiments were performed in duplicate using independently prepared protein samples
to ensure spectral reproducibility. The change in fluorescence intensity at 340 nm was
plotted against respective L-cysteine concentrations to calculate the binding affinity of
Nfs1(C421A)-Isd11 to L-cysteine. Best-fit simulation to data was obtained using the
DynaFit curve fitting software227.
2.3.5 Functional properties of proteins
UV-visible spectroscopy: UV-visible spectroscopy was used to measure the
affinity of Nfs1(C421A)-Isd11 to its substrate L-cysteine. In this experiment, 50 µM
purified Nfs1(C421A)-Isd11 in 20 mM HEPES and 300 mM NaCl at pH 7.5 was titrated
consecutively with freshly made L-cysteine. Protein samples were carefully mixed and
incubated for 10 min after each addition of L-cysteine; spectra were measured at a 1.0
nm scan pitch using Shimadzu UV-1800 Spectrophotometer. Each addition was timed 1
min after the start of spectra acquisition to maintain consistency between data points.
All spectra were collected at 25 °C under anaerobic conditions and corrected for
dilution. Experiments were performed in duplicate using independently prepared protein
samples to ensure spectral reproducibility. The change in spectral intensity at 340 nm
was plotted against respective L-cysteine concentrations to calculate the binding affinity
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of Nfs1(C421A)-Isd11 to L-cysteine. Best-fit simulation to data was obtained using
DynaFit curve fitting software227.
Cysteine desulfurase activity assay: An acid labile sulfide detection assay was
performed to calculate the Michaelis-Menten kinetics parameters for the Nfs1-Isd11
complex. In this assay, Fe3+ with sulfide liberated from the enzyme aids the conversion
of N, N-dimethyl-p-phenylenediamine sulfate (DPD) to methylene blue. Its characteristic
visible absorption feature at ~750 nm is used to quantify sulfide production with the use
of a calibration curve. Nfs1-Isd11 complex was incubated with a series of L-cysteine
concentrations ranging from 100 µM to 2 mM. Each reaction was handled separately to
maintain accuracy of timing and measurements. Assay mixture contained 100 mM
HEPES (pH 7.5), 150 mM MaCl, 50 µM PLP, 12 µM purified Nfs1-Isd11 and distilled
water and the total reaction volume was 100 µl. Each reaction was prepared by first
mixing the assay components together in an eppendorf tube covered with rubber septa
(Sigma-Aldrich-Z565717) to prevent air escaping. Respective L-cysteine amounts were
then introduced to each tube using a gas-tight Hamilton syringe. After a 5 min
incubation at 30 °C, the reaction was stalled by adding 100 µl of 20 mM DPD in 7.2 N
HCl and 30 mM FeCl3 in 1.2 N HCl also using gas-tight Hamilton syringes and each
addition was timed 45 s apart to maintain the consistency between each reaction.
Distilled water was added up to 800 µl. Each tube was then vortexed for 10 s before
incubating for 20 min at 30 °C for efficient color development. All tubes were spun at
14000 x g for 2 min to remove protein precipitation before measuring the absorbance at
750 nm using a 1 ml cuvette with Varian Cary-50 Bio UV-Visible Spectrophotometer.
The amount of persulfide liberated at each concentration was determined using a
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standard plot constructed using known Na2S concentrations. Measurements were
corrected for dilution and the initial rate of reaction (µM/min) was plotted against Lcysteine concentration (µM) to calculate enzyme kinetics parameters.
2.3.6 Structural studies of Nfs1
Homology modeling: Homology modeling was used as a tool to model the threedimensional structure of Nfs1. Published X-ray crystal structure of bacterial IscS (PDB:
1P3W) was used as the input model for the SWISS-MODEL workspace228
(https://swissmodel.expasy.org) provided by the SIB ExPASy Bioinformatics Resource
Portal. Modeled Nfs1 structure was viewed using the PyMOL Molecular Graphics
System (Version 1.8.2.2 Schrödinger, LLC) to inspect the overall structure and identify
the residue configuration of the active site.
2.4 Results
2.4.1 Co-expression of Nfs1 with Isd11 leads to stable complex formation
The solution stability of Nfs1 in complex with Isd11 is enhanced relative to pure
homogeneous protein.

Purified Nfs1-Isd11 complex exhibited a characteristic neon

yellow color indicative of PLP bound to the cysteine desulfurase. This complex was
soluble at 4 °C for 2-3 days at salt conditions as low as 150 mM. In contrast, Nfs1 and
Isd11 purified separately have poor solubility following isolation, as was previously
observed with other eukaryotic proteins229,230. When expressed in E. coli individually,
Isd11 is predominately contained within inclusion bodies. Isd11 could be resolubilized
using 8 M urea, and the protein could be purified in its denatured form (Figure 2.1).
However, as expected, Isd11 precipitated upon removal of urea below 2 M
concentrations (data not shown)231. Similarly, in a previous study, Isd11 purified from a
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soluble fraction of bacterial lysate aggregated and formed a polydisperse mixture of
oligomers in the absence of Nfs1231,232. When overexpressed alone, Nfs1 exhibited the
characteristic neon yellow color highlighted above.

The protein was comparatively

soluble, in contrast to Isd11 alone, and it could be purified from soluble fractions from
the bacterial cell lysate. It was, however, extremely important to maintain high salt
concentrations (300 mM NaCl) and low temperatures (< 20 °C) to keep Nfs1 in a
soluble unaggregated state. It was previously reported that Nfs1, from yeast
mitochondria, is prone to aggregation in the absence of its binding partner
Isd11113,233,234. These results are consistent with Isd11 coordination to cysteine
desulfurase contributing to the solubility and stability of the enzyme, which helps both
proteins maintain solubility.
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Figure 2.1: SDS-PAGE gel of purified proteins. Lanes represent 1: molecular weight
marker, 2: purified yeast Nfs1-Isd11 complex, 3: Nfs1, and 4: Isd11. Nfs1-Isd11 and
Nfs1 are present in non-denaturing media whereas Isd11 is present in 8 M urea.
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2.4.2 Molecular weight and protein stoichiometry of the Nfs1-Isd11 complex
Co-expressed Nfs1-Isd11 provided a stable protein complex that could easily be
characterized for overall size and protein stoichiometry. Purified Nfs1 and Isd11
migrated individually at ~50 kDa and ~12 kDa, respectively, on an SDS-PAGE gel
(Figure 2.1). These results are consistent with the predicted molecular weights of the
proteins derived from gene sequences, at 52,196.2 Da and 12331.1 Da for Nfs1-6xHis
and Isd11-6xHis, respectively. Nfs1 expressed alone appears to run mostly between
158,000 Da (γ-globulin) and 44,000 Da (Ovalbumin) (Figure 2.2, Line B), as judged by
size exclusion chromatography. The predicted molecular weight for a Nfs1 homodimer
from the gene sequence is 104,392.4 Da, consistent with the bulk of the protein
migrating as a homodimer. This is not unique since a homodimer has been seen for
other cysteine desulfurases216. A larger molecular weight species at > 600,000 Da is
also seen in our data, suggesting Nfs1 alone is prone to higher order oligomerization.
The Nfs1-Isd11 complex peak overlaps at a size of ca. 158,000 Da, as judged by size
exclusion chromatography (Figure 2.2, Line A).
Gel densitometric analysis of the Nfs1-Isd11 complex revealed a ratio of Nfs1 to
Isd11 of 1:2 (Figure 2.3). Since cysteine desulfurase runs as a stable dimer (as judged
by the size exclusion chromatography listed above), the Nfs1-Isd11 complex would be
consistent with 2 Nfs1 molecules and 4 Isd11 molecules producing the composite
protein complex structure. The predicted total molecular weight for this combination,
obtained from gene sequence data, adds up to 149,456.4 Da, which is close within error
bars of the technique, to the molecular weight deduced from this complex at 158,000
kDa from size exclusion chromatography. This combination is also in close agreement
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with results obtained from the human proteins, which also suggest a NFS1:ISD11
stoichiometry of 1:2213,229. Murine proteins have shown a ternary complex with NFS1ISD11-ISCU at a 1:2:1 ratio, and a quaternary complex with NFS1-ISD11-ISCU-FXN in
1:2:1:1 ratio235, again in close agreement with results from our yeast Nfs1-Isd11
complex, and from our Nfs1-Isd11-Isu1-Yfh1 multiprotein complex recently reported
(Stephen Dzul (2016) “Insights into de novo Fe-S cluster biogenesis via the eukaryotic
Fe-S cluster pathway (ISC) in vitro”, PhD dissertation). In combination, these results are
consistent with yeast Nfs1 existing as a stable homodimer, and it associates with four
Isd11 monomers to form a Nfs12-Isd114 protein complex when co-expressed.
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Figure 2.2: Size exclusion chromatograms of purified Nfs1 and Nfs1-Isd11
complex compared to the gel filtration standard proteins. Solid, dotted, and dashed
lines represent chromatograms for 1) gel filtration standard proteins, 2) Nfs1-Isd11
complex, and 3) Nfs1 expressed alone, respectively. Lines A and B indicate that Nfs1Isd11 and Nfs1 oligomeric structures correspond to molecular weights of ~150 kDa and
~100 kDa, respectively. Gel filtration standard proteins include 1: Thyroglobulin
(670,000 Da), 2: γ-globulin (158,000 Da), 3: Ovalbumin (44,000 Da), 4: Myoglobin
(17,000 Da), and 5: Vitamin B12 (1,350 Da). *Nfs1-Isd11 and Nfs1 chromatograms also
include additional peaks that correspond to higher order oligomeric forms of Nfs1-Isd11
and Nfs1, which elute at a smaller retention volume. Nfs1-Isd11 and Nfs1
chromatograms are offset for clarity.
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Figure 2.3: Gel densitometric analysis of the Nfs1-Isd11 complex. Molar band
volume is equivalent to percentage band volume (quantified using the Bio-Rad Image
Lab software) divided by expected molecular weight of each protein in the complex. The
ratio between molar band volumes corresponds to the ratio between Nfs1 and Isd11 in
the complex.
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2.4.3 Stabilization energetics of the Nfs1-Isd11 complex
Thermodynamic factors that impact the stability of the Nfs1-Isd11 complex have
also been characterized in detail within this report. Comparisons of energetic profiles
using Differential Scanning Calorimetry (DSC) revealed the Nfs1-Isd11 complex
possesses a thermal stability much greater than Nfs1 alone. An average melting
temperature for Nfs1 was measured to be 40.70 ± 0.24 °C (Figure 2.4). The raw melting
data for the molecule by itself was best simulated using two individual denaturation
events, possibly pertaining to the unfolding of two individual domains. In contrast, the
average melting profile from the Nfs1-Isd11 complex was 61.75 ± 0.05 °C, indicating a
thermal stability of over ~20 °C higher for the assembled complex compared to Nfs1
alone (Figure 2.4). Interestingly, the raw melting data for the Nfs1-Isd11 complex was
best simulated using three individual denaturation events, the additional peak likely
pertaining to the unfolding of Isd11 (Table 2.1). Our results are in good agreement with
the observation that the two proteins within the complex are more stable when coexpressed. Due to the limited solubility, we were unable to reach concentrations
required to measure the thermal stability of Isd11 alone. However, it can be concluded
from our data that complexation causes an enhancement in the thermal stability of the
Nfs1 enzyme.
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Figure 2.4: Differential Scanning Calorimetric thermal profiles for purified Nfs1
and the Nfs1-Isd11 complex. Solid black and dotted gray lines represent sum of bestfit simulations and raw data respectively. Dotted black lines represent simulated peaks
corresponding to domains and/or individual unfolding events in each structure. Melting
temperatures for simulated peaks are depicted in Table 2.1. The thermal profile for
Nfs1-Isd11 is offset for clarity.
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Table 2.1: Melting temperatures (°C) for each domain/unfolding event obtained
from Differential Scanning Calorimetry data for Nfs1 and Nfs1-Isd11.

Domain/unfolding event Melting Temperature (°C)
Nfs1
1

39.05 ± 0.6

2

41.95 ± 0.2
Nfs1-Isd11

1

56.9 ± 0.8

2

60.25 ± 0.4

3

62.05 ± 0.4
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2.4.4 Nfs1-Isd11 complex is more folded than Nfs1 itself
Structural changes that occur upon protein complexation may contribute to the
higher thermal stability seen for the Nfs1-Isd11 complex. ANS fluorescence
spectroscopy was used to test the hypothesis that Isd11 imparts stability on Nfs1 by
inducing a conformational change on the protein that allows Nfs1 to adopt a more
stable, more compact fold. This experiment, performed with Isd11 bound to Nfs1,
showed that the ANS fluorescence signal for the Nfs1-Isd11 complex is quenched by
35.0 ± 7.0 %, as compared to the signal from Nfs1 (Figure 2.5). Signal quenching can
be attributed to Isd11 displacing the ANS binding surface, or structural changes in local
environment of the ANS binding site(s). A previous study using Circular Dichroism (CD)
and Tryptophan fluorescence spectroscopies suggested that the Nfs1-Isd11 complex
has substantially rearranged structural elements as opposed to Nfs1231. Therefore ANS
fluorescence results would be consistent with Isd11 inducing a conformational change
on Nfs1, maybe pushing the protein to rearrange its structure profoundly and adopt a
compact fold.
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Figure 2.5: ANS fluorescence spectra for purified Nfs1 and for the Nfs1-Isd11
complex. Solid and dashed lines represent Nfs1 and Nfs1-Isd11, respectively.
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2.4.5 Yeast Nfs1-Isd11 binds the substrate L-cysteine with millimolar affinity
Due to the presence of bound pyridoxal-5’-phosphate cofactor, UV-visible
spectra of purified Nfs1 and Nfs1-Isd11 complex contain a characteristic PLP spectral
feature at 420 nm215. This feature is attributed to the protonated internal aldimine
formed between PLP and the yeast Nfs1 Lysine residue (K299) at the enzyme’s
substrate-binding site. Upon addition of the substrate L-cysteine, intensity of this feature
diminishes while a new spectral feature appears at ~340 nm218,236. This new feature is
attributed to the L-cysteine-PLP ketimine adduct that will undergo a nucleophilic attack
from a catalytic cysteine residue (C421) to form a persulfide intermediate231,237.
Because these spectral features represent reaction intermediates before and after
substrate binding, both are useful to determine substrate binding kinetics for the Nfs1Isd11 complex. However, as observed, these features are also sensitive to persulfide
formation on the protein238,239 and therefore they do not correlate directly to substrate
binding. To isolate the spectral changes associated only with L-cysteine binding on
Nfs1-Isd11, we developed a mutant Nfs1-Isd11 complex carrying C421A mutation in
Nfs1. The Nfs1(C421A)-Isd11 complex is incapable of making the nucleophilic attack;
hence the reaction is anticipated to stall after substrate binding with no acidic labile
sulfide being formed (Figure S2.3). We verified by CD spectroscopy and DSC that the
Nfs1(C421A)-Isd11 complex is not significantly different in secondary structure and
stability as compared to the wild type complex (Figures S2.1 and S2.2, Table S2.1). A
quantitative titration of L-cysteine into the Nfs1(C421A)-Isd11 sample was monitored at
340 nm (Figure 2.6-A) to measure ketimine intermediate formation. These data
indicated a substrate binding affinity (or Kd) of 0.76 ± 0.14 mM (Figure 2.6-B). A similar
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affinity, with a Kd in the millimolar range, has been reported for several bacterial
cysteine desulfurases219,237.
2.4.6 Nfs1-Isd11 is a moderately efficient enzyme
Michaelis-Menten kinetics was calculated to determine the catalytic efficiency of
the Nfs1-Isd11 complex following an acid labile sulfide detection assay. Under these
assay conditions, the Nfs1-Isd11 complex exhibited Michaelis-Menten kinetics with a
Michaelis constant (KM) of 0.49 ± 0.07 mM for L-cysteine, a kcat of 13.1 ± 0.4 min-1, and
a catalytic efficiency (kcat/KM) of 456 ± 263 M-1s-1 (Figure 2.7). The calculated Michaelis
constant (KM) for yeast Nfs1-Isd11 complex was in close agreement with published KM
values of 0.34 mM and 0.43 mM for human system207,230. However, the reported KM
value for the bacterial cysteine desulfurase IscS (an enzyme that is functional in the
absence of Isd11) is approximately a hundred fold lesser (KM = 0.0027 mM) than the
values reported for eukaryotic homologs112. On the other hand catalytic efficiency (kcat/
KM) follows the trend of a gradual decrease from E. coli IscS (~52,000 M-1s-1)112 to yeast
Nfs1-Isd11 complex (~460 M-1s-1; our result) to human NFS1-ISD11 (~100 M-1s-1)207.
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Figure 2.6: Titration of L-cysteine to Nfs1(C421A)-Isd11 monitored by UV-visible
spectroscopy. A: Consecutive spectra were collected after each addition of L-cysteine.
Lines represent the following concentrations: bold solid: 0 mM, bold dashed: 0.010 mM,
bold dotted: 0.035 mM, bold dash-dot: 0.084 mM, bold dash-dash-dot-dot: 0.183 mM,
thin solid: 0.430 mM, thin dashed: 0.919 mM, thin dotted: 1.901 mM, thin dash-dot:
4.346 mM, thin dash-dash-dot-dot: 9.200 mM. Arrows indicate the direction of change of
spectral features upon consecutive addition of L-cysteine. B: Plot shows the change in
absorbance at 340 nm as a function of L-cysteine concentration. Solid black line
indicates the best-fit simulation obtained using DynaFit curve fitting software.
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Figure 2.7: Rate of persulfide formation by Nfs1-Isd11 complex shown as a
function of L-cysteine concentration. Solid black line indicates the best-fit curve.
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2.4.7 Nfs1-Isd11 complex undergoes a conformational change during L-cysteine
binding
We have modeled the structure of Nfs1 to help provide a structural
understanding of our results. Since three-dimensional structures of an eukaryotic
cysteine desulfurase is not yet available, the published X-ray crystal structure of the
bacterial cysteine desulfurase served as primary references for modeling the yeast
structure. IscS, the cysteine desulfurase within ISC pathway of E. coli, exhibits the
highest sequence identity to Nfs1; the two ortholog sequences share a 57% sequence
identity and a 74% sequence similarity. We therefore selected the E. coli IscS223
structure as the template to model the Nfs1 structure. Sequence alignments between E.
coli IscS and yeast Nfs1 shows an overhanging group of 98 amino acids at the Nterminal region of yeast Nfs1 (Figure 2.8-A). The first 33 amino acids of this yeast
specific region is the mitochondrial targeting sequence (MTS) that facilitates import of
the Nfs1 precursor protein into the mitochondria220. This sequence gets cleaved by the
mitochondrial processing peptidase (MPP) following import240. Three additional amino
acids are removed from the nascent yeast N-terminus by the Icp55 peptidase to
produce the mature Nfs1 molecule240. The first 62 amino acids of mature mitochondrial
Nfs1 does not overlap with IscS, and the function of this overhang region is still
unknown, and this region could not be modeled. Of the region of sequence overlap, the
modeled Nfs1 homodimer was shown to be very similar to the E. coli IscS structure. The
yeast structure retained most secondary structural elements of IscS (Figure 2.8-B)
during the modeling. Each substrate-binding site (including the PLP cofactor binding
site) incorporates residues from both monomers, and PLP could be modeled as being
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attached to the K299 residue on each monomer via formation of an internal aldimine
(Figure 2.8-C). The location of the substrate-binding site in the modeled structure is
found buried beneath the dimer interface, suggesting the requirement of a
conformational change on Nfs1 in order to bind L-cysteine in this pocket. The distance
between catalytic cysteine residue C421 and PLP is over 15 Å, as calculated from the
β-SH group of C421 to the aldehyde group on C4 of PLP. In the current state, this
distance would be too far for a successful nucleophilic attack from the thiol group of 421
to the Cys-ketimine PLP adduct to occur. Therefore, a second conformational change
on Nfs1 would also be required to bring the catalytic C421 to the substrate-binding site
to promote persulfide formation.
ANS was used to attempt to detect any change in Nfs1 fold upon substrate
binding. The ANS fluorescence signal for Nfs1(C421A)-Isd11 was monitored after
addition of L-cysteine. As previously outlined, Nfs1(C421A)-Isd11 allows us to isolate
the substrate-binding step from persulfide formation step, and to monitor structural
perturbations caused only by L-cysteine binding on the enzyme, albeit in a perturbed
(mutant) state. Following substrate addition, the fluorescence signal of Nfs1(C421A)Isd11 was only quenched by 8.9 ± 0.8 % when L-cysteine was added, however the
emission maxima was shifted from 480 nm to 470 nm (Figure 2.9-A). A blue shift in the
fluorescence indicates the polarity of the ANS binding environment on Nfs1(C421A)Isd11 decreased upon substrate binding. This result would be consistent with L-cysteine
binding to Nfs1(C421A)-Isd11 as a result of a protein conformational change.
Tryptophan

fluorescence

spectroscopy

was

also

used

to

monitor

a

conformational change on Nfs1 resulting from substrate binding. Each Nfs1 monomer
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contains three tryptophan residues that emit an intrinsic fluorescence signal, while Isd11
does not contain a tryptophan. As a result, changes in tryptophan fluorescence during
this experiment reflect changes in the tryptophan local environment within Nfs1. The
tryptophan fluorescence signal for Nfs1(C421A)-Isd11 simultaneously reduced during
the continuous L-cysteine titration. Consecutive addition of L-cysteine to Nfs1(C421A)Isd11 resulted in a quench in fluorescence intensity at 340 nm (Figure 2.9-B). A best-fit
curve for changes in the fluorescence intensity vs. L-cysteine concentration yielded a Kd
of 0.46 ± 0.08 mM, in close agreement with the Kd value we determined using UVvisible spectroscopy for substrate binding. This further confirms that the overall change
in tryptophan fluorescence was due to a conformational change in Nfs1 caused by
substrate binding. With this result it could be concluded that a change in protein fold
facilitates L-cysteine binding to Nfs1-Isd11.
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Figure 2.8: Homology modeling of Nfs1. A: Clustal Omega alignment between yeast
Nfs1 and E. coli IscS sequences. Asterisks represent, 1: MPP cleavage site, 2: Icp55
cleavage site, 3: PLP binding Lys299 residue, and 4: catalytic Cys421 residue. B: Nfs1
homodimer model based on IscS x-ray crystal structure (PDB: 1P3W). Small domain
and large domain of each monomer are shown in magenta and yellow, respectively. C:
Substrate/PLP binding region of Nfs1 homodimer. Residues constituting the
substrate/PLP binding site are depicted as surfaces to emphasize the pocket nature of
the site. PLP bound to the site is shown in magenta and K299 residue which forms a
Schiff base with PLP is shown in yellow. Residues from the two dimers are colored in
cyan and green. The catalytic C421 residue is shown in red.
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Figure 2.9: Change in ANS and tryptophan fluorescence intensities of
Nfs1(C421A)-Isd11 upon addition of L-cysteine. A: Change in ANS fluorescence of
Nfs1(C421A)-Isd11 after addition of 20 equivalents of L-cysteine. Solid and dashed
lines represent spectra before and after addition of substrate, respectively. B: Titration
of L-cysteine to Nfs1(C421A)-Isd11 monitored with tryptophan fluorescence signal.
Lines represent the following concentrations: bold solid: 0 mM, bold dashed: 0.010 mM,
bold dotted: 0.035 mM, bold dash-dot: 0.084 mM, bold dash-dash-dot-dot: 0.183 mM,
thin solid: 0.430 mM, thin dashed: 0.919 mM, thin dotted: 1.901 mM, thin dash-dot:
4.346 mM, thin dash-dash-dot-dot: 9.200 mM. Solid downward arrow indicates the
direction of change of spectral feature at 340 nm upon consecutive addition of Lcysteine.
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2.5 Discussion
Given the indispensable roles of Fe-S clusters in biology, it is no wonder the
activity of proteins driving the assembly process are so highly synchronized and very
tightly regulated. While every protein within the ISC apparatus works together in an
orchestrated manner to drive Fe-S cluster assembly, it is the biophysical characteristics
of each molecule that dictates their unique role in the process. Therefore, real insight in
the bioassembly process can be gained by studying each molecule separately, followed
by investigating how the proteins interact and work together to accomplish the final goal
of Fe-S cofactor production. This report explores, in great detail, two of the four ISC
proteins from the yeast system (Nfs1 and Isd11) to understand their role in generating
the activated sulfur (via the persulfide) that is utilized during Fe-S cluster formation.
Since Isd11 is essential only in eukaryotic Fe-S cluster assembly, having an atomic
level understanding of Isd11 and Nfs1 alone provides fundamentals for revealing the
coordination details that promote activation of the protein complex from the inert starting
materials. Our goal in this report was to elucidate how cooperativity between yeast Nfs1
and Isd11 allows these proteins to work together to provide the sulfur substrate required
for Fe-S cluster assembly within the ISC pathway.
Details related to the Nfs1-Isd11 complex obtained from this study provide an
enhanced understanding of how the cysteine desulfurase reaction is accomplished
when these proteins are coordinated, in contrast to being in their inactive homogeneous
states. Here we present a molecular picture of the yeast Nfs1-Isd11 where the individual
units alone are thermodynamically unstable, however when combined they form a
complex that is highly soluble. Within this Nfs1-Isd11complex, Nfs1 exists as a
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homodimer while coordinating with 2 Isd11 molecules per Nfs1 monomer in a
quaternary structure of (Nfs1-Isd112)2 when combined. This quaternary structure is
similar in stoichiometry to that reported in other eukaryotic systems213,229,235, and in the
Nfs1-Isd11 subunit structure of our co-expressed Nfs1/Isd11/Isu1/Yfh1 complex [Dzul
(2016) et al. Metallomics (in press)]. Our results do not match the observation by Terali
et al.231 suggesting a Nfs1:Isd11 ratio of 1:1 and a quaternary structure of a (Nfs1Isd11)3 heterohexamer, possibly due to differences in overexpression characteristics,
subtle differences in our protein amino acid constructs, or slight variations in solution
conditions between the studies. It is interesting that this stoichiometry is preserved
when we co-express yeast Nfs1-Isd11 with Isu1 and Yfh1. This Nfs1/Isd11/Isu1/Yfh1
complex shows relatively high cysteine desulfurase activity (~6 fold higher than Nfs1Isd11 alone) and high correlated Fe-S cluster assembly activity ((~3 fold higher than
Nfs1-Isd11 alone). With the observation of Nfs1 and Isd11 aggregating in the absence
of complexation, it was apparent that these two proteins have a mutual stabilization
effect on each other and thermal stabilities of Nfs1 and Nfs1-Isd11 complex assessed
using DSC confirmed this fact. Over 40 % of the residues for both Nfs1 and Isd11 are
hydrophobic, which is probably linked to the inherent insoluble nature of these two
proteins by themselves. Since complexation relieves any insolubility it is reasonable to
hypothesize that Isd11 may bind via hydrophobic interactions to minimize solvent
exposure of hydrophobic patches on both Nfs1 and Isd11. This notion is further
confirmed by ANS fluorescence spectroscopy, which shows exclusion of ANS from
binding to Nfs1 during complexation with Isd11. It is possible that the entire complex
becomes tightly folded encapsulating the hydrophobic regions within the inner core,
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making ANS inaccessible to the complex. Reported CD and Tryptophan fluorescence
data also suggested substantial structural rearrangement during complexation providing
additional proof for this hypothesis231. Therefore it is clear that association between
Nfs1 and Isd11 provides mutual stabilization and a soluble complex.
UV-visible spectroscopy is the best method to measure substrate-binding affinity
of the Nfs1-Isd11 complex. As a consequence of the PLP cofactor being bound to Nfs1,
reaction intermediates formed upon substrate binding created distinct spectral features
that could be used to determine substrate-binding kinetics as the reaction progresses as
previously reported218,237,239,241. Upon L-cysteine addition to Nfs1-Isd11, an absorption
feature at 420 nm diminished while a new feature gradually appeared at 340 nm
representing a mixture of reaction intermediates (i.e. internal aldimine and persulfide)
rather than a single intermediate. The Nfs1(C421A)-Isd11 mutant complex allowed
monitoring of spectral changes associated only with substrate binding. In addition, this
mutant confirmed the spectral feature at 340 nm only represents L-cysteine-PLP
ketimine adduct, the product directly consequential to substrate addition. Our Kd for
Nfs1(C421A)-Isd11 complex was consistent with the affinities reported for bacterial
cysteine desulfurases219,237. Given the pronounced differences between prokaryotes
and eukaryotes (i.e., the presence of Isd11), it can be suggested that Isd11 has minimal
effect on substrate binding on eukaryotic Nfs1. A previous study reported that Isd11
only took part in persulfide formation step and had no contribution towards substrate
binding in the Nfs1-Isd11116. Therefore Isd11’s role in the eukaryotic cysteine
desulfurase complex is not directly linked to substrate binding to Nfs1.
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Characterization of the kinetics of the yeast cysteine desulfurase enzyme is
essential in order to assess activity parameters affected by the evolution of cysteine
desulfurases from bacteria to humans. The most used assay to study cysteine
desulfurase activity is a colorimetric detection system that quantifies the acid labile
sulfide produced during catalysis242,218. This assay has been applied to study cysteine
desulfurase activity in several different systems112,207,230. In this assay, a colorimetric
measurement of methylene blue formed in proportion to the amount of persulfide
produced allows straightforward quantitation of the same using a standard curve
developed with inorganic sulfide. Although previous studies have quantified the amount
of methylene blue produced by measuring the spectral intensity at 650 nm, we
measured the absorbance at 750 nm, which is the second intense absorption maxima
for methylene blue. This feature showed the lowest variation (< 5 % of the total signal at
the highest L-cysteine concentration) for the blank reactions performed with varied Lcysteine concentrations similar to the actual experiment, and therefore had minutest
effect on the readings. Michaelis-Menten parameters calculated for the yeast Nfs1Isd11 complex from this report suggest that the yeast system falls between bacterial
and human systems in the scale of evolution. The Michaelis constant (KM) for yeast
Nfs1-Isd11 closely resembles that of the human homolog207,230, but largely deviates
from that seen for the E. coli IscS112, which is a hundred fold lesser than eukaryotes. An
increase in KM coupled to increasing complexity of the organism may indicate that
cysteine desulfurases have evolved to function near physiological L-cysteine
concentration of ~ 0.1 mM207. KM values near substrate concentrations allow enzymes
to catalyze at a rate of Vmax/2 and thereby regulate turn over based on substrate
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availability that is often adjusted to meet cellular demands. On the other hand, catalytic
efficiency (Kcat/KM) of the yeast Nfs1-Isd11 complex falls between bacterial and human
systems, in a series where catalytic efficiency decreases with increasing complexity of
organisms. Catalytic efficiency is a measure of enzymatic function at low substrate
concentrations and apparently it has been compromised in eukaryotic cysteine
desulfurases as opposed to IscS. Such a compromise may indicate an extra level of
regulation summoned to control the cysteine desulfurase reaction in eukaryotes.
Interestingly, Isd11 is only present in eukaryotes and complexation with Isd11 has an
activating effect on Nfs1. Given that IscS turns over at maximum velocity (when [S] >>>
KM, V=Vmax) and exhibits high catalytic efficiency, it is possible that additional regulation
was needed for cysteine desulfurase reaction within the mitochondria to eliminate the
formation of toxic levels of sulfides.
Although the function of eukaryotic Nfs1-Isd11 complex in Fe-S cluster
biogenesis is established, structural details on the complex are lacking. Therefore a
modeled structure for yeast Nfs1 developed from the published structure of the bacterial
orthologs222,223 will have to suffice for now. The SWISS-MODEL homology modeling
workspace243 was used with the E. coli IscS crystal structure to model Nfs1. However,
IscS may not be the ideal template since prokaryotic systems do not utilize Isd11. In
addition, the first 62 residues in Nfs1 N-terminus were absent from IscS, so the modeled
structure lacked that region. A previous attempt to model Nfs1 using a different
homology modeling platform yielded a structure without the flexible loop of 10 residues
harboring catalytic cysteine residue (C421) due to lack of corresponding segment on
IscS231. However our structure modeled with SWISS MODEL contained this missing
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segment. Therefore, we were able to measure the distance between the catalytic
cysteine and PLP, and predict that a conformational change is required for catalysis.
Another conformational change was also predicted for L-cysteine binding, as it was
apparent that the substrate-binding site was occluded in the model. Confirming this
hypothesis, ANS and tryptophan fluorescence experiments showed a conformational
change during substrate binding. Since Isd11 does not seem to be involved in the
substrate binding (as seen with UV-visible spectroscopy experiments) but only alters
catalytic activity it is likely that the second conformational change is facilitated by Isd11.
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2.6 Supplementary Material

Figure S2.1: Circular dichroism spectra of purified Nfs1-Isd11 and Nfs1(C421A)Isd11 protein complexes. Solid and dotted lines represent Nfs1-Isd11 and
Nfs1(C421A)-Isd11, respectively. Experiment was carried out at 25 °C in 5 mM
phosphate buffer at pH 7.5 supplemented with 100 NaF. Spectra were collected in the
far-UV region (180-260 nm) with a JASCO J-1500 CD Spectrometer using 0.5 µM
protein samples with 1 mm pathlength cuvette. Each displayed spectra represent a
smoothed average of spectra from three independent experiments and in each
experiment ten individual spectra were collected. Buffer scan was subtracted from the
averaged spectra to accomplish baseline correction. Simulation of averaged spectra
obtained using CDPro Analysis software, which used CONTIN as the method and
SP29, SP37, SP43, SMP50, and SMP56 as reference databases yielded the amount of
secondary structural elements present in each individual protein as listed in Table S2.1.
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Table S2.1: Secondary structural elements by percentage for Nfs1-Isd11 and
Nfs1(C421A)-Isd11 protein complexes from circular dichroism.

Secondary structural element

Nfs1-Isd11

Nfs1(C421A)Isd11

Helix

33.2 ± 2.6

38.5 ± 2.7

Strand

18.8 ± 2.9

13.9 ± 1.4

Turn

20.4 ± 0.5

20.7 ± 0.7

Undetermined

27.7 ± 0.3

26.9 ± 0.7

RMSD

0.14

0.15
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Figure S2.2: Differential Scanning Calorimetric thermal profiles of purified Nfs1Isd11 and Nfs1(C421A)-Isd11 protein complexes. Solid and dotted lines represent
Nfs1-Isd11 and Nfs1(C421A)-Isd11, respectively.
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Figure S2.3: Persulfide forming activity of Nfs1-Isd11 compared to Nfs1(C421A)Isd11. Columns A and B represents Nfs1-Isd11 and Nfs1(C421A)-Isd11, respectively.
Amount of sulfide formed by 15 µM protein is measured using the acid labile sulfide
detection assay as described in the main article in a buffer containing 20 mM HEPES,
and 300 mM NaCl at pH 7.5.
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CHAPTER 3
EFFECT OF YEAST FRATAXIN “YFH1”ON THE STRUCTURE AND FUNCTION OF
THE NFS1-ISD11 COMPLEX
3.0 Prelude
This chapter describes my work studying the effect of yeast frataxin homolog
Yfh1 on the structure and function of yeast cysteine desulfurase “Nfs1-Isd11” complex.
The function of frataxin within Fe-S cluster biogenesis has been a longstanding
discussion beginning with the discovery that its loss of function causes Friedreich’s
ataxia. Presently, frataxin is viewed more as a regulator of cluster assembly than as an
essential iron delivery protein. Involvement of frataxin in altering sulfur mobilization and
cluster assembly in both prokaryotes and mammalian cells has been studied
extensively over the past years, as described later in this chapter. But less attention has
been paid towards investigating these events in yeast besides the radiolabeling
experiments showing Yfh1 directly stimulating cysteine desulfurase by exposing binding
sites to facilitate substrate binding116. The objective of my work was to fill in the gaps in
knowledge of the Yfh1/Nfs1-Isd11 interaction and the effect of Yfh1 on cysteine
desulfurase activity. Isothermal titration calorimetry and surface plasmon resonance
studies were proposed to determine the binding affinity of Yfh1 to Nfs1-Isd11. UV-visible
spectroscopy and acid labile sulfide detection assays were used to monitor the effect of
Yfh1 on L-cysteine binding affinity and catalytic activity of Nfs1-Isd11 complex
respectively. Finally, differential scanning calorimetry detected changes in thermal
stability upon Yfh1 binding to the complex. My results presented below suggest that
Yfh1 has minimal effect on Nfs1-Isd11 structure and function by itself but might be
synergistic with other factors, such as Isu1.
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3.1 Introduction
Frataxin was first discovered two decades ago as the protein encoded by the
gene X25 located in the critical region of the FRDA locus of Friedreich’s ataxia (FRDA)
patients. Most patients were homozygous for an unstable GAA triplet repeat expansion
in the first intron of this gene188. Since then, a plethora of studies performed pertaining
to characterizing the structure and function of frataxin, not only in humans but also in
other organisms, has been tremendously useful in understanding the relation of frataxin
to the pathophysiology of FRDA. Initial studies on the yeast frataxin homolog protein
(Yfh1) encoded by the YFH1 gene reported involvement of this protein in iron
homeostasis and mitochondrial function. Loss of Yfh1 function lead to the accumulation
of iron within the mitochondria244,245, deficiency in function of specific mitochondrial
proteins (including cytochrome c oxidase), and hypersensitivity to H2O2, iron and
copper245. The frataxin gene is of nuclear origin, and the protein was found localized to
the mitochondria246-248 and predominantly expressed in tissues with high metabolic
demand247. In the search for frataxin’s function within the cellular milieu, several
hypotheses have been postulated and tested. A few postulates of frataxin’s function
include 1) regulation of mitochondrial iron efflux249, 2) employment of early antioxidant
defenses to prevent oxidative damage in the cell250, 3) activation of mitochondrial
energy conversion and oxidative phosphorylation251, and 4) serve as an iron chaperone
for proteins such as ferrochelatase252-256. Frataxin’s function, in relation to Fe-S clusters,
was discovered only when Fe-S proteins such as mitochondrial respiratory complexes I,
II, and III, and aconitase showed reduced activity with the deletion of frataxin gene257259

. A decrease in Fe-S cluster protein maturation in ∆yfh1 yeast strains260,261, reduction
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in mitochondrial Fe-S protein activities and Fe-S cluster association with the cytosolic
iron regulatory protein 1 (IRP1) in frataxin-depleted HeLa cells262 indicated that frataxin
is crucial for Fe-S protein biogenesis. Phylogenetic studies further confirmed the
evolutionary lineage of the frataxin gene to be directly involved in Fe-S cluster protein
assembly263. Frataxin’s mechanism of action within Fe-S cluster synthesis has been
extensively investigated in various systems in the past decade and multiple studies
provided evidence for frataxin’s function as an iron donor for Fe-S cluster assembly, as
well as a regulatory protein altering the function of other protein partners of the
assembly process. Such evidence is discussed in detail in the following sections.
3.2 Frataxin’s function in Fe-S cluster assembly
3.2.1 Iron binding ability and iron chaperone function of frataxin
In relation to frataxin’s proposed function as an iron donor, its ability to bind iron
has been tested in several studies. Affinities of all frataxin orthologs towards iron have
shown to be weak, within the micromolar range. Human frataxin’s (FXN) ability to bind
6-7 iron atoms with an affinity of Kd ~ 10-55 µM was quantified by iron-dependent
fluorescence

measurements

and

ITC119.

Similarly,

bacterial

frataxin

(CyaY)

demonstrated binding of two ferrous ions per monomer with a Kd of 4 µM264. A more
comprehensive study on monomeric Yfh1 characterized its iron binding properties and
provided a detailed description of bound iron and the protein’s metal-binding sites.
Monomeric Yfh1 was capable of binding two Fe2+ atoms in the high spin state with
micromolar affinities (Kd1 ~ 3 µM and Kd2 ~ 2 µM) at the two independent sites. The
coordination geometry of the iron binding sites was determined as six-coordinate with
Fe-O/N based ligands attributed to the residues within the acidic patches on the
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protein206. Weak micromolar affinities towards iron have been considered important for
frataxin’s function as an iron chaperone within the cell.
Structural studies provided a framework for mapping the key residues involved in
iron binding. Both solution and crystal structures are available for the bacterial, yeast,
and human frataxin orthologs252,265-269 and these proteins are extremely similar. All
frataxins in common have an α-β sandwich structure motif with two terminal α-helices in
one plane and five antiparallel β-strands constructing a second plane, which are
intersected by a sixth β-strand120. Although frataxin has mostly been characterized as
an iron binding protein, it somewhat lacks structural features of a typical iron binding
protein, such as hydrophilic iron binding pockets or cavities and typical iron chelating
residues (histidines and/or cysteines)265,270. Iron binding in all frataxins has been
confined to a patch of acidic residues mostly comprising of conserved aspartates and
glutamates (negatively charged carboxylate side chains serve as iron binding ligands) of
N-terminal region of these proteins. These residues are located in the α1 and β1
secondary structural elements. NMR chemical shift perturbation experiments on
CyaY269

and Yfh1252 identified amino acid residues which underwent substantial

chemical shift changes upon titration of iron.
Requirement for oligomerization for iron loading to frataxin has also been studied
extensively. Yfh1’s ability to self assemble into spherical multimers in the presence of
iron and to sequester iron in a bioavailable form have also been reported271,272. Similarly
human frataxin is capable of making an iron-binding stable homopolymer273 while
bacterial frataxin CyaY behaves similar to Yfh1 and forms aggregates with iron loading
capacity274. Hence oligomerization was considered an important property of all frataxins
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and suggested an iron storage function. However the physiological relevance of higher
order multimers was questioned at that time due to the non-conserved nature of
aggregation between species274 and in due course iron-induced oligomerization and
iron storage in Yfh1 was found dispensable for heme and Fe-S cluster assembly in
vivo275,276. Therefore, frataxin’s function as an iron chaperone was deemed redundant.
In summary, these studies indicated that although weak binding affinity towards
iron and iron-dependent oligomerization predicted frataxin’s function as an iron
chaperone, this function is not a critical function in cells.
3.2.2 Frataxin interacts with other key proteins in Fe-S cluster assembly pathway
De novo synthesis of Fe-S clusters is a complex process that involves multiple
proteins3,175. Since frataxin was found to be essential for this process, initial studies
attempted to identify its individual interaction partners within the cell. Direct interactions
between frataxin and the respective scaffold protein within the Fe-S assembly
machinery in human, yeast and bacterial systems have been reported many times,
postulating frataxin’s function as an iron donor for the process119,277-282. In eukaryotes,
this interaction is iron dependent, its Kd is nanomolar119,282 and requires frataxin
oligomerization283. Isu1 binding residues on yeast Yfh1 have been located to the β–
sheet adjacent to the acidic iron binding ridge280-282. Similarly, direct interactions with
ISD11 have also been identified defining ISD11 as a mediator for frataxin to interact
with other cluster assembly components284. The interaction between frataxin and
cysteine desulfurase has been demonstrated in a different context: frataxin as a
regulator of cysteine desulfurase activity and of sulfur delivery. Pull-down assays
confirmed bacterial frataxin CyaY interacting with cysteine desulfurase IscS208,279 and
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NMR experiments mapped CyaY residues involved in the interaction in to an iron
binding region208 comprising of α1, β1, and α1β1 loop285. Modeled structures identified
CyaY bound at a site near the IscS dimer interface and the stoichiometry of CyaY:IscS
was reported as 1:1 (from ITC, SAXS and NMR) with a Kd of 18.5 µM (from ITC)285. This
lower

affinity

CyaY-IscS

complex

could

not

be

isolated

by

gel

filtration

chromatography286. Similarly in the human system, no SDF (NFS1-ISD11-FXN)
complex was observed from gel filtration chromatography and frataxin had no direct
effect on cysteine desulfurase activity as well207. Characterization of these individual
interactions added a new level of knowledge towards understanding frataxin function,
yet the quest to understand frataxin’s function continues.
Besides the direct interactions with each individual component, frataxin’s
involvement in core Fe-S assembly complex (consisting of all four components, cysteine
desulfurase (S) and its accessory protein (D), scaffold (U), and frataxin (F): SDUF
complex) has been in the limelight in the past few years. Evidence of mammalian
frataxin binding to the preformed SDU complex207,229,235,283 and mutations/other variants
of frataxin binding weakly to the same287,288 suggested frataxin’s involvement in the core
assembly complex. The role of frataxin in the SDUF complex has been studied
extensively, and the most common hypothesis is that frataxin stimulates cluster
assembly by enhancing sulfur delivery. The next section reviews this hypothesis.
3.2.3 Frataxin as a regulator of Fe-S cluster synthesis through controlling
cysteine desulfurase activity
In the search for frataxin’s function within the Fe-S cluster assembly process,
much evidence is directed towards defining it as a regulator for cysteine desulfurase

99
activity (i.e. sulfur delivery). Formation of a multiprotein complex between human NFS1,
ISD11, ISU2 and FXN enhanced catalytic efficiency and the KM for cysteine desulfurase
activity within the quad complex dramatically in an ISU2-dependent manner, as
compared to the NFS1-ISD11 (SD) complex alone. Addition of one equivalent of ferrous
iron further stimulated cysteine desulfurase activity of this complex207. This notion was
further confirmed when frataxin mutants/variants showed decreased binding affinities to
the SDU complex, diminished Fe-S cluster synthesis, and lowered cysteine desulfurase
activities of the SDUF complex287,288. In dissecting the mechanism of activation by
frataxin, it was found that FXN stabilized a confirmation of the SDU complex that
accelerated the formation of persulfide on NFS1. Simultaneously to that, FXN also
facilitated inter-protein sulfur transfer between NFS1 and residue C104 of ISCU2,
leading to acceleration of cluster assembly289. Studies on the yeast system suggested
that Yfh1 directly and specifically enhances cysteine binding to Nfs1 by exposing its
substrate-binding sites116. Notably, in the murine system, FXN enhanced the cysteine
desulfurase activity of the SDU complex but the impact of iron on the stimulatory effect
was only minimal and not specific to iron. The same study also reported that iron entry
into the SDUF complex is contingent upon activation of cysteine desulfurase by FXN;
hence suggesting a concerted mechanism for iron and sulfur entry. Assembly of a 4Fe4S cluster was observed in both SDU and SDUF complexes but cluster transfer was
only efficient in the presence of FXN235. Controversially to all of the above, a novel study
showed that FXN is not required for persulfide formation on NFS1, but it specifically
enhances sulfur transfer from NFS1 to ISCU, thus increasing the rate of sulfide
production in the SDUF complex in a global scale. FXN also stimulated sulfide release
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from NFS1 by enhancing the reduction of persulfide on NFS1 by thiols such as DTT,
although it is not relevant or efficient for Fe-S cluster synthesis290.
On the other hand, bacterial frataxin CyaY is suggested as an iron-dependent
inhibitor of 2Fe-2S cluster formation through binding to cysteine desulfurase IscS208 by
directly inhibiting cysteine desulfurase activity291. In an experiment in which human and
prokaryotic cluster assembly components were interchanged, CyaY could functionally
replace FXN and activate human cysteine desulfurase while FXN failed to activate
bacterial IscS. Therefore the inhibitory effect was determined by the identity of the
cysteine desulfurase, not frataxin292.
Taken together, these studies support the model that frataxin is a regulator of FeS cluster synthesis in all organisms. Eukaryotic frataxin most probably facilitates sulfur
transfer from the cysteine desulfurase to the scaffold protein. The observed stimulation
of cysteine desulfurase activity on the SDUF complex could either be a direct
repercussion of frataxin on the cysteine desulfurase enzyme, or a global scale effect
observed due to enhanced sulfur transfer. Therefore the explicit function of frataxin in
mammalian Fe-S cluster synthesis still remains elusive. In contrast prokaryotic frataxin
is an inhibitor of cluster formation via decreasing cysteine desulfurase activity. The
functional discrepancy of frataxin between eukaryotic and prokaryotic systems is
surprising yet interesting and requires careful rationalization through further
investigations.
My goal in this report was to fill in the gaps in knowledge of the Yfh1/Nfs1-Isd11
interaction and the effect of Yfh1 on structure and function of Nfs1-Isd11 in the yeast
system. Experiments outlined below were carried out in such context.
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3.3 Experimental methods
3.3.1 Bacterial expression and isolation of proteins
3.3.1.1 Expression of yeast Fe-S cluster synthesis proteins
Expression of Nfs1 (and C421A)-Isd11: pST39 co-expression vectors containing
Δ1-33 Nfs1-6xHis-Isd11 or Δ1-36 Nfs1(C421A)-6xHis-Isd11 were transformed into BL21
(DE3) cells. In both these constructs Nfs1 lacks mitochondrial targeting sequence but
Isd11 remains full length. Starter cultures were made by inoculating a transformed
colony in Luria Bertani (LB) broth supplemented with 100 µg/ml ampicillin. These
cultures were incubated in a rotating shaker for 16 hours (overnight) at 230 rpm and 37
°C. Starting OD of the growth cultures (1 L) supplemented with 100 µg/ml ampicillin
were set to 0.075 by adding appropriate amount of starter culture and the cells were
grown until cell density reached 0.4 OD600. Growth temperature was then switched to 18
°C and cells were induced at 0.7 OD600 using of 0.8 mM IPTG supplemented with 10 µM
PLP. Cells grew for 18 hours and then they were harvested by centrifugation at 15900 x
g for 30 min. If not lysed immediately, cell pellets were flash frozen and stored at -80 °C
for future use.
Expression of Nfs1: pET21b vector containing Δ1-33 Nfs1-6xHis was
transformed into BL21 (DE3) codon plus cells. Starter cultures and growth cultures (1 L)
were treated as mentioned above except they were supplemented with 34 µg/ml
chloramphenicol in addition to 100 µg/ml ampicillin. Cells were grown at 37 °C until cell
density reached 0.4-0.5 OD600. Growth temperature was then switched to 25 °C and
cells were induced at 0.7 OD600 with of 1 mM IPTG, supplemented with 10 µM PLP.
Cells were continued to grow at 25 °C for 3 hours before harvesting, again by

102
centrifugation. If not lysed immediately, cell pellets were flash frozen and stored at -80
°C for future use.
Expression of Yfh1 and Yfh1-6xHis: Mature full length Yfh1 was expressed as
described previously252. Briefly pET11a vector containing Δ1-52 Yfh1 or Δ1-52 Yfh16xHis was transformed into BL21 (DE3) Star cells. Starter cultures and growth cultures
(1 L) were treated as mentioned above and were supplemented with 100 µg/ml
ampicillin. Cells were grown at 37 °C until cell density reached 0.8 OD600 and were
induced with 1 mM IPTG. Cells were continued to grow at 37 °C for 6 hours before
harvesting by centrifugation. If not lysed immediately, cell pellets were flash frozen and
stored at -80 °C for future use.
3.3.1.2 Purification of yeast Fe-S cluster synthesis proteins
Purification of Nfs1, Yfh1-6xHis, Nfs1-Isd11, and Nfs1(C421A)-Isd11 proteins:
Frozen cell pellets were resuspended in pH 7.5 lysis buffer containing 50 mM Sodium
Phosphate, 150 mM NaCl for Yfh1-6xHis, Nfs1-Isd11, and Nfs1(C421A)-Isd11
complexes/300 mM NaCl for Nfs1 alone, 5% Glycerol, 20 mM Imidazole, and 5 mM β–
ME (4 ml/g of cells). In addition, cOmplete™ EDTA-free protease inhibitor cocktail
(Roche), lysozyme (10 mg/ml), and DNAse (10 µg/ml) supplemented with 5 mM MgCl2
were also included in the lysis buffer. Protein purification was performed at 4 °C. Cell
suspensions were incubated at 4 °C for 30 min while stirring at a slow pace before
passing through the Emulsiflex cell homogenizer three times for cell lysing. Cell lysates
were then centrifuged at 53000 x g for 1 hour. Crude soluble fractions were filtered
(0.20 µm) before passing through Ni affinity columns. Nfs1-Isd11 soluble fraction was
passed through His-Trap HP 5 ml Ni column (GE Healthcare) using an AKTA FPLC
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chromatography system (Amersham Biosciences/GE Healthcare); Yfh1-6xHis, Nfs1 or
Nfs1(C421A)-Isd11 soluble fractions were passed separately through pre-equilibrated
high density Ni-NTA Agarose Beads (GoldBio) manually packed in bench-top columns.
Ni columns were first washed with 20 column volumes of binding buffer to eliminate any
residual unbound proteins. Bound proteins were then eluted by flowing an imidazole
gradient of 20-500 mM across the columns and fractions containing Yfh1-6xHis, Nfs1,
Nfs1-Isd11, and Nfs1(C421A)-Isd11 complexes were identified using SDS-PAGE.
Active fractions were pooled and concentrated to ~ 1 ml using 10 kDa molecular weight
cutoff Amicon centrifugal filter devices (Millipore). Nfs1 containing protein preparations
were incubated with excess PLP to ensure 100 % loading of PLP to all Nfs1 units.
Similarly, Yfh1-6xHis protein preparation was incubated with 5 mM EDTA to ensure
removal of any bound iron. Concentrated Nfs1, Nfs1-Isd11, and Nfs1(C421A)-Isd11
proteins and Yfh1-6xHis were passed through HiPrep 16/60 Sephacryl S-200 HR and
HiLoad 16/600 Superdex-75 size exclusion columns (both GE Healthcare) respectively
to further remove impurities and to transfer to pH 7.5 final buffer comprising of 20 mM
HEPES,
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NaCl

for

Yfh1-6xHis,

Nfs1-Isd11,

and
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complexes/300 mM NaCl for Nfs1 alone, and 5mM β–ME. Fractions containing Nfs1,
Nfs1-Isd11, and Nfs1(C421A)-Isd11 complexes were pooled and concentrated to store
at -80 °C in aliquots until further use in experiments. Yfh1-6xHis fractions were
concentrated and stored under oxygen depleted nitrogen atmosphere at 4 °C and was
used within two weeks of isolation to ensure protein integrity. All purified proteins were
>90% pure (Figure 3.1).
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Purification of Yfh1: The mature form of Yfh1 was purified as described
previously252. Briefly frozen cell pellets were resuspended in pH 8.0 lysis buffer
containing 25 mM Tris HCl, 10 mM EDTA, and 5 mM β–ME (4 ml/g of cells). In addition,
cOmplete™ EDTA-free protease inhibitor cocktail (Roche), lysozyme (10 mg/ml), and
DNAse (10 µg/ml) supplemented with 5 mM MgCl2 were also added to the cell
suspension. Protein purification was performed at 4 °C. Cell suspensions were
incubated at 4 °C for 30 min while stirring at a slow pace before passing through the
Emulsiflex cell homogenizer three times for cell lysing. Cell lysates were then
centrifuged at 53300 x g for 1 hour. Crude soluble fractions were filtered (0.20 µm) and
subjected to two ammonium sulfate precipitation steps: (1) contaminating proteins
precipitated by incubating with 40% ammonium sulfate for 20 min and centrifugation at
15900 x g for 20 min and (2) Yfh1 precipitation from resulting supernatant by incubating
with 60% ammonium sulfate for one hour and centrifugation at 15900 x g for 20 min.
Resulting Yfh1 pellet was resuspended in a minimal volume of lysis buffer before
dialyzing twice for 3 hours each in 2 L of the same buffer to remove any ammonium
sulfate. Then the protein mixture was passed through HiLoad 26/10 Q-Sepharose
column (Amersham Biosciences/GE Healthcare) pre-equilibrated with pH 8.0 buffer
containing 25 mM Tris HCl, 10 mM EDTA, and 5 mM β–ME and eluted using an
increasing 1 M NaCl gradient. Fractions containing Yfh1 were identified using SDSPAGE, pooled, and dialyzed as before to remove any salt. Further purification of Yfh1
involved passing through pre-equilibrated HiLoad 26/10 Phenyl-Sepharose column
(Amersham Biosciences/GE Healthcare) and eluting with a decreasing 1 M ammonium
sulfate gradient at pH 8.0. Solid ammonium sulfate was added to the protein mixture
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prior loading to the column to make the starting ammonium sulfate concentration 1 M.
Fractions containing Yfh1 identified by SDS-PAGE were concentrated to 1 ml, before
treating with 5 mM EDTA at pH 8.0 for 30 min. Metal-free protein was then loaded on to
pre-equilibrated HiLoad 16/600 Superdex-75 size exclusion column (GE Healthcare) for
further purification and buffer exchange to final 20 mM HEPES, 150 mM NaCl, and 5
mM β–ME pH 7.5 buffer. Pure Yfh1 (>90%) (Figure 3.1) was concentrated using a 10
kDa molecular weight cutoff Amicon centrifugal filter device (Millipore) and was stored
under oxygen depleted nitrogen atmosphere at 4 °C. Purified frataxin was used within
two weeks of isolation to ensure protein integrity.
3.3.2 Isothermal Titration Calorimetry
ITC experiments were executed to determine the Yfh1 binding affinity to the
Nfs1-Isd11 complex, as well as the maximum Yfh1/Nfs1-Isd11 stoichiometry. Titrations
were carried out at 30 °C on a TA instruments Nano-ITC calorimeter under anaerobic
conditions. Concentrated Yfh1 and Nfs1-Isd11 proteins were diluted to 500 µM and 25
µM respectively in degassed pH 7.5 buffer containing 20 m HEPES, 150 mM NaCl, and
5 mM β–ME. Twenty fold excess Yfh1 was loaded on to the syringe while 950 µl of
Nfs1-Isd11 remained in the cell stirring at 200 rpm. A total of forty 5 µl injections of Yfh1
were titrated consecutively at 300 s intervals to achieve the thermal titration profile. The
TA Instruments NanoAnalyze software package was used to analyze the titration profile
and identify the best-fit values for the dissociation constant, stoichiometry, and heat of
enthalpy change for the Yfh1/Nfs1-Isd11 interaction.
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3.3.3 In vitro pull-down assay
A Ni-NTA agarose affinity pull-down assay was performed to observe any
complex formation between Yfh1 and Nfs1-Isd11 proteins. Purified Nfs1-Isd11 (-6xHis
tag on Nfs1) was incubated with 100 µl of high density Nickel-NTA Agarose Beads
(GoldBio) pre-washed with Milli-Q water and equilibrated with 20 mM HEPES, 150 mM
NaCl, and 5 mM β-ME pH 7.5 buffer, within a BioRad Micro Bio-Spin column. Maximum
binding of Nfs1-Isd11 to the resin was allowed by end-to-end mixing on a rotating
platform for 30 min at 25 °C. The sample was spun at 295 x g for 1 min using a tabletop
centrifuge to remove the flow through from the column and subsequent washes with the
same buffer removed any unbound protein. Beads saturated with bound Nfs1-Isd11
were then treated with four-times molar excess of Yfh1 for 30 min on the rotating
platform at 25 °C to allow maximum binding. Beads were extensively washed with buffer
as before until no protein was detected in the collected washes, monitored using the
Advanced protein detection solution. After a single 20 mM imidazole wash, bound
proteins were eluted with 500 mM imidazole buffer and subsequently detected with
SDS-PAGE.
3.3.4 Differential Scanning Calorimetry
Changes in the thermal stability of Nfs1, or the Nfs1-Isd11 complex, upon
addition of Yfh1-6xHis were assessed using differential scanning calorimetry (DSC).
Purified and concentrated proteins were mixed and incubated at 25 °C for 10 min to
achieve respective stoichiometrically proportioned mixtures (~0.5-3 mg/ml). Samples
were prepared in 20 mM HEPES, 300 mM NaCl, 5 mM β-ME at pH 7.5 buffer, degassed
to remove dissolved air. Protein samples were loaded in the sample cell of a TA
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Instruments Nano-DSC calorimeter; the reference cell was filled with matched buffer.
The total volume for the capillary cell is 0.3 ml, however an excess of solution (~0.6 ml)
is used for loading to prevent trapping air bubbles. Both capillary cells were manually
pressurized to maintain a constant pressure of 3 atm during the scan. Each protein
sample was scanned at a rate of 1 °C/min from 10 °C to 90 °C, and the melting curves
for Nfs1:Yfh1 (1:2) and Nfs1-Isd11:Yfh1 (1:2) were assessed to identify differences in
thermal stability of Nfs1 and Nfs1-Isd11 during complexation with Isd11. Experiments
were done in duplicate using independently isolated proteins to ensure data
reproducibility. Thermal profiles were simulated using the TA instruments NanoAnalyze
software package to identify the best-fit values for melting temperatures (Tm).
3.3.5 UV-visible spectroscopy
UV-visible spectroscopy was used to identify if the affinity of Nfs1(C421A)-Isd11
to L-cysteine is altered in the presence of Yfh1-6xHis. In this experiment, 50 µM purified
Nfs1(C421A)-Isd11 was incubated with 100 µM Yfh1-6xHis (in 1:2 molar ratio) at 25 °C
for 10 min. Samples were prepared in 20 mM HEPES and 300 mM NaCl at pH 7.5 and
the protein mixture was then titrated consecutively with freshly made L-cysteine. Protein
samples were carefully mixed and incubated for 10 min after each addition of Lcysteine; spectra were measured at a 1.0 nm scan pitch using a Shimadzu UV-1800
Spectrophotometer. Each addition was timed 1 min after the start of spectra acquisition
to maintain consistency between data points. All spectra were collected at 25 °C under
anaerobic conditions and corrected for dilution. Experiments were performed in
duplicate

using

independently

prepared

protein

samples

to

ensure

spectral

reproducibility. The change in spectral intensity at 340 nm was plotted against
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respective L-cysteine concentrations to calculate the binding affinity of Nfs1(C421A)Isd11 to L-cysteine in the presence or absence of Yfh1-6xHis. Best-fit simulation to data
was obtained using DynaFit curve fitting software227.
3.3.6 Cysteine desulfurase activity assay
An acid labile sulfide detection assay was performed to measure the activity of
Nfs1-Isd11 complex in the presence or absence of Yfh1-6xHis. In this assay, Fe3+ with
sulfide liberated from the enzyme aids the conversion of N, N-dimethyl-pphenylenediamine sulfate (DPD) to methylene blue. The characteristic blue color, i.e.
the visible absorption feature at ~750 nm was used to quantify sulfide production along
with the use of a calibration curve for signal intensity prepared with a series of known
sodium sulfide concentrations. The purified Nfs1-Isd11 complex (12 µM concentration)
was incubated with 1 mM L-cysteine in the absence or presence of stoichiometric Yfh16xHis (1:2). An assay mixture contained 100 mM HEPES (pH 7.5), 150 mM NaCl, 50
µM PLP, and distilled water, and the total reaction volume was 100 µl. Each reaction
was prepared by first mixing the assay components together in an eppendorf tube
covered with rubber septa caps (Sigma-Aldrich-Z565717) to prevent air escaping.
Respective L-cysteine amounts were then introduced to each tube using a gas-tight
Hamilton syringe. After a 5 min incubation at 30 °C, the reaction was stopped by adding
100 µl of 20 mM DPD in 7.2 N HCl and 30 mM FeCl3 in 1.2 N HCl. This was also
performed using a gas-tight Hamilton syringe and each addition was timed 45 s apart to
maintain the consistency between each reaction. Distilled water was added up to 800 µl.
Each tube was then vortexed for 10 s before incubating for 20 min at 30 °C for efficient
color development. All tubes were spun at 14000 x g for 2 min to remove protein
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precipitation before measuring the absorbance. Absorbance was measured at 750 nm
using a 1 ml cuvette on a Varian Cary-50 Bio UV-Visible Spectrophotometer. The
amount of persulfide liberated at each concentration was determined using the standard
curve. Measurements were collected in triplicate, averaged, and corrected for dilution.
3.4 Results
3.4.1 Purified proteins are > 95% pure
All proteins purified by following respective protocols listed above were > 95 %
pure. Nfs1 was present as a homodimer, the typical oligomerization state attributable to
cysteine desulfurase enzymes (data shown in chapter 2). Nfs1-Isd11 and Nfs1(C421A)Isd11 were heteromeric complexes comprising of Nfs1 (wild type or mutant)
homodimers and 4 Isd11 units in each complex (data shown in chapter 2). Yfh1
(with/without -6xHis tag) was present in its monomeric form as observed with size
exclusion chromatography (data not shown).
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Figure 3.1: SDS-PAGE gel of purified proteins. Lanes represent 1: molecular weight
marker, 2: purified yeast Nfs1-Isd11 complex, 3: Nfs1(C421A)-Isd11 complex, 4: Yfh1,
and 5: Yfh1-6xHis.
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3.4.2 ITC experiments suggest a possible interaction between Nfs1-Isd11
complex and Yfh1
To provide evidence that Nfs1-Isd11 and Yfh1 physically interact during Fe-S
cluster synthesis, and to quantify the interaction, isothermal titration calorimetry was
performed. Titration of Yfh1 into Nfs1-Isd11 yielded the raw binding isotherm (Figure
3.2-A) that could be simulated to obtain the best-fit binding isotherm (Figure 3.2-B) and
corresponding binding parameters. The Kd, stoichiometry, and enthalpy for the
interaction were 7.4 ± 3.2 µM, 1.5 ± 0.1, and -4.9 ± 0.7 kJ/mol respectively. Detection of
a binding event with ITC suggested a physical interaction of Yfh1 with Nfs1-Isd11 under
these experimental conditions. Weak binding affinity in the micromolar range was
consistent with a previously published micromolar Kd for the interaction between
bacterial orthologs IscS and CyaY285. Stoichiometry of 1.5 ± 0.1 indicated that
approximately 2 Yfh1 units associate with Nfs1-Isd11 complex, in agreement with the
1:1 Nfs1:Yfh1 (per Nfs1 monomer) stoichiometry observed in SDUF quaternary
complexes in several systems229,235. Although this result suggested a physical
interaction between Nfs1-Isd11 and Yfh1, it was also questionable due to few concerns.
The Nfs1-Isd11 complex was unstable under these experimental conditions and
precipitation of protein was observed during continuous stirring of Nfs1-Isd11 within the
cell, regardless of measures taken to prevent precipitation (i.e. decreased stirring
speed, addition of stabilizers such as glycerol). Protein precipitation created a shifted
but stable baseline with minimal noise. Due to these reasons, reproduction of these
results was impossible. Therefore the validity of ITC results was subjected to skepticism
and the interaction observed here could be an outcome of aggregation during
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experiment and be superficial. Therefore, more evidence to strengthen the validity of
these results is required.
3.4.3 In vitro pull-down assay indicates no interaction between Nfs1-Isd11 and
Yfh1
To ascertain the existence of an interaction between Yfh1 and Nfs1-Isd11, an in
vitro Ni-affinity pull-down assay was performed. Nfs1-Isd11 bound to the resin could not
retain any Yfh1 upon incubation, as Yfh1 readily eluted with the subsequent washes
(Lanes 5-7, Figure 3.3). No Yfh1 was found bound to Nfs1-Isd11 when eluted with
imidazole (Lanes 12-14, Figure 3.3). Even though a weak interaction with micromolar
affinity was observed between Yfh1 and Nfs1-Isd11 with ITC under similar conditions,
the same interaction was not observed with pull-down assay. This indicated that an
interaction was unlikely under these experimental conditions, and ITC results were
indeed superficial. An interaction between human orthologs NFS1-ISD11 and YFH1
was also not detected in a previous study207. Hence, results from ITC and pull-down
assay may suggest that an interaction between Nfs1-Isd11 and Yfh1 is mostly not a
tight interaction, but rather they could be transient/weak and impossible to detect within
the sensitivity limits of these techniques.
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Figure 3.2: Raw isothermal titration calorimetry data (A) and binding isotherm
data (B) for Yfh1 titration into Nfs1-Isd11 complex. Solid black line in panel B
indicates best-fit simulation to binding isotherm data obtained using fitting programs.
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Figure 3.3: Poly-histidine tag pull-down assay for Nfs1-Isd11 interaction with
Yfh1. Flow through and washes were collected after addition of each protein and
separated on SDS-PAGE along with elution fractions to identify binding partners. Lanes
labels read: 1-molecular weight marker, 2-Nfs1-Isd11 flow-through, 3, 4-two consecutive
washes after Nfs1-Isd11 binding to the resin, 5-Yfh1 flow-through, 6-11- consecutive
washes after Yfh1 addition, 12- 20 mM imidazole wash, and 13-15 consecutive elutions
with 500 mM imidazole.
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3.4.4 Association of Yfh1 with Nfs1/Nfs1-Isd11 does not affect the stability of the
proteins
It is also likely that the association between Nfs1-Isd11 and Yfh1 is transient, and
that this flexibility is essential to achieve certain functional goals during the Fe-S cluster
assembly process. It is possible that the binding partners alter each other’s stability via
such an interaction (similar to the effect Isd11 has on Nfs1, discussed in chapter 2).
Such an effect was monitored by comparing the thermal profiles of Nfs1 and the Nfs1Isd11 complex in the presence and absence of Yfh1 using Differential Scanning
Calorimetry (DSC). Thermal profiles of neither Nfs1 (top panel-Figure 3.4) nor Nfs1Isd11 (bottom panel-Figure 3.4) were substantially affected by incubation with Yfh1
(Table 3.1). Therefore it is likely that either Nfs1-Isd11 and Yfh1 does not interact in FeS cluster biosynthesis machinery, or their transient interaction has minor structural
perturbations on both partners.
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Figure 3.4: Differential Scanning Calorimetric thermal profiles for purified Nfs1
and Nfs1-Isd11 complex in the presence or absence of Yfh1. Letters represent
thermograms of: A-Nfs1 only, B and E-Yfh1 only, C-Nfs1 with Yfh1 (1:2), D-Nfs1-Isd11
only, and F-Nfs1-Isd11 with Yfh1 (1:2). Solid black and gray lines represent raw data
and sum of best-fit simulations respectively. Dashed lines represent simulated peaks
corresponding to domains and/or individual unfolding events in each structure. Melting
temperatures for simulated peaks are depicted in Table 3.1. B, C, E, and F thermal
profiles are offset for clarity.
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Table 3.1: Melting temperatures (°C) for each domain/unfolding event obtained from
Differential Scanning Calorimetry data for Nfs1 and Nfs1-Isd11 in the absence/presence
of Yfh1. Melting temperatures related to Yfh1 in each case are shown in italics.
Protein(s)

Domain/unfolding
event

Melting Temperature
(°C)

Nfs1

1

39.1 ± 0.6

2

42.0 ± 0.2

1

39.2 ± 0.2

2

41.7 ± 0.2

3

53.2 ± 0.2

Yfh1 only

-

53.1 ± 0.2

Nfs1-Isd11

1

56.9 ± 0.8

2

60.3 ± 0.4

3

62.1 ± 0.4

1

56.4 ± 0.1

2

59.8 ± 0.4

3

61.7 ± 0.1

4

51.9 ± 0.1

Nfs1+Yfh1 (1:2)

Nfs1-Isd11+Yfh1 (1:2)
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3.4.5 Yfh1 does not alter substrate binding affinity of Nfs1-Isd11
In order to determine any functional relationship between Nfs1-Isd11 and Yfh1,
UV-visible spectroscopy was utilized to monitor any changes in substrate binding affinity
of Nfs1-Isd11 in the presence of Yfh1. As described in the previous chapter, the C421A
mutant of Nfs1 was used for this assay to isolate the substrate-binding step from
catalytic step of the enzyme. Titration of L-cysteine to the Nfs1(C421A)-Isd11 construct
incubated with and without Yfh1 yielded binding curves that are not distinctly different
from each other (Figure 3.5). Best-fit simulations for binding data revealed Kd values of
0.76 ± 0.13 mM and 0.78 ± 0.14 mM in the absence and presence of Yfh1, respectively.
The almost identical substrate binding affinities, regardless of the presence of Yfh1,
agrees along with the prediction that Nfs1-Isd11 and Yfh1 may not interact or interact
transiently to alter a different function other than substrate binding in Fe-S cluster
biosynthesis machinery.
3.4.6 Effect of Yfh1 on cysteine desulfurase activity of Nfs1-Isd11 is minimal
In order to determine if a transient interaction with Yfh1 may alter cysteine
desulfurase activity of Nfs1-Isd11 complex, an acid labile sulfide assay was performed.
This assay was used to compare the rates of sulfide liberation in the absence and
presence of Yfh1. The rate of acid labile sulfide formation within first five minutes of the
reaction was not significantly altered by the presence of Yfh1 (only a slight
enhancement of 16% was observed: Figure 3.6). Similarly, in the human system,
frataxin had no direct effect on cysteine desulfurase activity of the human complex207.
Therefore it is likely that Yfh1 may not interact with Nfs1-Isd11 in Fe-S cluster
biosynthesis machinery in a functional point of view.
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Figure 3.5: Titration of L-cysteine to Nfs1(C421A)-Isd11 in the presence/absence
of Yfh1 monitored by UV-visible spectroscopy. Black and white markers represent
the change in absorbance at 340 nm at each L-cysteine concentration in the absence
and presence of Yfh1, respectively. Solid and dashed lines indicate the respective bestfit simulations obtained using DynaFit curve fitting software.
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Figure 3.6: Persulfide forming activity of Nfs1-Isd11 in the presence/absence of
Yfh1.
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3.5 Discussion
The exact function of frataxin within mitochondrial Fe-S cluster biogenesis has
been a longstanding question since the protein was discovered to be defective in
Friedreich’s ataxia, a neurodegenerative disorder affecting 1/30,000 Caucasians.
Although initial in vitro studies provided evidence to ascertain the protein’s function as
an iron chaperone delivering Fe for the cluster assembly machinery, later studies
proved additional functions were also likely. In recent years, frataxin has been identified
as a regulator of Fe-S cluster assembly. Evidence was presented to prove that frataxin
achieves this by enhancing cysteine desulfurase activity and sulfur delivery of the core
assembly complex207,235,289. Much of the mechanism of this effect was elucidated in the
human and murine systems, but studies on yeast orthologs are lacking. The objective of
my research was to identify an interaction between Yfh1 and the yeast Nfs1-Isd11
complex, and then to study the effect of Yfh1 on the structure and function of this
system. In such a context, it was proposed that we isolate the necessary proteins and
utilize techniques such as ITC, pull-down assays, and DSC to identify any interaction. In
addition, we planned to use our UV-visible assay and activity assay to study any
possible effect. This chapter describes experimental details and results pertaining to
those projected studies.
The expression and purification of all proteins required for these experiments
were straightforward, since we have already established protocols and our lab is
equipped with required instruments. All isolated proteins were > 90 % pure (Figure 3.1).
Some of the initial experiments used Yfh1 with no additional tag, but later a 6xHis
tagged version of Yfh1 became available for use with an easier, less time-consuming
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and resource-consuming isolation protocol. Therefore later experiments used Yfh1Hisx6. There is no detectable difference in the structure and function of these two Yfh1
variants, and this was confirmed by experiments performed by a fellow graduate student
in the lab (Stephen Dzul). Therefore, results obtained with both versions are directly
comparable. However, for clarity and integrity, each individual experiment was
performed only with one version or the other. The use of the Nfs1(C421A)-Isd11 mutant
complex for UV-visible spectroscopy studies was justified in chapter 2, and our CD,
DSC, and activity assay experiments confirmed it is not significantly different from the
wild type complex.
ITC experiments were proposed to identify a possible interaction between Yfh1
and Nfs1-Isd11 and elucidate physical parameters such as the dissociation constant
and stoichiometry (Figure 3.2). These experiments were plagued with protein
precipitation issues that caused us to question the validity of our ITC results.
Continuous stirring during the experiments seemed to affect the stability of the Nfs1Isd11 complex, although it was more stable as a complex than its constitutive proteins
were individually (chapter 2). Experimental conditions (i.e. stirring speed and buffer
composition) were changed to prevent precipitation; nonetheless it could not be
avoided. Despite protein precipitation, the shifted baseline was surprisingly stable and
not noisy. Although after baseline correction, binding data for one experiment yielded
probable binding parameters in the range of published values for the bacterial system,
subsequent runs failed to reproduce this. Therefore, our results observed here are more
likely to be an outcome of aggregation rather than actual interaction between Nfs1Isd11 and Yfh1. However the binding affinity obtained from this single experiment was
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similar to the published binding affinity seen between the bacterial orthologs285, and the
preliminary results reported by a previous lab member (Swati Rawat) for yeast proteins*.
These preliminary results were obtained using a different ITC instrument and no
precipitation has been documented for her experiment. Since ITC experiments were
subjected to technical limitations, a less rigorous method, surface plasmon resonance
(SPR) was proposed. SPR involves immobilizing a 6xHis-tagged protein on a Ni-affinity
chip and passing the ligand protein over the bound molecule along with the solvent to
allow maximum association. In the next step, dissociation is allowed by passing the
ligand free solvent and the changes in SPR signal during association and dissociation
steps are used to determine equilibrium binding constants. Yfh1 with no tag was passed
with PBST (Phosphate Buffered Saline and Tween-20) buffer over Nfs1-Isd11 (-6xHis)
complex immobilized on the sample channel as well as the empty reference channel.
Interestingly, this technique was also subjected to technical limitations simply because
Yfh1 unexpectedly started binding to the reference channel despite the absence of a
6xHis-tag associated with it. Hence, no reference measurement could be made for
accurate data analysis (data not shown). Association of Yfh1 with nickel ions is not
novel, as reports show nickel serving as a mediator for Yfh1’s interaction with other
cluster assembly components within humans, while other metals act as inhibitors284.
Presumably, frataxin’s acidic ridge, proposed to serve as the iron-binding region, may
facilitate interaction with nickel in this case. Therefore SPR was not capable of verifying
the questionable results from ITC. An in vitro pull-down assay was performed using
purified proteins as the last resort to observe a possible Yfh1 interaction with Nfs1*

Rawat, Swati, "Molecular Details Of The Mitochondrial Iron Sulfur Cluster Assembly Pathway" (2011).
Wayne State University Dissertations. Paper 204.
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Isd11. Nfs1-Isd11 was immobilized to Ni-NTA Agarose resin and subsequent washes
removed any adventitiously bound protein before incubation with Yfh1. Yfh1 was used
in excess (4 times) to ensure maximum and efficient association with the immobilized
complex. Washes immediately after Yfh1 addition contained a significant amount of
unbound Yfh1. Interestingly, the first few washes also contained a minute amount of
Nfs1-Isd11, eluted with excess unbound Yfh1 (Figure 3.3). This could potentially be due
to a displacement of some of the Nfs1-Isd11 complex from the resin by Yfh1 (given that
Yfh1-Ni interaction was observed in SPR experiments too). This is likely however not
due to Yfh1 pulling-down Nfs1-Isd11. No Yfh1 was present in subsequent elution
fractions, indicating no stable association between Yfh1 and Nfs1-Isd11, at least under
the assay conditions we used. Similarly, human NFS1-ISD11 and YFH1 showed no
physical interaction in gel filtration chromatography207. In that context, ITC results could
be confirmed superficial. Overall, these results suggested that a stable interaction
between Nfs1-Isd11 complex and Yfh1 is unlikely. It is therefore likely that this
interaction is transient under these experimental conditions.
In the event of a transient binding interaction, it is possible that Yfh1 interacts
with Nfs1-Isd11 to reach certain functional goals, even though the physical association
is beyond the sensitivity limits of our experimental techniques. To identify if Yfh1 had
any effect on stability, substrate binding affinity, and activity of Nfs1-Isd11, DSC, UVvisible, and activity assay measurements were performed, respectively. DSC thermal
profiles obtained for Nfs1 and Nfs1-Isd11 in the presence of Yfh1 were not significantly
different from their individual thermal profiles (Figure 3.4). Melting temperatures
obtained for individual denaturation events within each profile were not substantially
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affected by Yfh1, indicating that it does not induce changes in protein fold on Nfs1 or
Nfs1-Isd11 globally, or in the domains level of the proteins. Similarly, Yfh1 did not have
any effect on the substrate binding affinity of Nfs1-Isd11 complex (Figure 3.5). In a
previous study, Yfh1 was reported to enhance cysteine binding to Nfs1 by exposing
substrate-binding sites to the exterior116. Therefore it is reasonable to expect a change
in the substrate binding affinity in the presence of Yfh1. However, the opposite was
observed. Yfh1 also had no significant effect on cysteine desulfurase activity of Nfs1Isd11 (Figure 3.6), similar to that seen in the human system207.
With all these evidence, it is reasonable to assume that no stable physical
interaction between Nfs1-Isd11 and Yfh1 exists in yeast Fe-S cluster biosynthesis
machinery. No discrepancy in the structure and function of Nfs1-Isd11 in the presence
of Yfh1 was measured by assessing the thermal stability, substrate binding affinity, and
catalytic activity comparatively. This further supports a lack of any appreciable stable
binding interaction. My results in this chapter add an extra level of comprehension on
the role of eukaryotic frataxin on regulating the cysteine desulfurase. Since human
orthologs show similar behavior207, it is possible to assume that eukaryotic frataxins
have no dramatic effect on their respective cysteine desulfurases when viewed as an
individual binding event. It is now logical to hypothesize that the effect of yeast frataxin
on cysteine desulfurase activity is contingent on the presence of Isu1229. Altered activity
by frataxin in the Nfs1-Isd11-Isu1-Yfh1 (SDUF) cluster synthesis complex was reported
for other systems (discussed in section 3.2.3). The direction of research in such a
context is therefore discussed in detail in a following chapter.
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CHAPTER 4
SOLUBILITY BARRIER PREVENTS STRUCTURAL AND FUNCTIONAL STUDIES
ON ISD11
4.0 Prelude
This chapter describes my initial work on purifying Isd11, the functional partner of
Nfs1 within yeast mitochondrial ISC biogenesis pathway. The objective of this study was
to characterize the molecular features of Nfs1-Isd11 complex by isolating each protein
separately and characterizing their interaction. Isothermal titration calorimetry was
proposed to determine the binding affinity and stoichiometry of Nfs1 and Isd11, and
nuclear magnetic resonance (NMR) spectroscopy, along with chemical shift
perturbations assignments, was to be performed to elucidate the solution structure of
Isd11 and to locate Isd11 residues involved in Nfs1-Isd11 interaction. Work presented
below describes the strategies I employed to purify Isd11 to make protein available for
the experiments suggested above. Isd11 purified partially from soluble fractions
contained predominantly higher order species that were confirmed by western blot
analysis to be our desired protein. Denatured Isd11 purified from insoluble fractions by
urea denaturation failed to recover from urea efficiently in an attempt to refold protein to
its native conformation. Therefore, due to its inherent insolubility and typical “orphanprotein” like nature232, sufficient amounts of Isd11 could not be obtained with either
methods employed. Details of the methods and some preliminary results obtained
during the initial characterization are included in this chapter for general knowledge
since the time and effort I spent working on this protein was significant.
4.1 Introduction
The accessory protein Isd11, first discovered a decade ago by two groups, was
shown to be an 11 kDa protein essential for mitochondrial Fe-S cluster synthesis in
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yeast113,233. Gene deletion experiments verified Isd11 (Iron Sulfur cluster biogenesis
Desulfurase interacting protein) is present in all eukaryotic species but not in any
prokaryote. Isd11 is classified in the LYR family of proteins due to the presence of a
LYR/K amino acid residue segment near its N-terminus113,233. Cellular localization
experiments and the absence of any predicted transmembrane segments confirmed
that Isd11 is a mitochondrial matrix protein loosely associated with the inner
membrane113,233. It does not contain a cleavable mitochondrial targeting sequence, and
it is imported into mitochondria in a ∆Ψ-dependent manner233. In studies performed to
search for the function of Isd11, cells depleted of Isd11 have shown reduced maturation
of Fe-S clusters and decreased activity of Fe-S proteins such as aconitase and
succinate dehydrogenase. Isd11 depleted cells further expressed iron accumulation
characteristics. It is for both reasons that Isd11 was suggested to have a function linked
to Fe-S cluster biogenesis and cellular iron homeostasis113,233. Yeast cysteine
desulfurase Nfs1 forms a stable complex with Isd11 in vivo and in the absence of Isd11
Nfs1 aggregates. Therefore Isd11 was also predicted to have a stabilizing effect on
Nfs1 when the enzyme operates to provide sulfur component for the cluster synthesis.
These initial studies also reported that Isd11 is not required for sulfide production
activity by Nfs1 in vitro113,221,233, however Isd11 and complex formation with Nfs1 are
needed for the maturation of Fe-S proteins in vivo, implying that Nfs1-Isd11 is the
physiological cysteine desulfurase complex.
A similar study in HeLa cells showed localization of human ISD11 to the
mitochondria and nuclei, and formation of a complex with human cysteine desulfurase
ISCS. Co-expression of ISCS with ISD11 in bacteria recovered ISCS from being
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sequestered to inclusion bodies by facilitating correct folding and enhanced cysteine
desulfurase activity. ISD11 deficiency caused a cytosolic iron deficiency phenotype and
activated iron regulatory proteins IRP1 and IRP2 in cells, leading to the conclusion that
ISD11 is important in maintaining cellular iron homeostasis in humans293.
A number of studies that followed examined Isd11’s binding partners and
attempted to understand the exact function of Isd11 within the Fe-S cluster biosynthesis
pathway as well as understanding its role in maintaining cellular iron homeostasis. The
findings of such studies are discussed below.
4.1.1 Structure and oligomeric state of Isd11
Isd11 lacks a characterized crystal or solution structure, likely due to the inherent
insolubility of the protein that has been reported many times since its discovery. One
study attempted to look at Isd11 three dimensionally using an ab-initio structure
prediction server Robetta to build the best possible structure of Isd11. The model
primarily consisted of α-helices, as predicted previously (with secondary structure
prediction software)217. Docking experiments predicted the attachment of Isd11 to the
Fe-S cluster assembly complex containing Isu1, Yfh1, and Nfs1234. A single far-UV
circular dichroism (CD) study performed recently indicated that the protein’s structure
was comprised of 57% α-helices and 10% β-sheets232 further confirming the α-helical
nature of ISD11.
This same study isolated human ISD11 from E. coli in the soluble form (by
expressing in conjunction with a cleavable N-terminal GST tag)232. This protein was not
found to be monomeric, but instead it existed as a heterogeneous mixture comprising of
large and small oligomeric units of dimer-tetramer and monomer-dimer species
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respectively. Ratios between oligomers in each species varied with the concentration
and purified lifetime of Isd11, and therefore the oligomers were proposed to be in
equilibrium. CD thermal denaturation profile for ISD11 revealed a relatively higher
melting temperature of ~67 °C, but the integrity of this result is questionable due to the
oligomeric nature of purified ISD11232. Besides these reports, no structural details are
available for Isd11, and this hinders us from understanding its function better.
4.1.2 Functional interactions of Isd11 in Fe-S cluster assembly
In the search for the precise function of Isd11 during Fe-S cluster synthesis,
numerous studies have discovered individual interacting partners on Isd11 as well as
multiprotein complexes containing Isd11.
One such study on human system reported that frataxin (FXN) interacts with
ISD11 of the NFS1/ISCU complex and a knockdown of ISD11 creates frataxin
deficiency like phenotypes, aconitase deficiency and cellular iron overload. Pull-down
assays confirmed that I154F and W155R point mutations of FXN inhibit its interaction
with ISD11. Therefore it was suggested that ISD11 serves as an adaptor between FXN
and NFS1/ISCU complex284. This fact was further confirmed when the same FXN point
mutations

depicted

above

promoted

a

reduced

affinity

towards

the

SDU

(NFS1/ISD11/ISCU) complex287. Similarly, the yeast Nfs1-Isd11 complex directly
interacts with oligomeric yeast frataxin homolog (Yfh1) and the interaction is mediated
at least in part by contact between Isd11 and Yfh1283. A modeled structure for yeast FeS cluster assembly protein complex (including Yfh1, Nfs1, Isd11, and Isu) with two
Isd11 proteins shows that Isd11 and Yfh1 are in close proximity, providing implications
on Isd11’s involvement in mediating the Yfh1-Nfs1 interaction234.
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Evidence for interactions of Isd11 with the scaffold protein Isu have only been
reported once. This study utilized 15N TROSY-HSQC NMR experiments to show that the
addition of unlabeled human ISD11 to labeled scaffold protein ISCU leads to no
changes in NMR spectra, and this indicate that ISD11 does not interact directly with
ISCU294.
Interactions of Isd11 with its functional binding partner Nfs1 has also been
studied, but again due to inherent instability of both proteins in the absence of complex
formation (as described in chapter 2), the number of such studies is limited. The only
reported binding data between the proteins is available for human ISD11, which binds to
human NFS1 with a Kd of 100 nM, as measured by surface plasmon resonance (SPR)
spectroscopy230. Eight ISD11 residues (F40, L63, R68, Q69, I72, Y76, L81, and E84)
are critical for the NFS1-ISD11 interaction, and these were identified recently. Mutating
them compromised the NFS1-ISD11 interaction and this led to reduced Fe-S cluster
assembly and diminished mitochondrial respiration214.
Existence of Isd11 within multiprotein complexes with other partners of the Fe-S
cluster assembly machinery has been reported, along with their stoichiometry discussed
in several systems, most of which are outlined in chapter two.
4.1.3 Role of Isd11 in Fe-S cluster assembly
Since its discovery, Isd11 was found associated with its functional partner
cysteine desulfurase in all eukaryotic systems. Elucidating the purpose and role of such
interaction is an area of interest within the Fe-S cluster assembly field. Proposed
functions of Isd11 include activating catalytic function of cysteine desulfurase and
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stabilizing cysteine desulfurase by preventing aggregation. These hypotheses have
been tested in several studies over the past years.
4.1.3.1 Isd11 prevents aggregation of Nfs1
The effect of Isd11 preventing Nfs1 aggregation was reported in the two initial
studies within yeast. In one report, isolated mitochondria depleted of Isd11 contained
higher order aggregates of Nfs1 within the insoluble fraction, following incubation of the
system at 37 °C. Moreover, in lysed mitochondria, Nfs1 was prone to proteolytic
degradation by endogenous proteases and also showed a lack of association with
mitochondrial membranes in the absence of Isd11233. Similarly, the other study reported
the presence of Nfs1 within the pellet when mitochondria were isolated from heatshocked conditional Isd11 mutant strains. During prolonged incubation at nonpermissive temperatures, Nfs1 readily degraded113. Both studies concluded that Isd11
functions as a stabilizer for Nfs1 in vivo.
An additional study suggested that Isd11 binds to Nfs1 in its oligomerization
surface in the three-dimensional modeled structure for yeast Fe-S cluster assembly
protein complex, and thereby prevents the aggregation seen in the previous
examples234. More recently, eight human ISD11 residues were identified as important
for the NFS1-ISD11 interaction, and they were also marked as being essential in
preventing aggregation of NFS1 in vitro214.
Chapter two of this dissertation describes the work performed to elucidate the
biophysical basis of the stability imparted by Isd11 onto yeast Nfs1. Instability of Nfs1,
when expressed and purified not in complex with Isd11, was again observed in vitro.
The hypotheses that the Nfs1-Isd11 co-complex must possess higher thermal stability
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than the proteins alone, and that complex formation stabilizes Nfs1 by binding and
inducing a more compact and stable fold in Nfs1 were tested using differential scanning
calorimetry and fluorescence spectroscopy respectively. The SD complex was over 20
°C more stable than Nfs1 alone and a conformational change on Nfs1 induced by Isd11
binding was suggested to alter the fold of the enzyme. Therefore my work provides
insight into how Isd11 stabilizes Nfs1.
4.1.3.2 Isd11 activates cysteine desulfurase
Although initial studies proposed that Isd11 complexation with Nfs1 is only
essential for maturation of Fe-S proteins in vivo but not in vitro, recent studies have
proved otherwise213,224. It was discovered that the assays previously utilized to measure
sulfide production did not clearly eliminate other sources of sulfide within the assay
mixture, hence providing false positive results224. A recent study utilized a novel
approach to prove that Nfs1 by itself was inactive, but that Isd11 was capable of
activating the cysteine desulfurase function within isolated mitochondria as well as with
purified proteins. A carefully designed radiolabeling experiment, which separated the
substrate-binding step of Nfs1 from its persulfide forming step, revealed that Nfs1 is
capable of binding its substrate cysteine even in the absence of Isd11, but persulfide
formation is strictly dependent on the presence of Isd11. It was suggested that Isd11
binding to Nfs1 induces a conformational change that brings the catalytic cysteine
residue and bound substrate in close proximity for persulfide formation116,224.
4.1.4 Other functions of Isd11 in cellular milieu
Since it was shown that Isd11 enhances the cysteine desulfurase reaction by
associating with Nfs1, the role of this protein was also deemed important for other
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pathways that Nfs1 serves as the sulfur donor. One study reported that yeast Isd11 is
essential for tRNA thiolation in addition to its function in Fe-S cluster assembly within
the flagellate Trypanosome brucei system. Isd11 forms a stable complex with Nfs1 and
aids in sulfur delivery to drive tRNA thiolation in both cytoplasm and mitochondria295.
4.1.5 Isd11 and human diseases
So far, the number of diseases associated with defective Isd11 is limited to one.
A mutation in the LYRM4 gene encoding ISD11 in humans causes combined oxidative
phosphorylation deficiency (COXPD), a disease in which respiratory complexes I, II, and
III and several other Fe-S proteins are deficient in muscle and liver213. Consequentially
due to defective oxidative phosphorylation, patients develop neonatal lactic acidosis,
respiratory distress and hypotonia296. A recent study showed that the R68L mutation
that causes COXPD impairs the ability of ISD11 to form a stable complex with NFS1214.
Given the importance of Isd11 in activating cysteine desulfurase during cluster
assembly, it is no wonder if more diseases associated with Isd11 are discovered in the
future.
4.2 Experimental methods
4.2.1 Bacterial expression and isolation of Isd11
4.2.1.1 Purification of Isd11 from soluble fraction of the cell lysate
Isd11-6xHis was expressed and purified from the soluble fraction as described
previously, only with slight modifications to the protocol225. Briefly, the pET21b vector
containing Isd11 with a C-terminal 6xHis tag was transformed into BL21 (DE3) codon
plus cells to express Isd11-6xHis. Starter cultures were made by inoculating a
transformed colony in LB broth supplemented with 100 µg/ml ampicillin and 34 µg/ml
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chloramphenicol, and this was incubated in a rotating shaker overnight at 200 rpm and
37 °C. Growth cultures (200 ml) were supplemented with 100 µg/ml ampicillin and 34
µg/ml chloramphenicol, and the starter culture was diluted in LB in 1:40 ratio. Cells were
grown at 37 °C in LB broth until the cell density reached 0.6 OD600; then the shaker
temperature was switched to 25 °C. After a 10 min incubation at the lower temperature,
cells were supplemented with 0.5 M filtered sorbitol and induced with 0.2 mM IPTG after
incubating for 15 min. Cells were allowed to grow at 25 °C for 72 hours before
harvesting

by

centrifugation.

This

protocol

yielded

a

significant

amount

of

overexpressed Isd11 within soluble fraction, as opposed to the regular 3-hour induction
at 37 °C protocol. Cell pellets were resuspended in lysis buffer containing 50 mM Tris
HCl (pH 8.0), 10 % glycerol, and 1 mM PMSF. Cells were lysed by six rounds of
sonication (20 s each round and 2 min intervals while samples are kept on ice). Lysate
was spun at 12100 x g for 30 min at 4 °C and the supernatant was mixed with His-select
Ni affinity resin (600 µl resin, Sigma P6611, pre-washed with water and lysis buffer) for
3 hours at 4 °C on a rocking platform to allow end-to-end mixing. After removing
unbound protein, the resin was further washed with 50 mM Tris HCl (pH 8.0), 10 %
glycerol, 10 mM imidazole, and 1 mM PMSF at wash buffer to eliminate any residual
unbound protein. Bound protein was then eluted using elution buffer containing 50 mM
Tris HCl (pH 8.0), 10 % glycerol, 400 mM imidazole, and 1 mM PMSF. Fractions
containing soluble Isd11 were identified using SDS-PAGE. All buffers used were made
fresh by mixing suitable stock solutions as needed and fresh Ni affinity resin was used
each time.
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4.2.1.2 Purification of Isd11 from insoluble fraction of the cell lysate
Expression and purification of Isd11-6xHis from insoluble fractions followed a
deviated protocol from the one above225. Briefly, same protocol as above was followed
to start growth cultures. Cells were grown at 37 °C in LB broth until the cell density
reached 0.7-0.8 OD600. Cells were then induced with 0.5 mM IPTG. Cells were allowed
to grow at 37 °C for 3 hours before harvesting by centrifugation. When cells were grown
under these conditions, the majority of overexpressed Isd11 was found in bacterial
inclusion bodies due to lack of solubility. Cell pellets were resuspended in lysis buffer
containing 50 mM Tris HCl (pH 8.0), and 1 mM PMSF. Cells were lysed by six rounds of
sonication (20 s each round and 2 min intervals while samples are kept on ice). Lysate
was spun at 12100 x g for 30 min at 4 °C and crude soluble fraction was removed.
Pellet containing insoluble Isd11 was dissolved with a denaturing buffer containing 50
mM Tris HCl (pH 8.0), 8 M urea, and 1 mM PMSF, and the resulting suspension was
spun at 65000 x g at 20 °C for 30 min. Supernatant was mixed with His-select Ni affinity
resin (600 µl resin, Sigma P6611, pre-washed with water and denaturing buffer) for 3
hours at room temperature on a rocking platform to allow end-to-end mixing. After
removing unbound protein, the resin was further washed with denaturing buffer to
eliminate any residual unbound protein. Bound protein was then eluted using 50 mM
Tris HCl (pH 8.0), 8 M urea, 400 mM imidazole, and 1 mM PMSF buffer. Fractions
containing denatured Isd11, identified using SDS-PAGE were pooled and stored at
room temperature until further use. All buffers used were made fresh by mixing suitable
stock solutions as needed and fresh Ni affinity resin was used each time.
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4.2.2 Western blot
In preparation for western blot analysis, samples containing purified Isd11 were
subjected to SDS-PAGE. Samples were run on a 4-20 % gel (Bio-Rad Mini-PROTEANTGX) at 120 V to allow separation of proteins. Nitrocellulose membrane (0.2 µm) was
cut to overlap with the dimensions of the gel and then pre-soaked in transfer buffer
containing 25 mM Tris, 192 mM glycine, 20 % methanol, and 0.1 % SDS. This was
done along with fiber pads and filter papers required to make the transfer sandwich. The
SDS-PAGE gel was also pre-soaked in transfer buffer for 15 min. Transfer cassette was
assembled so as to sandwich the gel and nitrocellulose membrane between filter paper
and fiber pads on both sides without introducing air bubbles; this was done to allow
smooth transfer of proteins to the membrane. Protein transfer was performed overnight
at 22 V in the cold room (4 °C) under stirring conditions. Membrane was washed with
TBST buffer (20 mM Tris, 150 mM NaCl, 0.1 % Tween-20 at pH 7.5) for 5-10 min on a
rocking platform. Efficiency of protein transfer was checked by staining the membrane
with Ponceau Red solution (0.2 % Ponceau S dye, 3 % trichloroacetic acid, and 3 %
sulfosalicylic acid) for 5 min. Background stain was removed by thoroughly washing with
water. Once the bands were visualized for successful transfer, Ponceau Red stain was
completely removed by washing with water and TBST buffer. Membrane was blocked
using blocking solution containing 5 % (w/v) skim milk powder in TBST buffer for 30
min. The membrane was then treated with primary antibody (anti-Isd11 rabbit antiserum
in blocking solution, 1:500 dilution) for 3 hours on a rocking platform. Membrane was
further washed three times (10 min each) with TBST buffer to remove unbound primary
antibody before incubating with the secondary antibody solution (Bio-Rad anti-rabbit
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HRP conjugated antibody, 1:10,000 dilution) for one hour at room temperature.
Unbound secondary antibodies were removed by washing with TBST buffer three times,
10 min each. Isd11 was identified by incubating the membrane for 5 min with Bio-Rad
Clarity Western ECL Substrate and detecting chemiluminescence with a digital imager.
Urea solubilized Isd11 served as the positive control for the experiment.
4.2.3 Protein refolding
This section describes techniques I used in the attempt to refold urea denatured
Isd11 isolated from bacterial inclusion bodies. All methods were unsuccessful towards
yielding soluble monomeric Isd11. Typical results provided protein aggregates that
precipitated out of solution. Only one method, using a liquid chromatography desalting
column could recover soluble protein, but this method did not yield sufficient protein to
perform any of the proposed experiments.
4.2.3.1 Sequential dialysis
Purified urea-denatured Isd11 was dialyzed into a series of buffers with
decreasing urea concentrations and then finally into urea free buffer. Isolated protein
was originally placed in 50 mM Tris HCl (pH 8.0), 8 M urea, 400 mM imidazole, and 1
mM PMSF buffer. Protein samples were placed in Slide-A-Lyzer dialysis cassettes
(ThermoFisher Scientific) and dialyzed into 500 ml of buffer containing 50 mM Tris HCl
(pH 8.0), 6 M urea, 100 mM NaCl, 10 % glycerol, and 1 mM PMSF for 3 hours at room
temperature while stirring (buffer: protein ratio was maintained at 250:1). Subsequent
buffers had the same composition except the urea concentration was gradually lowered
to 4 M, 2 M, 1 M, and 0 M. Cassettes were checked visually for precipitation after each
dialysis step and any precipitation was removed by spinning down at 14000 x g for 10
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min before proceeding to the next buffer. Fresh cassettes were used in any incidents of
visible precipitation. Protein concentrations at each step were measured using the
Advance Assay to evaluate the amount of protein recovered.
4.2.3.2 Spin chromatography desalting column
In a second method, purified urea-denatured Isd11 in 50 mM Tris HCl (pH 8.0), 8
M urea, 400 mM imidazole, and 1 mM PMSF buffer was desalted to gradually remove
urea. Isolated protein samples (75 µl) were placed in a Micro Bio-Spin 6
chromatography column (Bio-Rad), which consists of a special grade polyacrylamide
gel designed to desalt proteins. Desalting was carried out by following the manufacturer
instructions. Fresh buffer containing 50 mM Tris HCl (pH 8.0), 6 M urea, 100 mM NaCl,
10 % glycerol, and 1 mM PMSF buffer was applied to the column pre-equilibrated with
the same buffer before spinning at 1030 x g for 4 min using a microcentrifuge. Flow
through was collected and subsequent buffers were applied, which had 6 M, 4 M, 3 M, 2
M, 1 M, and 0 M urea concentrations. Fresh columns were used for each dialysis step.
Protein concentrations at each step were measured using Advance Assay to evaluate
the amount of protein recovered in each step.
4.2.3.3 Refolding by immobilizing on a nickel chelating column
Cells containing Isd11 were grown using the protocol at section 4.2.1.2.
“Purification of Isd11 from insoluble fraction”. The same protocol was followed to
separate the supernatant containing urea solubilized Isd11 by centrifugation at 65000 x
g for 30 min at 20 °C. The supernatant was then diluted (1:3) with a buffer comprised of
100 mM Tris HCl (pH 8.0), 0.5 M NaCl, 10 % glycerol, 1 mM PMSF, and 0.5 M arginine
for the final urea concentration in the supernatant to reach 2 M. His-select Ni affinity

140
resin (600 µl resin, Sigma P6611) was pre-washed with the above buffer before
applying the supernatant to the resin. Isd11 was allowed to bind to the resin by end-toend mixing on a rocking platform for 3 hours at 4 °C. The flow through was collected
and the column was washed with a buffer containing 100 mM Tris HCl (pH 8.0), 0.5 M
NaCl, 10 % glycerol, 1 mM PMSF, 0.2 M sucrose, and 0.5 M arginine. To remove nonspecifically bound protein, the column was further washed with the same buffer
although with 10 mM imidazole added. Isd11 bound to the column was eluted by using
0.4 M imidazole buffer with all the additional components outlined above.
4.2.3.4 Liquid chromatography desalting column
Purified urea-denatured Isd11 was passed through HiTrap Desalting column (GE
Healthcare) attached (5 ml) to an AKTA FPLC system (GE Healthcare) as a means to
allow refolding by removing denaturant. The column was pre-equilibrated with 50 mM
Tris HCl (pH 8.0), 10 % glycerol, 250 mM NaCl, and 1 mM PMSF buffer before applying
the denatured Isd11 (1.5 ml of sample made by diluting 1:1 with the same running
buffer). The column was then run at 1 ml/min flow rate. Fractions containing refolded
protein were identified from the chromatogram and SDS-PAGE gel, and they were spun
down at 14000 x g for 5 min to remove any precipitate present. Pooled fractions were
concentrated using 10 kDa Amicon centrifugal filter devices. Isd11 concentrations
before and after passing through the column were measured using Advanced Assay®
for protein detection to calculate the yield after desalting and protein was stored at -80
°C for further use.
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4.2.4 Circular dichroism
Circular dichroism spectra were collected to check the integrity of Isd11 structure
following refolding. CD data of a 40 µM Isd11 sample in 1 mM sodium phosphate buffer
(pH 8.0) were collected at room temperature using the Applied Photophysics π* 180 CD
instrument with a 0.2 mm quartz CD cell. Eight independent scans were collected over a
wavelength range of 190-260 nm. Buffer baseline was subtracted from averaged
spectra to obtain baseline correction and spectral simulations by CDNN software of
Applied Photophysics suggested secondary structural elements for refolded Isd11.
4.3 Results
4.3.1 Bacterial expression and isolation of Isd11
4.3.1.1 Isd11 purified from soluble fraction of the cell lysate
Our purification protocol to isolate Isd11 from the soluble fraction of bacterial cell
lysate yielded a small amount of monomeric Isd11 (yield of total purified protein was
~150 µg per 1 liter of bacterial cells), but also contained higher order oligomeric
structures as well (Figure 4.1, lanes 9 and 10). This observation is in agreement with
the results published recently saying Isd11 purified from soluble fraction is polydisperse
and comprised of a heterogeneous mixture of oligomers232. This protocol did not yield
sufficient amounts of Isd11 (mg quantities) required to perform my suggested
experiments. Even if the yield was substantial, due to the heterogeneous nature of
purified Isd11, use of such protein in further experiments was questionable. Scaling up
preparation was not an option, as it increased the amount of impurities in isolated
protein samples (data not shown).
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Figure 4.1: SDS-PAGE for purification of Isd11 from soluble fraction of cell lysate.
Lane labels read: 1-molecular weight marker, 2-cells pre-induction, 3-cells postinduction, 4-cell lysate, 5-supernatant, 6-pellet, 7- flow through, 8-unbound wash, 9elute 1, and 10-elute 2.
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4.3.1.2 Isd11 purified from insoluble fraction of the cell lysate
Our purification protocol to isolate Isd11 from the insoluble fraction of bacterial
cell lysate yielded ~100 % pure (yield of purified protein was ~5 mg per 1 liter of
bacteria cells) monomeric Isd11 (Figure 4.2). This protocol could yield sufficient
amounts of Isd11 (mg quantities) required to perform suggested experiments, but since
Isd11 was present in its denatured form dissolved in 8 M urea, refolding techniques
were attempted to refold Isd11 as described below.
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Figure 4.2: SDS-PAGE for purification of Isd11 from insoluble fraction of cell
lysate. Lane labels read: 1-molecular weight marker, 2-cells post-induction, 3-cell
lysate, 4-supernatant, 5-inclusion bodies pellet, 6-solubilized inclusion bodies, 7-flow
through, 8-unbound wash, 9-elute 1, 10-elute 2, and 11-elute 3.
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4.3.2 Western blot
In order to confirm the oligomers present in the Isd11 preparation from soluble
fraction of cell lysate are indeed oligomers of Isd11, a western blot was performed
against Isd11. The higher order oligomers and monomers of Isd11 transferred to the
membrane, expressed chemiluminescence signals upon detection (Figure 4.3),
indicating that Isd11 isolated from soluble fraction most certainly forms oligomeric
structures. This observation further confirms the results above from SDS-PAGE
analysis, which immediately followed purification and results published recently saying
Isd11 purified from soluble fraction comprised of a heterogeneous mixture of
oligomers232.
4.3.3 Protein refolding
4.3.3.1 Sequential dialysis
In the attempt to refold urea denatured Isd11 isolated from bacterial inclusion
bodies using the sequential dialysis method, Isd11 continuously aggregated and fell out
of the solution as the urea concentration was gradually lowered. No precipitation was
observed when transferred to 6 M urea, but there onwards protein levels gradually
decreased, as measured with Advanced Assay® reagent (Table 4.1). The minimum
concentration of urea required to detect a significant amount of Isd11 remaining in
solution was 2 M and no protein could be detected thereafter.
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Figure 4.3: Western blot for Isd11 purified from soluble fraction. Lane labels read:
1-urea denatured Isd11 (positive control), 2 and 3-Isd11 from soluble fraction.
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Table 4.1: Protein concentrations measured in each dialysis buffer in the sequential
dialysis method to refold urea denatured Isd11.
Urea concentration in
dialysis buffer

Isd11 concentration remaining
after each step

Precipitation observed

8M

309 µM

-

6M

-

No

4M

134 µM

Yes

2M

56 µM

Yes

1M

Not detected

No

0M

Not detected

No
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4.3.3.2 Spin chromatography desalting column
With the use of Micro Bio-Spin 6 chromatography columns, Isd11 levels
continuously decreased as measured with Advanced Assay® reagent (Table 4.2) when
the protein was transferred to lower urea concentrations. The minimum concentration of
urea required to detect a significant amount of Isd11 remaining in solution was 3 M and
no protein could be detected thereafter.
4.3.3.3 Refolding by immobilizing on a nickel chelating column
In the attempt to refold urea denatured Isd11 while being immobilized to the
nickel affinity column, Isd11 eluted as a suspension with white precipitate from the
column. The suspension was spun down to remove any precipitated protein and the
amount of protein remaining in the supernatant was measured using Advanced Assay®
reagent. No remaining protein was detected.
4.3.3.4 Liquid chromatography desalting column
We used a HiTrap Desalting column to elute Isd11 out with the refolding buffer,
and monitored the buffer exchange process using conductivity measurements (Figure
4.4). An SDS-PAGE gel of the peak fractions revealed the presence of ~97% pure
monomeric Isd11 (Figure 4.5). Most fractions contained visible white precipitate,
indicating some level of oligomerization, but once the precipitate was removed only the
monomeric species remained in the soluble fraction. Isd11 concentrations measured
before and after passing through the column showed that ~90 % of protein present in
urea media is lost due to aggregation during refolding (Table 4.3).
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Table 4.2: Protein concentrations measured in each dialysis buffer in the spin
chromatography desalting method to refold urea denatured Isd11.

Urea concentration in
dialysis buffer

Isd11 concentration remaining
after each step

8M

309 µM

6M

314 µM

4M

310 µM

3M

186 µM

2M

Not detected

1M

Not detected

0M

Not detected
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Figure 4.4: Desalting chromatogram for urea denatured Isd11. UV intensity and
conductivity are depicted as a solid line and a dashed line respectively. Refolded Isd11
elutes out with the new buffer in the void volume of the column. Buffer containing urea
elutes later.
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Figure 4.5: SDS-PAGE of Isd11 containing fractions from desalting column. Lanes
1 to 6-fractions containing Isd11, 7-molecular weight marker.
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Table 4.3: Isd11 concentrations measured before and after passing through HiTrap
desalting column.
Attempt

Concentration before column

Concentration after
column

% Recovery

1

222 µM

22 µM

10.0

2

208 µM

21 µM

10.1
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4.3.4 Circular dichroism (CD) of refolded Isd11
CD spectra of refolded Isd11 suggested the secondary structure was primarily
helical (Figure 4.6). Spectral simulations for eight individual scans estimated the
percentage of each secondary structural element in Isd11 as depicted in Table 4.4.
Having a greater percentage of ordered structural elements, as opposed to random
coils, suggested that Isd11 may have refolded to its native structure. But, due to
heterogeneity of Isd11 purified from the soluble fraction, a direct comparison of refolded
Isd11 versus soluble Isd11 was not feasible. To make a comparison, no CD structure
analysis results have been published previously for the yeast Isd11 either.
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Figure 4.6: Circular dichroism spectra of refolded Isd11. CD data of a 40 μM Isd11
sample in 1 mM sodium phosphate buffer (pH 8.0) were collected at room temperature.
This spectrum represents the average of eight spectra.
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Table 4.4: Secondary structure elements of refolded Isd11 determined by far-UV CD.
Secondary structural elements

%

α-helices

26.20 (± 0.12)

Antiparallel β-sheets

17.90 (±0.50)

Parallel β-sheets

8.52 (±0.13)

β-turns

17.90 (± 0.08)

Random coils

29.51 (±0.59)
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4.4 Discussion
Since its discovery, Isd11 has been suggested to function within the eukaryotic
mitochondrial Fe-S cluster biogenesis pathway by primarily associating with the
cysteine desulfurase Nfs1 and promoting Nfs1 activation towards persulfide formation.
Functional association between Nfs1 and Isd11 within a complex has been reported, but
no attempts were made to elucidate the characteristics of the interaction. Such
information can help explain how Isd11 exerts its modulating effect on Nfs1
stability/activity. Moreover it would also provide insight into the need to have Isd11
exclusively in eukaryotic species, as it is required to aid cysteine desulfurase activity in
eukaryotes but prokaryotic cysteine is perfectly self sufficient. In such context, it was
proposed to isolate the two partner proteins (Nfs1 and Isd11) separately and
characterize the interaction between them by NMR and ITC. This chapter described the
efforts made to isolate Isd11 individually. Despite the number of methods employed,
sufficient amounts of protein could not be yielded to perform experiments due to
inherent insolubility and/or instability of Isd11 in the absence of Nfs1. Hence the project
is currently stalled until a better method of isolating pure homogeneous Isd11 can be
determined.
The observed oligomeric nature of purified Isd11 lead to the conclusion that
Isd11 could be present as a heterogeneous mixture of oligomers under non-denaturing
conditions. Higher order oligomers were present when Isd11 was isolated from the
soluble fraction of the cell lysate, in close agreement with the polydisperse nature of
Isd11 under reported recently non-denaturing conditions232. Oligomerization is
inevitable, even when denatured Isd11 is refolded by transferring to non-denaturing
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conditions, which further confirms the tendency of Isd11 to cluster when forced to exist
in the absence of its binding partner, Nfs1. This nature could very well be attributed to
the “complex-orphan protein” like behavior of Isd11 that was proposed recently by
another group232. Complex-orphan proteins are difficult to produce in the absence of its
native binding partner and/or cofactor, as they tend to aggregate although they may not
necessarily be unstable/defective in a thermodynamic standpoint286. Therefore it is
possible that the aggregated state of Isd11 may also be functionally significant, although
it may not represent its true physiological oligomeric state. This nature is also seen for
other proteins involved in Fe-S cluster biogenesis such as IscU286 and Isu1 (by
experience from ongoing projects our lab). As mentioned in Chapter 2 and reported in
previous publications113,214,233,234, the fact that Isd11 prevents the aggregation of Nfs1 by
binding to its oligomerization surface can be postulated in reverse in this context: Nfs1
prevents aggregation of Isd11 as well. Therefore, the Nfs1-Isd11 interaction could
primarily be functional in activating cysteine desulfurase activity as a complex, and
secondarily as a mutual relationship in maintaining protein stability for efficient catalysis.
The fact that Isd11 oligomers could be observed in the denaturing SDS-PAGE is
surprising, knowing that SDS denatures proteins and disrupts their interactions. But
given the nature of intermolecular interactions, SDS may not necessarily denature all
secondary structures and completely disrupt all interactions, especially the stronger
ones. The fact that Nfs1-Isd11 is soluble and stable as a complex but the two proteins
aggregate in the absence of each other suggests the interaction interface between
these two proteins could predominantly be hydrophobic. Covering up hydrophobic
regions of both proteins by complexation could very well stabilize them as a single
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functional unit. If such notion is correct, oligomerization of Isd11 in the absence of Nfs1
could be an attempt to hide exposed hydrophobic patches in an enclosed environment.
Based on the affinity of the interactions between units in the oligomer, it is possible that
SDS is not capable of disrupting them completely; hence oligomers can be visualized
even in denaturing SDS-PAGE gels. Western blots performed against Isd11 further
confirmed these oligomers as comprising of Isd11.
Various methods were employed in the attempt to refold denatured Isd11
isolated from bacterial inclusion bodies. Sequential dialysis allowed the gradual
decrease of urea in the protein’s environment, which is essential to drive correct
refolding of Isd11 by populating folding intermediates that will most likely aggregate if a
direct dilution is performed. Moreover, refolding using any desalting chromatography
column with a porous resin provides a favorable pace at which Isd11 could interact with
the renaturant, that allows slow folding kinetics and physical separation of refolding
intermediates preventing aggregation. Similarly, nickel-chelating columns provide a
matrix for unfolded protein to attach during refolding and thereby prevent unwanted
intermolecular interactions leading to aggregation. Chemical additives such as Larginine and sucrose are also commonly used as refolding aiding agents297. In
sequential dialysis lesser protein was detected even at 4 M urea compared to spin
desalting column, which gave higher protein at 3 M urea. Therefore it is apparent that
Isd11 prefers the assistance of a porous environment in refolding. But even with the use
of a spin desalting column, no Isd11 was remaining in the final non-denaturing buffer
probably because applying centrifugal forces to elute Isd11 must not have provided
sufficient time for refolding. Immobilization on nickel chelating column yielded no
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refolded protein, probably due to incompatibility of Isd11 and chemical additives used.
Clearly the best method to refold Isd11 was the use of liquid chromatography desalting
column because it allowed recovery of at least 10 % protein in the non-denaturing buffer
while other methods failed to recover any. The porous resin environment and controlled
flow rate must have provided better conditions to refold Isd11. Overall, none of the
techniques were able to recover Isd11 from the denaturing conditions, and therefore
failed to provide sufficient amounts to perform experiments.
Structural details of Isd11 are scarce, and a potentially easy technique to obtain
a crude estimation of its secondary structure constituents is using circular dichroism. It
is also a perfect measurement to observe if Isd11 isolated from insoluble fraction has
refolded to its native structure upon removal of urea by comparison with native Isd11
isolated from the soluble fraction. Unfortunately, due to the oligomeric nature of Isd11 in
the soluble fraction (as described in section 4.3.1.1.), a direct comparison could not be
performed. Having a greater percentage of ordered structural elements, as opposed to
random coils, suggested that Isd11 may have refolded to its native structure. But, as
mentioned above, the certainty of this fact could not be verified. Although this result
agrees with the secondary structure prediction studies217 and ab-initio protein modeling
attempts234 that suggest yeast Isd11 structure as primarily helical, it is deviated farther
from the results obtained for human ISD11 in a recent far-UV circular dichroism (CD)
study. That study confirmed a higher α-helical content for ISD11, 57% and 10% βsheets232. Human ISD11 and yeast Isd11 shares ~60 % sequence similarity. This may
suggest that the ratios of structural elements we see for refolded yeast Isd11 could be
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superficial due to improper folding and yeast Isd11 could be more helical than we
observed.
In conclusion, all results point towards the notion that complex formation between
Nfs1 and Isd11 is mutual necessity to maintain the structure of both partners as much
as it is important functionally. Individual proteins are unstable and the efforts to study
them separately may not provide physiologically relevant information as much as for the
complex. Therefore the opportunity to understand the reason behind the requirement for
the presence of Isd11 for cysteine desulfurase activity in eukaryotes relies on the
attempts to obtain the crystal structure of this complex. Significant effort has been made
towards that goal in our lab.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
5.0 Prelude
A number of human disorders show direct correlations to disrupted iron
homeostasis within the body. Among them are the most common neurodegenerative
disorders (Alzheimer’s, Parkinson’s, Friedreich’s Ataxia and Huntington’s), all of which
are complicated due to iron induced oxidative damage of nerve cells that is caused by
iron accumulation in the central nervous system. Pertaining to the growing occurrence
and devastating burden associated with these diseases, the emphasis towards
understanding the pathophysiology related to the role of iron homeostasis within these
disorders becomes more and more important every day. As the second most prominent
class of iron cofactor within the body, Fe-S clusters play an essential role in helping the
body maintain proper iron homeostasis. In the case of Friedreich’s ataxia, caused by a
deficiency in the protein frataxin that is indispensable during Fe-S cluster assembly, the
impact of iron homeostasis related to the disorder is directly obvious. Friedreich’s ataxia
and other disorders associated with defective Fe-S cluster assembly accentuate the
need to unravel the structural and functional aspects of this fundamental biochemical
pathway. Effective disease treatment has been hampered by the lack of a molecular
level understanding for the individual roles key proteins play in Fe-complex formation.
The work described in this dissertation attempts to diminish this knowledge gap by
providing a comprehensive biophysical characterization of the key proteins involved in
sulfur mobilization during the yeast mitochondrial Fe-S cluster synthesis process. The
role of the accessory protein “Isd11” within the catalytic activity of the cysteine
desulfurase “Nfs1” has been assessed in a detailed manner for the first time as a part of
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this work. Our results will lay the groundwork for understanding a possible regulatory
function of Isd11 and possibly help identify the evolutionary requirement for its activating
function on Nfs1 in eukaryotes only. The effect of Yfh1 on sulfur mobilization by the
Nfs1-Isd11 complex has also been evaluated in detail. Our results suggest that frataxin
impacts cluster assembly mostly at the level of the assembled complex rather than at
the individual protein level. This information adds an extra level of understanding for the
regulatory role of Yfh1 within the yeast mitochondrial Fe-S cluster assembly pathway.
This work, therefore, provides novel and significant insight into how the cluster
assembly proteins function, and sets the groundwork for which additional experiments
that need to be designed to further unravel the mechanistic details of sulfur mobilization
during Fe-S cluster bioassembly. These molecular level details will assist in future drug
design strategies directed at treating the disease states outlined above. In addition, this
chapter concludes the dissertation by summarizing the final outcomes of the previous
three chapters and also by providing potential routes the project can take. Some
preliminary work performed in relation to our future objectives is included in this chapter.
5.1 Summarization of dissertation and conclusions
5.1.1 Molecular characterization of yeast Nfs1-Isd11 complex
Although several studies have provided details regarding how the Nfs1-Isd11
complex functions from a biochemical point of view, many of the biophysical details of
how the complex functions are lacking. Chapter 2 provided findings regarding a
comprehensive in vitro biophysical characterization of the yeast Nfs1-Isd11 protein pair.
Successful purification of these proteins was followed by experiments that were
performed to unveil basic properties of the complex. Co-expressing Nfs1 with Isd11 led
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to formation of a stable complex and prevented Nfs1 aggregation, indicating Isd11
coordination to Nfs1 contributed to the stability and solubility of the enzyme. Additional
studies confirmed the precise molecular weight and stoichiometry of the proteins within
the complex, and also provided the exact oligomeric arrangement of the proteins in our
overexpressed complex. Subsequent experiments attempted to rationalize the
requirement for Isd11 within yeast Nfs1 Fe-S cluster biosynthesis. Biophysical studies
revealed that Isd11 imparts a high thermodynamic stability on Nfs1, most likely by
altering the structure of Nfs1 in a manner that is not yet clear. Our measurements
testing the substrate binding affinity of Nfs1 suggested Isd11 likely does not exert a
direct effect on altering Nfs1’s substrate binding affinity. Subsequent activity
measurements however proved that Isd11 alters the catalytic activity of eukaryotic Nfs1.
Kinetic parameters, such as KM and catalytic efficiency, were significantly altered during
the emergence of Isd11 in eukaryotes in the evolutionary lineage compared to
prokaryotes. Homology modeling was used to generate a structure framework for us to
predict yeast Nfs1 biophysical properties. The modeled structure suggested that
conformational changes would be required for substrate binding and persulfide
formation; these results were supported by our Fluorescence experiments. Taken
together, the second chapter of this dissertation supports the idea that cooperativity
between Nfs1 and Isd11 is essential to bring about the full functional outcome of
cysteine desulfurase complex in yeast. Isd11 alters the catalytic activity of Nfs1 in
addition to functioning as a stabilizer for the protein. Having this multifaceted level of
control within eukaryotes may be a safeguard established by evolution to eliminate
unwanted product formation within higher developed organisms.
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5.1.2 The transient effect of frataxin on Nfs1-Isd11 activity
Recently, frataxin was identified as a regulator of the cysteine desulfurase within
the ISC Fe-S cluster biosynthetic pathway. This function however has not been
completely clarified at a molecular level in any eukaryotic system. Experiments in
Chapter 3 were designed to test the hypothesis that Yfh1 interacts directly with the
Nfs1-Isd11 complex to regulate the complex’s activity. In addition, this chapter tested
the effect of Yfh1 on the structure and activity of the complex. Isothermal titration
calorimetry was used to explore for a stable physical interaction between proteins,
however our work was limited in its outcome due to protein aggregation issues. Pulldown assays were used as an alternative method to explore inter-protein interactions,
and our results suggested a transient but not stable interaction between Yfh1 and the
complex. Additional biophysical experiments tested the ability of Yfh1 to alter the
thermal stability, substrate binding affinity and catalytic activity of Nfs1-Isd11 in order to
determine if we could detect any evidence of this transient interaction, however no
impact of Yfh1 was identified. Therefore, it is plausible that an interaction between Yfh1
and Nfs1-Isd11 does not exist, or that this interaction is not stable enough to be
measured under the conditions we explored. In alignment with similar results observed
with human orthologs, it is reasonable to assume that eukaryotic frataxin interacts with
the cysteine desulfurase only when it is part of the complete cluster assembly complex
that also include Isu1 along with Nfs1 and Isd11.
5.1.3 Challenges in expression and purification of Isd11
In an effort to study the functional association between molecules within the
Nfs1-Isd11 complex, it was proposed that we isolate the two proteins individually.
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Chapter 4 described the attempts we made towards this directive, and how we
rationalize our inability to isolate Isd11 separately. All failed attempts pointed towards
the notion that complex formation between Nfs1 and Isd11 is a mutual necessity in
order to maintain the structure and functionality of both partners. Our differential
scanning experiments described in Chapter 2 supported this idea.
5.2 Future directions
Although the Fe-S cluster biogenesis pathway has been under investigation for
several decades, many questions regarding how the molecules within the pathway
operate together remain unanswered. While genetics and cellular studies on the yeast
cluster assembly system are well understood, little is known about the molecular
aspects of how the proteins work together during Fe-S cofactor assembly. Given its
reduced complexity, the yeast model system serves as a bridge between the
prokaryotic and eukaryotic cluster assembly systems. The yeast system therefore
provides a unique opportunity to explore the fine details of how proteins within the Fe-S
cluster assembly pathway interact. Sulfur mobilization, which is used during de novo FeS cluster assembly, contains specific gaps in our knowledge of how the proteins work
together to operate, and as a result there are several questions that need to be
addressed in this area. I performed several preliminary new experiments in this context,
and the results I have obtained during these exploratory but yet to be completed
experiments are provided below.
5.2.1 Elucidation of x-ray crystal structure of Nfs1-Isd11
Not having exact structural details for the structure of Nfs1-Isd11 has hindered
our progress in understanding how these proteins function. Some of the specific

166
questions that still remain unanswered include: 1) What are the molecular details
regarding the interaction between Nfs1 and Isd11?, 2) What is the location and
proximity of the PLP-bound active site relative to the catalytic cysteine residue?, and 3)
What are the structural rearrangements that drive chemistry related to the substrate
bound cysteine?. In order to address this knowledge gap, we have attempted to
crystallize the yeast Nfs1-Isd11 complex. In-house crystal screens were set for purified
Nfs1-Isd11 with Qiagen NeXtal Tubes JCSG Core Suites I-IV using the sitting drop
method. These crystal trays were set at temperatures of 4 and 25 °C. Screens are
currently being monitored for visible crystals and once suitable hits are obtained, more
elaborate screens will be developed to find the best crystallization condition(s) to obtain
suitable diffracting crystals. Crystal diffraction and structure elucidation procedures are
being done in collaboration with Dr. Amy Rosenzweig’s laboratory at Northwestern
University.
5.2.2 Role of Acyl Carrier Protein in cysteine desulfuration and Fe-S cluster
assembly
Most recently, the Acyl Carrier Protein (ACP) involved in mitochondrial fatty acid
synthesis was identified to be an essential component of the yeast Fe-S cluster
assembly complex210. This study reported the role of ACP in Fe-S cluster biogenesis as
functioning to stabilize the Nfs1-Isd11 complex, because Nfs1 and Isd11 were found as
insoluble aggregates in yeast ACP knockdown strains. This work is supported by the
fact that Nfs1 and Isd11, expressed and isolated from bacteria, require ACP. As we
observed, purified yeast Nfs1-Isd11 always carries a single impurity of ~18 kDa that we
could not separate from our constituent proteins (Chapter 2, Figure 2.1). We actually
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identified this protein by mass spectrometry several years ago as potentially being the
E. coli Acyl Carrier Protein (data not shown). In the absence of the yeast ACP ortholog,
recombinant Nfs1 and Isd11 do associate with the E. coli ACP during our preps, and
this indicates the significance of the protein in in helping form the Fe-S cluster assembly
complex. Our next step in trying to elucidate the function of ACP will be to assess its
effect on the activity of our in vitro cysteine desulfurase-Isd11 complex. Interestingly,
activity measurements on purified yeast Nfs1-Isd11 performed to date have already
been completed in the presence of bacterial ACP (although we have not quantified the
stoichiometry), as a result of the protein’s tendency to co-purify with Nfs1-Isd11 at high
quantities. If the bacterial ACP is associated with the yeast Nfs1-Isd11 in the correct
stoichiometry, or if it fully complements the capabilities of the yeast ACP ortholog are
questions that still need to be addressed. To test if increasing the expression of E. coli
ACP will have any stimulatory effect on yeast cysteine desulfurase activity, autoinduction methods were tested during bacterial cell growth in an attempt to coordinate
yeast protein expression with the enhanced expression of bacterial ACP. Unfortunately
there was no significant difference in bacterial ACP levels observed by using autoinduction as opposed to growth under IPTG inducible conditions. Therefore, we will try
co-expressing yeast ACP with yeast Nfs1-Isd11 directly in E. coli using a cotransformed plasmid vector. In this manner, we will try to coordinate yeast ACP
expression with the expression of the complex. Additional strategies, such as a ΔACP
E. coli expression strain, will also be utilized to eliminate the expression of E. coli ACP.
This should allow us to obtain an ACP free complex that we can use for side-by-side
comparison of protein activity.
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5.2.3 Elucidation of cysteine desulfurase mechanism of Nfs1-Isd11
At present, the molecular details of the cysteine desulfurase reaction mechanism
have been identified in detail in only a small number of systems; the best of which is in
the bacterial systems219,237,238,298. Reaction mechanisms followed by different cysteine
desulfurase orthologs during their catalytic activity vary only slightly. The resting state of
all the PLP containing cysteine desulfurases consist of a functional internal aldimine
formed between PLP and an active site lysine residue. The incoming cysteine substrate
forms an external Cys aldimine with the PLP cofactor at the active site, which in turn
gets deprotonated to form a Cys quinonoid intermediate. The subsequent protonation at
the α-C4 atomic position converts this intermediate to a Cys ketimine adduct, which
then undergoes nucleophilic attack by the deprotonated catalytic cysteine residue. The
end result is an enzyme bound persulfide and an Ala enamine. Thereafter, the alanine
gets released and the persulfide gets transferred to a sulfur acceptor216 (Figure 5.1).
However, eukaryotic cysteine desulfuration requires the accessory protein Isd11 for
activity, and therefore Isd11 plays a direct or an indirect role in this enzymatic reaction
mechanism. Having a complete characterization of the eukaryotic cysteine desulfurase
reaction mechanism will allow for a direct comparison between the prokaryotic and
eukaryotic sulfur mobilization mechanisms, something that may be possible since the
bacterial reaction mechanism has already been solved. Obtaining this information will
therefore provide direct answers regarding why Nfs1 has evolved to catalyze the
persulfide product with an aid of a second protein Isd11, in contrast to the bacterial
protein, which did not.
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In order to begin to elucidate the mechanism of Nfs1-Isd11, we have expressed
and purified two mutant forms of Nfs1 and we will use these to monitor the fate of three
separate intermediates formed during the reaction mechanism. As mentioned in
Chapter 2, monitoring the characteristic 420 nm UV-vis signal from wild type Nfs1-Isd11
revealed that it is a compound signal representing both internal aldimine (between K299
and PLP) and persulfide formation (on C421). As the reaction progresses, the
consumption of the aldimine species upon substrate binding causes a diminution in the
420 nm signal, while persulfide formation causes an increase in the signal (Figure 5.2A). Our Nfs1(C421A)-Isd11 mutant, in which the catalytic cysteine residue essential for
persulfide formation is mutated, was incapable of performing the nucleophilic attack
leading to persulfide formation. Therefore, the reaction stalled at the Cys ketimine stage
(Figure 5.2-B). The decrease in the 420 nm signal observed for this mutant only
represents the consumption of internal aldimine leading to Cys ketimine formation,
eliminating the signal for the production of a persulfide. In contrast, my Nfs1(K299A)Isd11 mutant was not expected to make a progression upon substrate addition, as this
mutant was incapable of binding PLP in the active site; this Lys-299 residue forms the
internal aldimine with PLP at the resting state of the enzyme. However our studies
showed that the Nfs1(K299A)-Isd11 complex was still capable of accommodating PLP
in the active site, this interaction is likely facilitated by interactions with amino acids in
the active site vicinity. Interestingly as a result of the K299A mutation, the signal around
420 nm from the internal aldimine was only slightly viable (only a low intensity peak at
405 nm was present, Figure 5.2-C). Upon substrate addition, this signal steadily
increased, indicating persulfide formation, which was masked before by the internal
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aldimine signal (Figure 5.3-A, and B). In addition, the increasing L-cysteine
concentration caused a red shift in the data that was observed from 405 nm to 424 nm.
A previous report attributes the red shift to an increase in the pKa of an acidic group on
PLP due to persulfide formation238, supporting the identity of the red shift we observed
for the Nfs1(K299A)-Isd11 complex. Therefore, the Nfs1(K299A)-Isd11 complex can be
used to observe the fate of the persulfide intermediate in the second half of the reaction.
On the other hand, in the wild type and mutant complexes, the signal at 340 nm might
represent a single intermediate, which is likely the Cys ketimine (Figure 5.2-A/B, and
Figure 5.3-B). Having the capability to monitor three separate reaction intermediates
during the reaction process will allow for the explicit design of stopped flow
spectrophotometric experiments that could be performed using isotope labeled
substrate (deuterated L-cysteine and H2O) to help elucidate the complete reaction
mechanism.
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Figure 5.1: Proposed chemical mechanism for the cysteine desulfurase reaction
[by Behshad (2009) et al. for bacterial cysteine desulfurases237].
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Figure 5.2: Absorbance measurements for three variants of yeast Nfs1-Isd11.
Absorbance change measured over time at 340 nm (white circles) and 420 nm (black
circles) for (A) Nfs1-Isd11 wild type and (B) Nfs1(C421A)-Isd11 protein complexes upon
addition of 20 molar excess L-cysteine. (C) Absorption profiles of Nfs1(C421A)-Isd11
(dashed line) and Nfs1(K299A)-Isd11 (solid line) protein complexes for comparison.
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Figure 5.3: Titration of L-cysteine to Nfs1(K299A)-Isd11 monitored by UV-visible
spectroscopy. (A) Consecutive spectra were collected after each addition of Lcysteine. Lines represent the following concentrations: bold solid: 0 mM, bold dashed:
0.010 mM, bold dotted: 0.035 mM, bold dash-dot: 0.084 mM, bold dash-dash-dot-dot:
0.183 mM, thin solid: 0.430 mM, thin dashed: 0.919 mM, thin dotted: 1.901 mM, thin
dash-dot: 4.346 mM, thin dash-dash-dot-dot: 9.200 mM. (B) Plots show the change in
absorbance for Nfs1(K299A)-Isd11 at 340 nm (white circles) and 420 nm (black circles)
as a function of L-cysteine concentration.
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5.2.4 Effect of frataxin on the cysteine desulfurase activity of Nfs1/Isd11/Isu1/Yfh1
complex
As discussed in Chapter 3, Yfh1 showed no direct interaction with or effect on the
stability, substrate binding affinity, and activity of the Nfs1-Isd11 complex alone. These
results suggest the effect of frataxin on this complex is transient and/or contingent upon
other factors. However, the effect of Yfh1 on the Fe-S cluster assembly activity in the
Nfs1/Isd11/Isu1/Yfh1 complex has been established*. To test the hypothesis that Yfh1’s
ability to alter cluster assembly within the Nfs1/Isd11/Isu1/Yfh1 complex occurs by
altering the cysteine desulfurase function, I completed some initial preliminary
experiments. Yfh1’s ability to alter substrate binding affinity of Nfs1-Isd11 within a
reconstituted Nfs1/Isd11/Isu1/Yfh1 complex was tested first. The Nfs1/Isd11/Isu1/Yfh1
quad complex was reconstituted by combining individually purified Nfs1-Isd11 (mutant
or wild type), Yfh1 and Isu1 proteins together at a 1:2:1:1 stoichiometric ratio. This ratio
was shown by others and us to match that identified in vivo213,229,235. Using the protocol
outlined in Chapters 2 and 3, UV-visible spectroscopy was used to study the substrate
binding affinity of reconstituted Nfs1(C421A)/Isd11/Isu1/Yfh1 complex. The absorbance
at 340 nm was monitored upon consecutive titration of L-cysteine to this quad complex.
The identical experiment was performed using the as purified Nfs1(C421A)/Isd11
complex alone as a control for comparison for possible alteration in substrate binding
affinity

within

the

quad

complex.

Titration

of

L-cysteine

to

reconstituted

Nfs1(C421A)/Isd11/Isu1/Yfh1 complex or the as purified Nfs1(C421A)/Isd11 yielded the
binding curves that are not distinctly different from each other (Figure 5.4). Best-fit

Stephen Dzul’s (2016) PhD dissertation “Insights into de novo Fe-S cluster biogenesis via the eukaryotic
Fe-S cluster pathway (ISC) in vitro”.
*
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simulations for binding data revealed Kd values of 0.58 ± 0.13 mM and 0.55 ± 0.14 mM
for Nfs1(C421A)/Isd11/Isu1/Yfh1 and Nfs1(C421A)/Isd11, respectively. However from
these results, no direct conclusion could be made regarding the effect Yfh1 had on
substrate

binding

affinity

of

Nfs1(C421A)/Isd11

within

the

reconstituted

Nfs1(C421A)/Isd11/Isu1/Yfh1 complex, due to two reasons: 1) During reconstitution, as
soon as purified Isu1 was added to the Nfs1(C421A)/Isd11/Yfh1 reaction mixture,
protein precipitation was visible and this continued through the entire experiment. No
precipitation was observed when the experiment was carried out with just the
Nfs1(C421A)/Isd11/Yfh1 complex (as outlined in Chapter 3), indicating Isu1 is likely
causative of aggregation. Wild type yeast Isu1 alone is unstable and prone to
aggregation, even at the slightest perturbation of conditions, during and/or after
purification (data not shown). Therefore, the similarity of the binding affinity data of
Nfs1(C421A)/Isd11 and Nfs1(C421A)/Isd11/Isu1/Yfh1 may have caused by the poor
solubility of Isu1 during reconstitution; 2) The absorbance values recorded for the
reconstituted quad complex were higher than those only for Nfs1(C421A)/Isd11
complex by a same amount at each point, even after correcting for dilution (Figure 5.4).
This too is an indication of the effect of poor solubility of Isu1 on the reading following
reconstitution since neither Yfh1 nor Isu1 alone absorb at 340 nm or 420 nm. Therefore
this experiment needs to be repeated using an alternative strategy to avoid Isu1
precipitation during the reaction, as reconstitution of separately purified proteins is not
the best approach. Nfs1/Isd11/Isu1/Yfh1 quad complex has been co-expressed and copurified in our lab for several years with high purity and stability. Therefore, it would be
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beneficial

to

repeat

this

experiment

with

a

co-expressed

and

co-purified

Nfs1(C421A)/Isd11/Isu1/Yfh1 quad complex.
Similarly, acid labile sulfide production activity within the reconstituted
Nfs1/Isd11/Isu1/Yfh1 was tested, as described above. However, no significant
enhancement in the persulfide formation activity within the Nfs1-Isd11/Isu1/Yfh1
complex was observed compared to the Nfs1/Isd11 complex (Figure 5.5). As mentioned
above, validity of this result is questionable due to aggregation of Isu1 during the assay,
and

therefore

this

experiment

should

be

repeated

with

the

co-purified

Nfs1/Isd11/Isu1/Yfh1 quad complex, which exists as a more stable.
To summarize, experiments proposed to help elucidate the structure and the
reaction mechanism of yeast Nfs1-Isd11 complex will greatly contribute towards closing
the knowledge gap regarding the sulfur mobilization step within de novo Fe-S cluster
assembly. The experiments that we proposed in order to study the effect of possible
regulators of the sulfur mobilization process (such as, ACP and Yfh1) will provide
comprehensive information on how cluster assembly if achieved on a global scale within
the regulated environment of the mitochondria. Taken together, these experiments will
produce a wealth of information that would contribute towards a better understanding of
the molecular details of the Fe-S cluster assembly process. This in turn will aid in
accentuating the drug design process for those diseases associated with cluster
assembly.
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Figure 5.4: Absorbance change measured at 340 nm for Nfs1(C421A)/Isd11 (white
circles), and Nfs1(C421A)/Isd11/Yfh1/Isu1 reconstituted complex (black circles)
upon addition of substrate L-cysteine. Substrate was incubated for 10 min after each
addition and spectra were measured at 25 °C.
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Figure 5.5: Persulfide forming activity of Nfs1-Isd11 and reconstituted
Nfs1/Isd11/Yfh1/Isu1 complex measured by acid labile sulfide detection assay.
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Disrupted iron homeostasis within the human body materializes as various
disorders. Pathophysiology of many of them relates to iron induced oxidative damage to
key cellular components caused by iron accumulation within the tissues. Pertaining to
the growing occurrence, cost of patient care and devastating burden associated with
these diseases, the call for understanding the role of iron homeostasis within these
disorders becomes inevitable. Being an abundant iron containing cofactor, the role of
Fe-S clusters in cellular iron homeostasis is indisputable in the case of Friedreich’s
ataxia, a disease caused by a deficiency in the protein frataxin that is indispensable
during Fe-S cluster assembly. Friedreich’s ataxia and similar disorders associated with
defective Fe-S cluster assembly accentuate the need to unravel the structural and
functional aspects of this fundamental biochemical pathway. Effective disease treatment
has been hampered by the lack of a molecular level understanding of the individual
roles of the key proteins in Fe-S cluster formation.
The work presented within this dissertation diminish this knowledge gap
significantly by providing a comprehensive biophysical characterization of the key
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proteins involved in the sulfur mobilization step during the yeast mitochondrial Fe-S
cluster synthesis process. The role of the accessory protein “Isd11” within the catalytic
role of the cysteine desulfurase “Nfs1” in delivering sulfane sulfur for cluster assembly
has been studied. The effect of Yfh1 on sulfur mobilization by the Nfs1-Isd11 complex
has also been evaluated in detail. Our results suggest a possible regulatory function of
Isd11 and possibly rationalize the evolutionary requirement for its role as an additional
cofactor introduced in eukaryotes. Frataxin’s effect on cluster assembly was evident to
materialize the most at the overall assembled complex level rather than at the individual
protein level. This work, therefore, provides novel and significant insight into how the
cluster assembly proteins function, and sets the groundwork for which additional
experiments that need to be designed to further unravel the mechanistic details of sulfur
mobilization during Fe-S cluster bioassembly. These molecular level details will assist in
future drug design strategies directed at treating the diseases outlined above.
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